Requirements for pre-catalytic B complex formation during exon- and intron-defined spliceosome assembly by Boesler, Carsten
 
 
Requirements for pre-catalytic B complex formation 






for the award of the degree 
„Doctor rerum naturalium“ 


















Members of the Examination Board: 
Prof. Dr. Reinhard Lührmann (1
st
 Referee) 
Department of Cellular Biochemistry 
Max Planck Institute for Biophysical Chemistry, Göttingen  
 
Prof. Dr. Henning Urlaub (2
nd
 Referee) 
Research Group Bioanalytical Mass Spectrometry  
Max Planck Institute for Biophysical Chemistry, Göttingen 
 
Prof. Dr. Markus Zweckstetter 
Department for NMR-based Structural Biology 
Max Planck Institute for Biophysical Chemistry, Göttingen 
  
Prof. Dr. Ralf Ficner  
Department for Molecular Structural Biology 
Georg-August-Universität Göttingen 
 
Prof. Dr. Holger Stark 
Research Group 3D Electron Cryo-Microscopy 
Max Planck Institute for Biophysical Chemistry, Göttingen 
 
Dr. Claudia Höbartner  
Research Group Nucleic Acid Chemistry  
Max Planck Institute for Biophysical Chemistry, Göttingen 
 
 








For my family, 
for my friends 
 
 
Table of contents 
Abstract .................................................................................................................................................. 1 
1. Introduction ...................................................................................................................................... 4 
1.1 Pre-mRNA splicing ......................................................................................................................... 4 
1.2 The two step mechanism of splicing ............................................................................................. 5 
1.3 Alternative splicing enhances the proteome post-transcriptionally............................................. 6 
1.4 Composition of spliceosomal snRNPs ........................................................................................... 7 
1.5 Protein inventory of the human snRNPs ....................................................................................... 9 
1.6 Stepwise assembly of the spliceosome ....................................................................................... 11 
1.7 The dynamic RNA-RNA network in the spliceosome .................................................................. 13 
1.8 Dynamics of the spliceosome’s protein composition ................................................................. 15 
1.9 The role of RNA helicases in splicing ........................................................................................... 17 
1.10 Structure of spliceosomal complexes ....................................................................................... 19 
1.11 Exon definition is an alternative pathway to initiate spliceosome assembly ........................... 20 
1.12 Aims ........................................................................................................................................... 23 
2. Materials and methods ................................................................................................................. 25 
2.1 Materials ..................................................................................................................................... 25 
2.1.1 Chemicals ............................................................................................................................. 25 
2.1.2 Chromatography materials and consumables ..................................................................... 27 
2.1.3 Commerical kits .................................................................................................................... 27 
2.1.4 Machines .............................................................................................................................. 28 
2.1.5 Nucleotides........................................................................................................................... 29 
2.1.6 Radiolabeled nucleotides ..................................................................................................... 29 
2.1.7 RNA oligonucleotides ........................................................................................................... 29 
2.1.8 Antibodies ............................................................................................................................ 30 
2.1.9 Enzymes ................................................................................................................................ 30 
2.1.10 Plasmids .............................................................................................................................. 31 
2.1.11 Bacteria strains ................................................................................................................... 31 
2.1.12 Cell line ............................................................................................................................... 31 
2.1.13 Buffers ................................................................................................................................ 31 
2.2 Methods ...................................................................................................................................... 35 
2.2.1 Molecular biology standard methods .................................................................................. 35 
2.2.1.1 Nucleic acid quantification ................................................................................................ 35 
2.2.1.2 PCI extraction .................................................................................................................... 35 
 
2.2.1.3 Proteinase K digestion ....................................................................................................... 35 
2.2.1.4 Generation of templates for run-off in vitro transcriptions .............................................. 36 
2.2.1.5 In vitro transcription .......................................................................................................... 36 
2.2.1.6 Denaturing polyacrylamide gel-electrophoresis ............................................................... 37 
2.2.1.7 Silver staining of RNA ........................................................................................................ 37 
2.2.1.8 Northern blot .................................................................................................................... 37 
2.2.1.9 Radioactive 5’-labeling of RNA oligonucleotides .............................................................. 38 
2.2.2 Protein-biochemistry standard methods ............................................................................. 38 
2.2.2.1 Protein quantification ....................................................................................................... 38 
2.2.2.2 Denaturing SDS polyacrylamide gel-electrophoresis (SDS-PAGE)..................................... 38 
2.2.2.3 Coomassie staining ............................................................................................................ 39 
2.2.2.4 Silver staining of proteins .................................................................................................. 39 
2.2.2.5 Western blot...................................................................................................................... 39 
2.2.2.6 Purification of MS2-MBP ................................................................................................... 40 
2.2.2.7 Purification of recombinant hPrp28 proteins ................................................................... 40 
2.2.2.8 Purification of antibodies .................................................................................................. 41 
2.2.3 Special methods ................................................................................................................... 42 
2.2.3.1 Cell culture ........................................................................................................................ 42 
2.2.3.2 Preparation of splicing active HeLa nuclear extract .......................................................... 42 
2.2.3.3 In vitro splicing reactions................................................................................................... 42 
2.2.3.4 Analysis of splicing complexes by native agarose gel-electrophoresis ............................. 43 
2.2.3.5 MS2 affinity-selection of splicing complexes .................................................................... 43 
2.2.3.6 Psoralen-mediated RNA-RNA crosslinking ........................................................................ 44 
2.2.3.7 UV crosslinking of spliceosomal complexes ...................................................................... 44 
2.2.3.8 Immunoprecipitation of protein-RNA crosslinks............................................................... 44 
2.2.3.9 Two-dimensional gel-electrophoresis of spliceosomal complexes ................................... 45 
2.2.3.10 Electron microscopy ........................................................................................................ 45 
2.2.3.11 Mass spectrometry .......................................................................................................... 46 
3. Results .............................................................................................................................................. 47 
3.1 A stable 45S B-like complex is formed upon addition of a 5’splice site-containing RNA 
oligonucleotide .................................................................................................................................. 47 
3.1.1 Stabilization of U4/U6.U5 tri-snRNP integration is not induced by removing U1 snRNP from 
the downstream 5’ss ......................................................................................................................... 49 
3.2 Formation of the 45S B-like complex is accompanied by the recruitment of B complex-specific 
proteins ............................................................................................................................................. 49 
 
3.3 EM reveals a major structural difference between the 37S exon and the 45S B-like complex .. 53 
3.4 Interaction of the 5’ss oligonucleotide with affinity-purified 37S exon complexes induces a 
structural change resulting in stable U4/U6.U5 tri-snRNP binding .................................................. 55 
3.4.1 ATP hydrolysis is not required for the shift in the S-value from 37S to 45S ........................ 58 
3.4.2 Phosphorylation of hPrp31 is not required for transforming the 37S exon complex into a 
45S complex .................................................................................................................................. 58 
3.5 EM reveals a structural change in the purified 37S exon complex after addition of the 5’ss 
oligonucleotide .................................................................................................................................. 59 
3.6 Sequence requirements of the 5’ss oligonucleotide for U4/U6.U5 tri-snRNP stabilization during 
B-like complex formation .................................................................................................................. 61 
3.6.1 The exon-intron junction of the 5’ss oligonucleotide interacts with the U5 protein hPrp8 in 
stably-assembled 45S B-like complexes ........................................................................................ 61 
3.6.2 Base pairing interactions between 5’ss and U6 ACAGAG box are not absolutely required for 
stable B-like complex formation ................................................................................................... 63 
3.6.3 Mutations of nucleotides at the exon-intron junction that contact hPrp8 abolish formation 
of a stable 45S B-like complex ....................................................................................................... 65 
3.6.4 Double mutations at the intron-exon boundary abolish binding of 5’ss oligonucleotide to 
the exon complex .......................................................................................................................... 66 
3.6.5 Recruitment of B complex-specific proteins is independent of complex stability in presence 
of heparin ...................................................................................................................................... 68 
3.7 A dominant-negative mutant of the DEAD-box helicase hPrp28 stalls spliceosome assembly 
prior to stable B complex formation ................................................................................................. 70 
3.8 Isolation and characterization of a novel intron-defined spliceosome assembly intermediate . 72 
3.9 The 37S cross-intron and 37S exon complexes have nearly identical protein compositions ..... 78 
3.10 Analysis of the RNA-RNA network in the 37S cross-intron complex......................................... 80 
3.11 Electron microscopy investigation of the 37S cross-intron complex ........................................ 82 
3.12 The 37S cross-intron complex is converted into a stable B complex in presence of a 5’ss 
oligonucleotide .................................................................................................................................. 85 
3.13 EM reveals that the purified 37S cross-intron complexes adopt a B complex appearance after 
incubation with the 5’ss oligonucleotide .......................................................................................... 88 
4. Discussion ........................................................................................................................................ 90 
4.1 Addition of a 5’ss-containing RNA oligonucleotide transforms the 37S exon complex into a 45S 
B-like complex with stably-integrated U4/U6.U5 tri-snRNP ............................................................. 91 
4.2 B complex-specific proteins are recruited upon formation of the 45S B-like complex, but are 
not required for stable integration of the U4/U6.U5 tri-snRNP ....................................................... 91 
4.3 Stable binding of the U4/U6.U5 tri-snRNP likely depends on the interactions with U2 snRNP 
proteins ............................................................................................................................................. 93 
4.4 The hPrp4 kinase is abundant solely in the 37S exon complex .................................................. 93 
 
4.5 The proteins THRAP3 and BCLAF1 are abundant in exon-defined spliceosomes ....................... 94 
4.6 The 37S exon complex undergoes a major structural change upon interaction with the 5‘ss 
oligonucleotide and adopts the appearance of a cross-intron B complex ....................................... 95 
4.7 Sequence requirements for the 5’splice site to induce stable U4/U6.U5 tri-snRNP binding ..... 97 
4.8 Structural implications for the stabilizing effect of a 5’ss sequence on stable U4/U6.U5 tri-
snRNP binding ................................................................................................................................. 100 
4.9 A dominant-negative mutant of the DEAD-box helicase hPrp28 inhibits stable B complex 
formation ........................................................................................................................................ 101 
4.10 Identification of a novel cross-intron assembly intermediate that is formed prior to hPrp28 
action ............................................................................................................................................... 102 
4.11 The 37S cross-intron complex can be converted into a stable B complex via addition of a 5‘ss 
oligonucleotide ................................................................................................................................ 103 
4.12 The 37S cross-intron and 37S exon complex adopt an almost identical appearance upon 
interaction with a 5’ss oligonucleotide ........................................................................................... 104 
4.13 Changes in the RNA-RNA network during spliceosome assembly prior to the first catalytic step
 ......................................................................................................................................................... 106 
4.14 The role of hPrp28 in formation of a stable B complex .......................................................... 107 
4.15 Perspectives ............................................................................................................................ 109 
5. References ..................................................................................................................................... 111 
6. Appendix ........................................................................................................................................ 119 
6.1 Abbreviations ............................................................................................................................ 119 
6.2 Danksagung ............................................................................................................................... 122 





In eukaryotes, most protein-coding genes are interrupted by non-coding sequences known as 
introns. The splicing of intronic sequences from a pre-mRNA is catalyzed by the spliceosome, an 
elaborate molecular machine formed by the interaction of five snRNPs and numerous splicing factors 
with the pre-mRNA. Initial assembly of the spliceosome can occur across an intron sequence (intron 
definition) or alternatively across an exon (exon definition). The latter is likely the prominent 
pathway for pre-mRNAs with long intronic sequences, which is characteristic for most human pre-
mRNAs. As splicing catalysis can only occur across introns, a rearrangement from the exon-defined to 
intron-defined state is required. This rearrangement can be a critical point during the decision 
whether to include or to skip an exon in the mature mRNA during the process of alternative splicing. 
Recently exon-defined spliceosomes were shown to contain not only U1 and U2 snRNPs, but also the 
U4/U6.U5 tri-snRNP (37S exon complex), and evidence was provided that it is possible for a cross-
exon complex to be converted directly into an intron-defined B complex.  
During my studies, I addressed the question what are the requirements for stable integration of the 
U4/U6.U5 tri-snRNP and formation of a pre-catalytic B complex during exon- and intron-defined 
spliceosome assembly, since this is a crucial point in which the alternative assembly pathways 
converge.  
To address this aim, I used a reductionist in vitro system to assemble the 37S exon complex on a 
single exon-containing RNA substrate in HeLa nuclear extract. The addition in trans of an RNA 
oligonucleotide containing a 5’splice site sequence (5’ss oligonucleotide) mimics an adjacent 
upstream 5’ss and induces the formation of a 45S B-like complex, which shares similarities with the 
intron-defined B complex. The transition from a 37S exon to a 45S B-like complex is accompanied by 
the stable integration of the U4/U6.U5 tri-snRNP within the complex and a significant shift in the 
sedimentation behavior, suggesting structural changes in the complex during its stabilization. Indeed, 
electron microscopy (EM) revealed major structural differences between 37S exon and 45S B-like 
complexes, likely due to a different orientation of the U2 snRNP and the U4/U6.U5 tri-snRNP with 
respect to each other, while the structure of the 45S B-like complex was highly similar to that of an 
intron-defined B complex. Thus, formation of a B-like complex and consequently the stable 
integration of the U4/U6.U5 tri-snRNP is indeed accompanied by significant structural remodeling of 
the spliceosome. 
To identify factors that might contribute to the structural remodeling and the stabilization of 




and 45S B-like complexes by 2D gel-electrophoresis. The comparison of their protein compositions 
showed the recruitment of a distinct set of B complex-specific proteins, namely RED, MFAP1, FBP21, 
hSmu-1, hPrp38 and hSnu23, upon formation of the 45S B-like complex. These proteins are also 
recruited during formation of the intron-defined B complex, underlining the compositional and 
structural similarities of the 45S B-like and B complex. However, the B complex-specific proteins do 
not appear to contribute to stable U4/U6.U5 tri-snRNP integration, since solely the interaction of the 
5'ss oligonucleotide with affinity-purified 37S exon complexes in the absence of splicing extract 
triggers the structural rearrangement that supports stable U4/U6.U5 tri-snRNP integration.  
The defined changes in structure, stability and protein composition during transition from a 37S exon 
to 45S B-like complex are induced solely by the addition of a 5’ss oligonucleotide to the splicing 
reaction. Thus, I investigated the requirements for functional interaction of a 5’ss sequence with 
components of the U4/U6.U5 tri-snRNP to induce the formation of a stable 45S B-like complex. 
Studies using 5’ss oligonucleotides with mutated sequences indicated that base pairing with the 
ACAGAG box motif of U6 snRNA is not required to trigger the observed structural rearrangement. But 
instead, highly conserved guanine residues at the exon-intron junction are essential for the 
formation of a stable 45S B-like complex and I could show that these residues within the 5’ss 
oligonucleotide are contacted only by the U5-specific protein hPrp8, pointing to a crucial role of 
hPrp8 in stabilizing the binding of the U4/U6.U5 tri-snRNP. Further, my studies provide evidence that 
the stable integration of the U4/U6.U5 tri-snRNP not only depends on the recognition of the 
exocyclic part of these guanines, but also on interactions with the ribose backbone of the RNA. 
Based on the results in the exon-defined assembly pathway and the similarities between the 45S B-
like and B complex, I assumed that stable incorporation of the U4/U6.U5 tri-snRNP during intron-
defined B complex formation also requires its interaction with the 5'ss of the pre-mRNA. 
Consequently, I set out to stall intron-defined spliceosome assembly just prior to stable B complex 
formation in order to test if the stable integration of the U4/U6.U5 tri-snRNP during B complex 
formation also relies on the interaction with a 5’ss. The DEAD-box helicase hPrp28 is involved in the 
displacement of U1 snRNP from the 5'ss and was recently shown to be essential for the formation of 
a stable intron-defined B complex. Thus, I chose hPrp28 as a target to inhibit spliceosome assembly 
prior to formation of a B complex. The use of a dominant-negative mutant of hPrp28, lacking its 
ATPase activity, inhibited B complex formation, but not formation of the A complex, and allowed me 
to affinity-purify a novel intermediate in the intron-defined spliceosome assembly pathway, namely 
the 37S cross-intron complex. Characterization of this complex showed that it contains all five 
snRNPs, but in contrast to the pre-catalytic B complex, the U4/U6.U5 tri-snRNP is not yet stably-
integrated. Thus, in the absence of hPrp28 function, the U4/U6.U5 snRNP can associate with the 




showed that in the 37S cross-intron complex U1 snRNA is base paired with the pre-mRNA, while the 
U6 snRNA establishes base pairing interactions with the U2 snRNA. In the B complex, no base pairing 
interactions between U1 and the pre-mRNA were detected. Instead we detected interactions 
between the U4/U6.U5 tri-snRNP and the pre-mRNA, while the U4 and U6 snRNA were still base 
paired. These data suggest that due to the retention of U1 snRNP at the 5’ss of the pre-mRNA, this 
sequence is not available for interaction with the U4/U6.U5 tri-snRNP and thus the transition to a 
pre-catalytic B complex is inhibited. Investigations of the protein composition of the 37S cross-intron 
complex by mass spectrometry and 2D gel-electrophoresis revealed distinct differences compared to 
the B complex, in particular the lack of the B complex-specific proteins. Surprisingly, the 37S cross-
intron complex is compositionally very similar to the 37S exon complex, indicating that the exon- and 
intron-defined assembly pathways both involve a similar intermediate where U4/U6.U5 tri-snRNP 
has docked, but is not yet stably-integrated. However, structural investigation of the 37S cross-intron 
complex identified differences in its appearance in comparison to the 37S exon complex, suggesting 
that despite their similar protein inventory, the organization of these complexes is different.  
The addition in trans of an accessible 5’ss in the form of a short RNA oligonucleotide to the splicing 
reaction resulted in the formation of a stable B complex, even in presence of the dominant-negative 
hPrp28 mutant. These results show that the 37S cross-intron complex is competent for stable 
B complex formation, but due to the lack of an accessible 5’ss that can interact with the U4/U6.U5 
tri-snRNP, the stable integration of the latter cannot occur. The stable integration of the U4/U6.U5 
tri-snRNP is also supported by addition of the 5’ss sequence to an affinity-purified 37S cross-intron 
complex, showing that all factors required for the stable integration of the U4/U6.U5 tri-snRNP are 
already present in the this complex. EM analyses of this stabilized cross-intron complex revealed 
structural features similar to those of the 37S exon complex after addition of the 
5’ss oligonucleotide, showing that the conformational remodeling that occurs during stable 
U4/U6.U5 tri-snRNP binding, leads to a nearly identical architecture of both complexes. These results 
indicate that the exon- and intron-defined assembly pathway of the spliceosome converge at the 
stage where the 37S complexes become committed to a 5’ss sequence via interaction with the 
U4/U6.U5 tri-snRNP. In summary, our studies provide new insights into the mechanisms underlying 
the stable association of the U4/U6.U5 tri-snRNP during B complex formation, which is a prerequisite 







1.1 Pre-mRNA splicing 
Most eukaryotic genes are first transcribed into a pre-mRNA, which contains protein-coding exon and 
non-coding intron sequences. During a process called splicing, the intronic sequences are excised 
from the pre-mRNA and the exons are ligated together in order to generate mature mRNAs. Pre-
mRNA splicing is catalyzed by the spliceosome, an elaborate and highly dynamic molecular machine 
that assembles de novo for each round of splicing [reviewed in Wahl et al., 2009, Will and Lührmann, 
2011].  
The most challenging task of a spliceosome is to identify the precise boundaries of an exon to avoid 
the production of aberrant mRNAs. Thus, pre-mRNA introns are characterized by short, conserved 
sequences, so-called splice sites, which define the ends of the intron (Figure 1.1). These conserved 
motifs are recognized by components of the spliceosome and initiate its assembly on the pre-mRNA. 
The 5’splice site (5’ss) sequence defines the boundary between an exon and a downstream intron, 
and is composed of AG/GURAGU in Homo sapiens (H. sapiens), where R stands for a purine (G or A) 
and ‘/’ indicates the exon/intron boundary [Zhang, 1998]. In Saccharomyces cerevisiae (S. cerevisiae) 
this sequence is composed of GUAUGU and is highly conserved with a sequence identity of more 
than 90 % [Lopez and Seraphin, 1999]. The 3’splice site (3’ss) sequence defines the boundary 
between an intron and the downstream exon, and in H. sapiens as well as in S. cerevisiae, it is 
composed of YAG, where Y stands for a pyrimidine (C or U) [Lopez and Seraphin, 1999]. Additionally, 
a conserved sequence element surrounds the adenosine that forms a branched intermediate during 
the first step of splicing. This sequence is therefore called the branch point sequence (BPS).  
 
Figure 1.1: Conserved splicing signals from H. sapiens and S. cerevisiae 
Schematic representation of conserved consensus sequences defining an intron. The branch point adenosine is 





In human pre-mRNAs the branch point is usually located 18-40 nucleotides (nts) upstream of the 3’ss 
and is defined by YURAY, where the branch point adenosine is underlined [Zhang, 1998]. In contrast, 
the yeast consensus sequence of the BPS is UACUAAC and the BP adenosine is usually located 10-40 
nucleotides upstream of the 3’ss [Spingola et al., 1999]. Additionally, most human introns contain a 
pyrimidine-rich region called the polypyrimidine tract (PPT), which is located between the branch 
point sequence and the 3’splice site. The PPT helps to recruit and stabilize the binding of 
spliceosomal factors and is an important splicing element in humans. 
1.2 The two step mechanism of splicing 
The excision of pre-mRNA introns is facilitated by two consecutive transesterification reactions 
[Moore and Sharp, 1993]. In the first reaction the 2’hydroxyl group of the branch point adenosine 
performs a nucleophilic attack at the phosphodiester bond of the 5’ss.  
 
Figure 1.2: Chemistry of the splicing reaction 
Two consecutive transesterification reactions lead to the excision of the intron with a lariat structure and the 





The cleavage of the pre-mRNA generates a free 5’exon and a lariat intermediate, in which the BP 
adenosine and the guanosine at the 5’end of the intron are connected by a 2’-5’phosphodiester-
bond. In the second step, the free 3’hydroxyl group of the 5’exon attacks the 3’ss resulting in the 
excision of the intron lariat and ligation of the 5’ and 3’exon to form the mature mRNA. The same 
reaction mechanism is used during the splicing of group II introns, since exactly the same 
intermediates and products are generated. Group II introns are self-splicing ribozymes that catalyze 
their own excision from pre-mRNAs [Pyle and Lambowitz, 2006]. Although the two step reaction is 
essentially iso-energetic, splicing is ATP-dependent because several factors necessary for the 
formation of the spliceosome and its structural rearrangements during catalysis require ATP for their 
function (see chapter 1.6). 
1.3 Alternative splicing enhances the proteome post-transcriptionally 
Alternative splicing plays a central role in eukaryotic gene expression and it is a key process in 
extending the coding potential of a genome post-transcritionally. In S. cerevisiae only ~3 % of the 
genes contain introns and the majority of these genes contain only a single intron that is usually a 
few hundred nucleotides in length [Barrass and Beggs, 2003, Spingola et al., 1999]. In contrast, 
human genes contain on average four introns per gene and a single intron can be one hundred 
thousand nucleotides in length [Deutsch and Long, 1999]. The average length of vertebrate exons is 
only ~137 nts and generally does not exceed more than 400 nts [Berget, 1995]. Thus, pre-mRNAs of 
higher eukaryotes are characterized by a mosaic-like structure, in which short exons are interrupted 
by much longer introns. In pre-mRNAs with multiple introns, different sets of exons can be joined in a 
process called alternative splicing. Alternative splicing enhances the number of mature mRNAs that 
are generated from a single gene and can result in translation of numerous protein variants with 
different functions. This post-transcriptional modification of the pre-mRNA sequence is a ubiquitous 
mechanism of pre-mRNA processing in higher eukaryotes, since more than 90 % of the human pre-
mRNAs are spliced alternatively [Wang et al., 2008]. The majority of alternative splicing events 
involve exon skipping (Figure 1.3, 1), in which an exon and its flanking introns are excluded from the 
mature mRNA by joining the direct upstream and downstream exons instead [reviewed in Keren et 
al., 2010]. Alternatively, sections of individual exons can be excluded or included from the mRNA by 
recognition and use of alternative 5’ss or 3’ss within the respective exon (Figure 1.3, 2 & 3). Further, 
the inhibition of spliceosome assembly or masking of 5’ss and 3’ss signals can result in the retention 
of intronic sequences within the mature mRNA (Figure 1.3, 4). In rare cases pre-mRNAs contain 
mutually exclusive exons resulting in splicing products that include either one or another exon, but 





Figure 1.3: Modes of alternative splicing 
Schematic representation of different modes of alternative splicing: (1) Exon skipping accounts for the majority 
of alternative splicing events. In this process an exon and its surrounding introns are spliced out from the pre-
mRNA. (2 & 3) An exon can contain more than one 5’ss or 3’ss, respectively. The use of these alternative 5’ or 
3’ss results in the exclusion or inclusion of partial exon segments in the mature mRNA. (4) Additionally, an 
entire intron can be retained in the mature transcript. (5) Two exons are mutually excluded from being in the 
mature mRNA. Constitutively spliced 5’ and 3’exons are indicated as blue and red boxes, respectively. 
Alternatively spliced regions are represented by grey boxes and introns are shown as solid lines. Dashed lines 
indicate splicing options. The figure was adapted from Keren et al. [Keren et al., 2010]. 
 
Alternative splicing of pre-mRNAs is modulated by auxiliary regulatory elements that either enhance 
or inhibit exon recognition. These exonic and intronic splicing enhancers (ESEs and ISEs) and silencers 
(ESSs and ISSs) are supplementary cis-acting elements that recruit regulatory proteins, which then 
stimulate or repress spliceosome assembly. In addition to their crucial role in alternative splicing, 
these regulatory elements can also act on constitutive splicing [reviewed in Black, 2003]. 
1.4 Composition of spliceosomal snRNPs 
The major, U2-dependent spliceosome is formed by the interaction of five snRNPs (U1, U2, U4, U5 & 
U6). Each snRNP particle is comprised of a uridine-rich small nuclear RNA (U snRNA) and a variable 




dependent spliceosome. This distinct spliceosome is composed of the U11, U12, U4atac and U6atac 
snRNPs, which are functional analogues of the U1, U2, U4 and U6 snRNPs, respectively [Will and 
Lührmann, 2005]. Thus, only the U5 snRNP is common to both spliceosomes. 
 
Figure 1.4: Sequences and conserved secondary structures of the spliceosomal snRNAs from H. sapiens 




The major spliceosomal RNAs can be divided into the Sm- and Sm-like (LSm) class of snRNAs based on 
their biogenesis and maturation. The Sm class is comprised of the U1, U2, U4 and U5 snRNAs. These 
snRNAs are transcribed by the RNA polymerase II as a precursor molecule containing a m7G-cap and 
undergo multiple maturation steps including export to the cytoplasm [reviewed in Matera et al., 
2007, Matera and Wang, 2014]. The maturation of these snRNAs requires export to the cytoplasm, 
where the Sm-proteins B, D1, D2, D3, E, F and G are assembled on a uridine-rich stretch of the 
respective snRNA in a ring-like structure. Following the assembly of the Sm-ring, the m7G-cap is 
hypermethylated to a 2, 2, 7-trimethylguanosine-cap and the 3’end of the snRNAs is trimmed. The 
Sm-core and the hypermethylated-cap induce then the re-import of the spliceosomal snRNAs into 
the nucleus, where the assembly of snRNA-specific proteins with the respective snRNA occurs.  
The U6 snRNA belongs to the LSm-class of snRNAs. It is transcribed by the RNA polymerase III, whose 
transcripts are characterized by a γ-monomethyl-cap. The U6 snRNA does not contain a Sm-ring, but 
seven LSm (LSm 2-8) proteins assemble also in a ring-like structure at its 3’end. The biogenesis and 
maturation of U6 snRNA occurs thereby completely in the nucleus. 
The snRNAs are characterized by extensive secondary structures and these structures are highly 
conserved in higher eukaryotes. The proposed secondary structures of the human snRNAs within 
their respective snRNPs are shown in figure 1.4, but several of these structures are rearranged during 
spliceosome assembly (see chapter 1.7). Notably, the U4 and U6 snRNAs are partially complementary 
to each other and therefore base pair within the U4/U6 di-snRNP via stem I and stem II [Brow and 
Guthrie, 1988].  
1.5 Protein inventory of the human snRNPs 
Each U snRNP contains, besides the Sm or LSm proteins, its own specific set of proteins. The human 
U1 snRNP contains only three additional proteins, namely U1-70K, U1-A and U1-C, and acquires 
thereby a Svedberg value (S-value) of 12S. U1-C is involved in stabilization of base pairing interactions 
between U1 snRNA and the 5’splice site of the pre-mRNA [Heinrichs et al., 1990], whereas U1-70K 
interacts with SR proteins to stabilize the interaction of U1 snRNP with the pre-mRNA [Kohtz et al., 
1994]. 
The 17S U2 snRNP is composed of U2A’, U2B’’ and the heteromeric subcomplexes SF3a and SF3b. 
The SF3a and SF3b proteins help to stabilize the base pairing between the U2 snRNA and the BPS by 
interactions with the pre-mRNA around the branch point [Gozani et al., 1996, Valcarcel et al., 1996], 
whereas SF3b14a directly interacts with the branch point adenosine [Will et al., 2001]. Furthermore, 




17S U2 snRNP, including hPrp43, SPF45, SPF30, SPF31, SR140, CHERP, PUF60, hPrp5 and the 
U2AF65/35 heterodimer [Will et al. 2002]. 
The 20S U5 snRNP contains the eight specific proteins hPrp8, hBrr2, hSnu114, hPrp6, hPrp28, hLin1, 
40K and hDib1 [Bach et al., 1989]. The factor hPrp8 is the largest protein in the spliceosome and was 
shown to contact the 5’ss, 3’ss and the BPS at different points of the splicing cycle [Reyes et al., 1996, 
Reyes et al., 1999, McPheeters and Muhlenkamp, 2003, Teigelkamp et al., 1995a, b]. The U5-specific 
proteins hPrp28 and hBrr2 are helicases that were identified to be essential for formation of a pre-
catalytic spliceosome and its subsequent activation, respectively [Mathew et al., 2008, Raghunathan 
and Guthrie, 1998]. The U5-specific proteins hPrp8 and hSnu114 have been shown to regulate hBrr2 
activity [Small et al., 2006, Mozaffari-Jovin et al., 2012, Mozaffari-Jovin et al., 2013].  
 
Figure 1.5: Protein composition of the human snRNPs 
Typical snRNP complexes are represented as colored circles and the S-value of each snRNP is shown on top. 
Shown below are the abundant factors associated with the U snRNPs including the Sm or Sm-like proteins.  
 
The U4/U6 di-snRNP is associated with the five specific proteins hPrp3, hPrp31, hPrp4, CypH and 
15.5K, resulting in an S-value of 13S [Behrens and Lührmann, 1991, Lauber et al., 1997]. Upon 
association of the 13S U4/U6 di-snRNP with the 20S U5 snRNP the 25S U4/U6.U5 tri-snRNP is formed, 
which additionally contains the three proteins hSnu66, hSad1 and 27K [Behrens and Lührmann, 
1991]. The U5-specific protein hLin1 is proposed to play a role during assembly of this 25S particle 
and is not present in the mature U4/U6.U5 tri-snRNP [Laggerbauer et al., 2005]. Since no interactions 
between the U5 and U4/U6 snRNAs are known, the assembly of the U4/U6.U5 tri-snRNP appears to 




role in assembly of the U4/U6.U5 tri-snRNP, as depletion of either protein abolishes U4/U6.U5 tri-
snRNP formation in vitro and in vivo [Makarova et al., 2002, Schaffert et al., 2004].  
1.6 Stepwise assembly of the spliceosome 
Spliceosome assembly occurs by the ordered interaction of the five snRNPs and numerous splicing 
factors with the pre-mRNA and proceeds sequentially with distinct intermediate stages, i.e. the E, A, 
B, Bact, B* and C complex [reviewed in Will and Lührmann, 2011]. Thereby, the spliceosome 
assembles anew onto each intron and rebuilds its catalytic center during each splicing cycle. The 
dynamic assembly and disassembly of the spliceosome requires the function of eight conserved 
DExH/D ATPases/helicases, whose detailed function is described in chapter 1.9.  
The stepwise assembly of the spliceosome is initiated by recognition of the 5’ss by the U1 snRNP 
(Figure 1.6). The U1 snRNA base pairs with the 5’ss of the pre-mRNA and U1 snRNP proteins stabilize 
this interaction. At the same time, SF1 and U2AF65/35 interact with the BPS and the PPT/3’ss, 
respectively [Heinrichs et al., 1990, Berglund et al., 1997, Ruskin et al., 1988]. Together, these 
interactions lead to formation of the E complex and already in this initial state of spliceosome 
assembly the conserved splicing signals of the pre-mRNA are recognized. The U2 snRNP is also 
associated with the E complex, but an ATP-dependent rearrangement mediated by the helicase Prp5 
is required to establish interactions between U2 snRNP and the BPS, which results then in formation 
of the A complex [Das et al., 2000, Dalbadie-McFarland and Abelson, 1990, Fleckner et al., 1997]. 
These interactions involve base pairing of the U2 snRNA with the BPS, which leads to bulging out of 
the BP adenosine, and interactions of the U2-associated SF3a and SF3b proteins near the BPS. The BP 
adenosine is directly contacted by the SF3b14a protein [Query et al., 1994, Will et al., 2001]. 
Moreover, SF3b155 not only interacts with the pre-mRNA, but also with the auxiliary factor U2AF65 
to stabilize the binding of U2 snRNP to the pre-mRNA [Gozani et al., 1998]. Thus, multiple 
recognitions of splicing signals is a general mechanism of spliceosome assembly and splicing catalysis 
that ensures the accuracy of this process. 
The spliceosomal B complex is formed upon association and stable binding of the pre-assembled 
U4/U6.U5 tri-snRNP with the A complex. The stable integration of the U4/U6.U5 tri-snRNP is 
mediated by the DEAD-box helicase Prp28, which destabilizes the interaction between the 5’ss and 
U1 snRNP, and enables an interaction of the 5’ss and the ACAGAG box of U6 snRNA [Staley and 
Guthrie, 1999, Mathew et al., 2008]. During stabilization of the B complex the U4/U6.U5 tri-snRNP 
associated factors hPrp31 and hPrp6 are phosphorylated by the hPrp4 kinase, which was shown to 
be essential for pre-mRNA splicing in vitro [Schneider et al., 2010b]. Although all spliceosomal 





Figure 1.6: Stepwise assembly of the human spliceosome 
Schematic representation of spliceosome assembly and disassembly during one splicing cycle. For simplicity the 
U snRNPs are represented as circles labeled with its respective U snRNA. The spliceosomal complexes are 
named according to the metazoan nomenclature. The eight conserved DExD/H-box ATPases/helicases, which 
are required for important RNP remodeling events, are indicated and their function is described in detail in 
chapter 1.9. Exons and introns are indicated as colored boxes or bold lines, respectively. Recycling of snRNPs is 
indicated by grey arrows [modified from Will and Lührmann, 2011]. 
 
During activation of the spliceosome the B complex undergoes major conformational and 
compositional rearrangements, which are accompanied by the release of the U1 and U4 snRNPs and 
recruitment of additional factors to form the Bact complex. The action of Prp2 transforms the 
spliceosome into a catalytically activated state, forming the B* complex that carries out the first step 
of splicing. The first step of splicing results in formation of the C complex, which contains the cleaved 
5’exon and the exon-intron lariat intermediate. Upon action of Prp16, the spliceosome undergoes a 
second structural rearrangement, which activates the complex for the second step of splicing. During 
the second step, the lariat intron is excised and the 5’ and 3’exons are ligated. Subsequently, the 
post-catalytic spliceosome is disassembled by Prp22 and the mRNA is released in form of an mRNP, 




displaced by the action of Prp43 and recycled for additional rounds of splicing, whereas the intron is 
degraded. 
1.7 The dynamic RNA-RNA network in the spliceosome 
The stepwise assembly of the spliceosome requires major structural rearrangements during the 
formation of its catalytic site. These conversions involve extensive changes in pre-mRNA-snRNA and 
snRNA-snRNA interactions underlining the highly dynamic nature of the RNA network within the 
spliceosome [reviewed in Wahl et al., 2009, Will and Lührmann, 2011]. Spliceosome assembly is 
initiated by the recognition of the 5’ss through base pairing interactions with the 5’end of U1 snRNA 
(Figure 1.7, blue). Subsequently, the U2 snRNA forms a short helix with the BPS (U2/BPS helix, 
turquoise), in which the BP adenosine is branched out (A complex). Then, the pre-assembled 
U4/U6.U5 tri-snRNP is recruited to the A complex resulting in formation of a pre-catalytic 
spliceosome. At this time the 3’end of U6 snRNA forms a short helix (U2/U6 helix II, purple) with the 
5’end of U2 [Nilsen, 1998]. The U4 and U6 snRNAs are still extensively base paired via U4/U6 stem I 
and stem II within the U4/U6.U5 tri-snRNP [Brow and Guthrie, 1998]. 
Upon activation of the spliceosome, a major remodeling of RNA-RNA interactions occurs in order to 
position the 5’ss and the branch point in a proper orientation for the first catalytic step of splicing. 
First, the U1 snRNA interaction with the 5’ss is replaced by base pairing of the 5’ss with the 
conserved ACAGAGA box of U6 snRNA (orange) [Staley and Guthrie, 1999]. Next the extensive base 
pairing of U4 and U6 snRNA is disrupted. Consequently, the U4 snRNA is displaced and a complex 
network of interactions between the U2 and U6 snRNA is formed (U2/U6 helix Ia and Ib, red) 
[Anokhina et al., 2013]. Thus, especially U2/U6 interactions appear to be highly dynamic and the 
RNA-RNA network mainly established by these snRNAs is believed to play a crucial role in splicing 
catalysis [Fica et al., 2013]. At this time, the U6 snRNA also forms an intramolecular stem-loop 
(U6 ISL, green), which is essential for the binding of a catalytically important metal ion [Yean et al., 
2000]. The contribution of the U6 ISL to splicing catalysis underscores the importance of the initial 
U4/U6 base pairing interaction, since catalytically important sequences of U6 snRNA are delivered in 
an inactive form, while still base paired. Thus, the U4 snRNA may act as a chaperone for U6 snRNA to 
prevent premature catalysis. Furthermore, the stem loop I of U5 snRNA interacts with the 5’exon and 
at a later stage of splicing additional interactions with the 3’exon are established [reviewed by Turner 
et al., 2004]. Thus, the U5 snRNA keeps both exons in close proximity and might align them for the 





Figure 1.7: Rearrangements of the RNA-RNA network during formation of a catalytically activated 
spliceosome 
Schematic representation of the rearrangement of RNA-RNA interactions during formation of a catalytically 
activated spliceosome. In the pre-spliceosome, U1 snRNA is base paired with the 5’ss (blue), while U2 snRNA 
interacts with the BPS (turquoise). The branch point adenosine is bulged out (bold). Upon recruitment of the 
U4/U6.U5 tri-snRNP, initial contacts between U6 and U2 snRNA via helix II (pink) are established. Subsequently, 
the base pairing between U1 snRNA and the 5’ss is disrupted and replaced by interactions of the 5’ss with the 
conserved ACAGAG motif of U6 snRNA (orange). Furthermore, the base pairing between U4 and U6 snRNA is 
disrupted, leading then to an extensive base pairing between U2 and U6 snRNA via helix Ia and Ib (red), as well 
as formation of an internal-stem loop (ILS) of U6 snRNA (green). The U2 snRNA remains base paired with the 
BPS and U5 snRNA contacts nucleotides of the exon. Exons are represented as dark grey boxes and introns are 
shown as a black line. 
 
The reaction mechanism of the spliceosome is identical to self-splicing group II introns, which do not 
require trans-acting factors for catalysis of splicing. However, spliceosome-mediated excision of 
introns requires proteins and ATP to facilitate splicing catalysis. Until recently it was not clear if the 
spliceosome uses an RNA-based or protein-mediated splicing mechanism. Compelling evidence that 
the spliceosome’s active site is composed of RNA first came from the crystal structure of a self-
splicing group II intron [Toor et al., 2008]. These studies revealed that the structural motifs shared by 
U6 snRNA and group II introns form the basis of the group II intron active site. Most recently, an 
elegant biochemical approach using metal rescue experiments provided compelling evidence that 
structures formed by U2/U6 snRNA, in particular U6 snRNA, are important for both steps of pre-




1.8 Dynamics of the spliceosome’s protein composition 
Spliceosome assembly and recycling of spliceosomal components involves not only extensive 
remodeling of RNA-RNA interactions, but also the protein composition of the spliceosome undergoes 
dramatic changes. Initial characterization of the spliceosome’s protein inventory via mass 
spectrometry indicated that more than 300 proteins interact with the spliceosome during its 
assembly and catalytic action [Rappsilber et al., 2002]. But these initial experiments analyzed a 
mixture of all assembly stages, i.e. E, A, B, C and mRNP complexes. 
However, characterization of the protein composition of these distinct intermediates is necessary to 
elucidate the recruitment and exchange of proteins, and assign splicing factors to a particular 
assembly or functional stage of the spliceosome. The purification of in vitro assembled splicing 
complexes with subsequent analysis of their protein compositions by mass spectrometry allowed a 
comprehensive insight into distinct human spliceosomal complexes, i.e. the A, B, Bact and 
C complexes, under comparable biochemical conditions [Behzadnia et al., 2007, Deckert et al., 2006, 
Bessonov et al., 2010]. These analyses revealed for the first time the protein dynamics of the 
spliceosome, i.e. the exchange of proteins, upon transition from one assembly/functional state to the 
next, and revealed that approximately 170 proteins are components of the human spliceosome, with 
individual complexes containing up to 120 proteins [reviewed in Wahl et al., 2009, Will and 
Lührmann, 2011]. Spliceosome-associated proteins include proteins of the U snRNPs plus a multitude 
of additional factors, which are not stably bound to purified U snRNPs and interact with the 
spliceosome either alone or as part of pre-formed protein complexes (Figure 1.8). These non-snRNP 
proteins interact either with one distinct assembly intermediate of the spliceosome or are integrated 
into a specific complex and are present throughout several stages of the splicing cycle.  
An example of a pre-formed subcomplex of the spliceosome is the Prp19 complex, which was shown 
to be essential for splicing by genetic studies in yeast [Ruby and Abelson, 1991, Tarn et al., 1994]. The 
human counterpart of the Prp19 complex is composed of seven proteins and plays an essential role 
in the activation of the spliceosome for the first step of splicing [Makarov et al., 2002, Makarova et 
al., 2004]. In the human spliceosome, several factors are considered to be related to the Prp19 
complex, because they were found together with Prp19 in the post-spliceosomal 35S U5 snRNP 
particle [Makarov et al., 2002]. Another non-snRNP protein complex is the trimeric RES (retention 
and splicing) complex that was identified in S. cerevisiae and enhances pre-mRNA splicing and 





Figure 1.8: Compositional dynamics of the human spliceosome  
The protein composition of the human B, B
act
 and C complexes based on 2D gel-electrophoresis and mass 
spectrometry analysis is shown. The relative abundance of proteins is indicated by bold (stoichiometric 
amounts) or light (substoichiometric amounts) lettering. Proteins are grouped according to snRNP association, 
function, presence in a stable heteromeric complex or association with a particular spliceosomal complex, as 






In human, homologs of the RES complex proteins were shown to be associated with the B, Bact and 
C complex [Bessonov et al., 2010], but their role in the human spliceosome is not yet clear. During 
the later steps of the splicing cycle, the heteromeric exon junction complex (EJC) is assembled onto 
the pre-mRNA, approximately 24 nts upstream of the splice junction, and stays bound to the 
processed mRNA even after its release from the post-catalytic spliceosome [reviewed in Le Hir and 
Seraphin, 2008]. The EJC is important for the quality control and export of the mature mRNA and is 
stripped from the mRNA during the first round of translation. 
Mass spectrometry and 2D gel-electrophoresis of affinity-purified spliceosomal complexes showed 
that upon stable integration of the U4/U6.U5 tri-snRNP within the spliceosome and formation of a 
pre-catalytic B complex, the proteins RED, MFAP1, FBP21, hSmu-1, hPrp38 and hSnu23 are recruited 
to the complex. These proteins are associated solely with the B complex, i.e. they are B complex-
specific proteins, being displaced upon activation of the spliceosome and transition to the 
Bact complex. The role of these proteins in the assembly of the spliceosome is presently not clear. 
Kinetically-assembled B complexes also contain proteins of the Prp19 complex [Deckert et al., 2006, 
Bessonov et al., 2010], but these factors are not essential for its formation, since the B complex is 
also formed in nuclear extract, in which the Prp19 complex was depleted [Makarova et al., 2004]. 
During transition from the pre-catalytic B complex to an activated spliceosome ~25 proteins are 
displaced from the spliceosome, among others the B complex-specific proteins along with the U4/U6 
snRNP and U4/U6.U5 tri-snRNP-specific proteins. Upon formation of the Bact complex ~20 proteins 
are recruited to the spliceosome, especially proteins associated with or related to the Prp19 
complex. During the transition from the Bact to the C complex, ~25 proteins leave the complex, while 
~20 proteins join the spliceosome, mainly the so-called C complex-specific proteins.  
In yeast ~90 proteins were shown to be associated with the spliceosome, while individual assembly 
intermediates contain ~50-60 proteins [Fabrizio et al., 2009]. Nearly all of these proteins have 
homologs in human and thus likely represent conserved factors of the spliceosomal core machinery.  
1.9 The role of RNA helicases in splicing 
During assembly, activation and disassembly of the spliceosome, RNA helicases act as key factors by 
mediating rearrangements in RNA-RNA or protein-RNA interactions. Eight conserved DExD/H-box 
ATPases/helicases, namely UAP56, Prp5, Prp28, Brr2, Prp2, Prp16, Prp22 and Prp43, are essential for 
rearrangements of RNA-RNA interactions and the remodeling of snRNPs during a single splicing cycle 
[reviewed in Staley and Guthrie, 1998]. These proteins couple the energy of ATP hydrolysis to 
structural and/or compositional rearrangements in the spliceosome at distinct steps of the splicing 




reaction, ensuring the fidelity of the splicing process [Semlow and Staley, 2012]. Most of these 
enzymes interact only transiently with the spliceosome, but nonetheless act as important molecular 
switches during spliceosome reaction. Brr2, in contrast, associates already in the B complex and 
remains associated until the spliceosome dissociates [Makarov et al., 2002]. Thus, a tight regulation 
of Brr2’s activation is required to prevent its pre-mature activation, a task carried out in part by other 
spliceosomal components and also modulated in some cases by posttranslational modifications.  
During the initial stages of the splicing cycle, Prp5 and UAP56 are required for the transition from the 
E to A complex by displacing SF1 from the BPS and rearranging U2 snRNA to enable its base pairing 
with the BPS [Dalbadie-McFarland and Abelson, 1990, Fleckner et al., 1997]. Then, Prp28 mediates 
the transition from the A to B complex, in which the U4/U6.U5 tri-snRNP is stably-integrated within 
the spliceosome. Genetic studies in S. cerevisiae have shown that Prp28 plays an essential role in 
destabilization of the U1:5’ss duplex, potentially by weakening the interaction of U1-specific proteins 
with the U1:5’ss helix [Staley and Guthrie, 1999, Chen et al., 2001]. Destabilization of the U1:5’ss 
interaction is required to allow an exchange of U1 for U6 snRNA interaction with the 5’ss of a pre-
mRNA. In S. cerevisiae, Prp28 interacts only transiently with the spliceosome, whereas the human 
homolog, hPrp28, is an integral component of the U4/U6.U5 tri-snRNP. It was shown that SRPK2-
mediated phosphorylation of hPrp28 is necessary for its integration into the U4/U6.U5 tri-snRNP and 
only a U4/U6.U5 tri-snRNP containing hPrp28 is competent for stable B complex formation [Mathew 
et al., 2008]. 
After the stable integration of the U4/U6.U5 tri-snRNP within the B complex, the action of Brr2 leads 
to a subsequent disruption of the U4/U6 base pairing interaction to allow annealing of U6 with 
U2 snRNA and the formation of the catalytically important U6 ISL [Laggerbauer et al., 1998, 
Raghunathan and Guthrie, 1998]. Brr2 is an integral component of the U4/U6.U5 tri-snRNP both in 
human and in yeast and since its substrate, namely the U4/U6 di-snRNP, is also present in the 
U4/U6.U5 tri-snRNP, the activation of Brr2 has to be precisely regulated to avoid pre-mature 
disruption of U4/U6 base pairing and thereby pre-mature activation of the U6 snRNA. The activity of 
Brr2 is regulated by the U5-specific proteins Prp8 and Snu114. The GTPase Snu114 blocks Brr2’s 
helicase activity when it is in a GDP-bound state, whereas Snu114’s GTP-bound form promotes 
helicase activity [Small et al. 2006]. Recently, it was shown that the C-terminal end of Prp8 can 
reversibly block the RNA-binding channel of Brr2 and thereby controls U4/U6 unwinding activity of 
Brr2 [Maeder et al., 2009, Mozaffari-Jovin et al., 2013]. Additionally, the RNase H domain of Prp8 
competes with Brr2 for binding to its substrate, showing that Brr2 activity is regulated in multiple 




In a subsequent step, the Bact complex is remodeled by Prp2 in cooperation with its co-factors Spp2 
and Cwc25 to catalytically activate the spliceosome for the first step of splicing [Kim and Lin, 1996, 
Warkocki et al., 2009]. Recent studies in S. cerevisiae indicate that Prp2 destabilizes and/or 
rearranges the U2-associated SF3a and SF3b proteins in the spliceosome to position the BP 
adenosine for its nucleophilic attack on the 5’ss [Warkocki et al., 2009]. The cleavage of the pre-
mRNA at the 5’ss results then in formation of the C complex, which contains the free 5’exon and the 
intron-lariat intermediate. In a subsequent step, Prp16 remodels the catalytic core of the C complex 
to generate a conformation that can catalyze the second step of splicing [Schwer and Guthrie, 1992, 
Ohrt et al., 2013]. After excision of the intron, release of the mature mRNA from the post-catalytic 
spliceosome is facilitated by Prp22 [Fourmann et al., 2013]. In the final step, Prp43 catalyzes the 
disassembly of the intron-lariat spliceosome. The Ntr1/Ntr2 heterodimer acts as a co-factor of Prp43 
to stimulate the release of the excised lariat-intron [Martin et al., 2002, Tsai et al., 2005, Fourmann 
et al., 2013]. The free intron is then degraded and the spliceosomal factors are recycled for the next 
round of splicing. 
1.10 Structure of spliceosomal complexes 
Although the composition of the spliceosome’s various assembly and functional states have been 
characterized in detail, less is known about the structure of the spliceosome. The size and structural 
variability of the spliceosome make it a particularly challenging object for structural studies [Newman 
and Nagai, 2010]. In recent years substantial progress has been made towards high resolution 
structure determination of large multi-component spliceosomal subunits, such as the human 
U1 snRNP, whose structure has been determined down to the atomic level [Pomeranz Krummel et 
al., 2009, Weber et al., 2010]. But aside from the U1 snRNP, high resolution structures generated by 
X-ray crystallography or NMR are restricted to individual proteins or single components of the 
spliceosome. Due to the complexity of the spliceosome and its highly dynamic character, to date it 
has not been possible to crystallize any spliceosomal assembly intermediates. Thus, electron 
microscopy (EM) is still the state of the art method to elucidate the 3D structure of the spliceosome 
and its structural dynamics during the transition from one intermediate to another [Lührmann and 
Stark, 2009]. Indeed, cryo-EM has provided valuable insights into the three-dimensional global shape 
of the splicing machinery [Golas et al., 2010]. Nevertheless, EM investigation of the spliceosome is 
also challenging as this protein-rich RNP complex is very labile and can easily disintegrate during 
purification and sample preparation. Therefore a method was established, in which the spliceosomal 
complexes are fixed under mild conditions during density-gradient centrifugation (GraFix) in order to 
preserve the structure of the intermediates and overcome the critical limitation of structural 




structural conservation of the complexes and accelerated the structural investigation of spliceosomal 
assembly intermediates significantly. For example, human B complexes prepared under GraFix 
conditions, exhibit a clearly more homogeneous appearance in EM analyses than unfixed 
B complexes [Boehringer et al., 2004, Deckert et al., 2006]. However, the resolution of EM structures 
is currently not good enough to allow a determination of their intrinsic complex organization. Thus, 
the localization of factors within the spliceosomal complexes is required to comprehend how they 
are arranged. A powerful strategy for topographical localization of relevant sites within the 
spliceosome is the specific immunolabeling of these factors and subsequent localization by EM. Using 
this approach, the U2 protein SF3b155 and various sites of the pre-mRNA have been located within 
the human B and C complex, and a comparison of these structures provides a first insight into how 
functionally important areas are rearranged within the spliceosome [Wolf et al., 2009, Wolf et al., 
2012]. Recently, investigations using cryo-EM revealed the three-dimensional architecture of the 
catalytically active C complex and its salt-stable core [Golas et al., 2010]. The location of the 5’exon 
within the C complex was determined by immunolabeling, and by combining different structural data 
including the 3D structure of the 35S U5 snRNP, it was possible to localize the catalytic core within 
the C complex. Thus, structural investigations of the spliceosome provide valuable insights into the 
architecture of functional sites and extend our understanding of how structural rearrangements in 
the spliceosome contribute to its function. 
1.11 Exon definition is an alternative pathway to initiate spliceosome 
assembly 
Pre-mRNAs of higher eukaryotes are characterized by a mosaic-like structure, in which short exons 
are interrupted by long intronic sequences. But the initial assembly of the spliceosome across an 
intron (intron definition) is limited to pre-mRNAs containing very short introns, i.e. less than 300 nts 
[Sterner et al., 1996]. On pre-mRNAs with long intronic sequences, the spliceosome initially 
assembles via an alternative pathway, in which the earliest spliceosomal complex first forms across 
an exon (exon definition) [Berget, 1995]. In fact, exon definition is thought to be the prominent 
pathway of spliceosome assembly for the majority of metazoan pre-mRNAs [Ast, 2004].  
The formation of a spliceosome across an exon is initiated upon base pairing of U1 snRNP to a 
downstream 5’ss, while U2 snRNP and U2AF65/35 interact with an upstream BPS and PPT/3’ss, 
respectively. During this process the boundaries of an exon are initially defined in contrast to the 





Figure 1.9: Molecular interactions during initial spliceosome assembly across an exon 
During initial assembly of an exon-defined, A-like complex, U2 snRNP binds to an upstream BPS and U1 snRNP 
to the downstream 5’ss, while the U2AF65/35 heterodimer interacts with the PPT/3’ss. SR proteins bind to 
exonic splicing enhancers (ESEs) within the exon sequence and bridge interactions with components of the 
general splicing machinery (indicated by red arrows). The polypyrimidine tract is represented by Y(n). 
 
In addition, auxiliary factors, namely SR and hnRNP proteins, bind to ESE or ESS sequences within the 
exon sequence and either support or inhibit exon recognition, respectively [Busch and Hertel, 2012]. 
SR proteins bind to ESE sequences within the exon and support spliceosome assembly by recruiting 
spliceosomal factors to the splice sites or by establishing protein-protein interactions with these 
factors to stabilize their interaction with the pre-mRNA [Lam and Hertel, 2002]. The SR proteins are 
characterized by consecutive RS-rich repeats (RS domain) and these RS domains interact with 
RS domains of spliceosomal factors to enable protein-protein interactions in the initial stages of 
spliceosome assembly. Thus, SR proteins establish a protein-protein network likely involving U1-70K 
and U2AF65/35 that bridges the interaction between U1 and U2 snRNP within the exon-defined A-
like complex (Figure 1.9). In contrast, hnRNP proteins bind to ESS sequences and exhibit in general an 
inhibitory effect on spliceosome assembly by impairing the recruitment of spliceosomal factors to 
the splice sites or inhibiting protein-protein interactions. The antagonistic effect of the activating SR 
and inhibitory hnRNP proteins on spliceosome assembly modulates the probably of inclusion or 
exclusion of an exon during alternative splicing. SR and hnRNP proteins are conserved in higher 
eukaryotes such as H. sapiens, Drosophila melanogaster (D. melanogaster) and Caenorhabditis 
elegans (C. elegans), but not in S. cerevisiae, and their abundance correlates with the amount of 
alternative splicing events that occur in these organisms [Busch and Hertel, 2012]. 
The chemical steps of splicing can only occur across an intron, and thus a rearrangement from the 
exon-defined state to an intron-defined organization must occur to pair the 5’ss and 3’ss of an intron 
(Figure 1.10). Previous studies indicated that commitment to splice site pairing occurs upon 




intron-definition occurs likely prior to the recruitment of the U4/U6.U5 tri-snRNP. But recent studies 
showed that the U4/U6.U5 tri-snRNP can associate with the exon-defined A-like complex resulting in 
formation of a cross-exon complex [Schneider et al., 2010a]. Elegant biochemical data showed that 
the addition of a short RNA oligonucleotide containing a 5’ss induces the formation of a B-like 
complex, which shares similarities with an intron-defined B complex [Schneider et al., 2010]. This 
suggests that the transition to an intron-defined organization can also occur when the U4/U6.U5 tri-
snRNP of the cross-exon complex directly engages an upstream 5’ss and thereby leads to the pairing 
of splice sites across an intron (Figure 1.10). Thus, the exon- and intron-defined pathways of 
spliceosome assembly can converge at later stages of splicing, likely upon formation of a pre-catalytic 
B complex. Afterwards, splicing proceeds with the catalytic activation of the spliceosome and 
catalysis of both splicing reactions to generate a mature mRNA.  
 
Figure 1.10: Alternative assembly pathways of the spliceosome 
Intron and exon definition during spliceosome assembly. In the intron-defined pathway, U1 and U2 snRNPs 
bind to the 5’ss and BPS of the same intron. Upon association of the U4/U6.U5 tri-snRNP a fully-assembled 
B complex is formed. During exon-definition, U2 snRNP interacts with an upstream BPS and the U1 snRNP with 
the downstream 5’ss of an exon. The recruitment of the U4/U6.U5 tri-snRNP results in formation of a cross-
exon complex. After transition to an intron-defined organization, spliceosome assembly proceeds with the 





Various studies showed that assembly of an exon-defined spliceosomal complex and the transition to 
an intron-oriented organization is an important point for the decision whether an exon is included or 
excluded from a mature mRNA during the process of alternative splicing [Bonnal et al., 2008, 
Izquierdo et al., 2005, House and Lynch, 2006, Sharma et al., 2008]. Inhibition of either exon 
recognition or the switch to an intron-defined organization results directly in exon skipping. 
However, the mechanism of the cross-exon to cross-intron transition remains for the most part 
unclear. 
1.12 Aims 
One of the most fascinating design principles of the spliceosome is that it forms its catalytic core 
anew during each round of splicing by the stepwise assembly of five snRNPs and numerous 
additional proteins. The B complex is an assembly intermediate, in which the pre-formed U4/U6.U5 
tri-snRNP is first stably-integrated into the spliceosome. Although much progress has been made in 
characterizing the protein dynamics that occur during splicing, further investigations are necessary to 
elucidate the role of many factors in splicing and their exact time of recruitment to the spliceosome. 
Little is known about which factors are minimally required to stably integrate the U4/U6.U5 tri-
snRNP within the spliceosome and in which order they act to ensure formation of a pre-catalytic 
B complex.  
The U5-specific protein hPrp28 was identified to be essential for the integration of the U4/U6.U5 tri-
snRNP into the B complex and studies from S. cerevisiae provide evidence that this DEAD-box 
helicase enables RNA-RNA interactions between the U4/U6.U5 tri-snRNP and the 5’ss of the pre-
mRNA, which are important for its stable association within the spliceosome [Mathew et al., 2008, 
Staley and Guthrie, 1999]. Upon formation of the human B complex the proteins RED, MFAP1, FBP21, 
hSmu-1, hPrp38 and hSnu23 associate with the spliceosome [Agafonov et al., 2011]. Nevertheless, 
the function of these B complex-specific proteins is currently unknown, in particular whether they 
play a role in stable binding of the U4/U6.U5 tri-snRNP. The U4/U6.U5 tri-snRNP-specific proteins 
hPrp31 and hPrp6 are phosphorylated by the hPrp4 kinase upon stable B complex formation 
[Schneider et al., 2010b]. The depletion of the hPrp4 kinase from the splicing reaction inhibits 
assembly of a stable B complex, suggesting that the phosphorylation of hPrp31 and hPrp6 might be 
necessary for stable association of the U4/U6.U5 tri-snRNP with the spliceosome. However, the 
detailed hierarchy of assembly, i.e. order in which factors are recruited, and the prerequisites for 
stable binding of the U4/U6.U5 tri-snRNP during B complex formation, remain unclear.  
Recently exon-defined spliceosomes were shown to contain the U4/U6.U5 tri-snRNP, providing 




defined B complex [Schneider et al., 2010a]. The addition of a RNA oligonucleotide containing a 5’ss 
induces the formation of a stabilized B-like complex, which shares similarities with an intron-defined 
B complex, including a stably-integrated U4/U6.U5 tri-snRNP. This transformation of the exon 
complex likely mimics the switch from an exon-defined to an intron-defined organization of the 
spliceosome. However, the prerequisites and order of events that occur during the transition from an 
exon-defined to an intron-defined B complex are only poorly understood.  
Thus, I addressed the question which factors constitute the minimum requirement to induce the 
stable integration of the U4/U6.U5 tri-snRNP and assembly of a pre-catalytic B complex. The aim of 
this study was to dissect B complex formation and spliceosome remodeling during the conversion 
from an exon- to intron-defined organization in terms of protein composition and particle 
architecture at the electron microscopy level. Results of these studies will help to elucidate at which 
point exon- and intron-defined assembly pathway converge and will provide valuable insights into 
this decisive step of the spliceosome assembly pathway. Results of this study are expected to provide 
important information about the structural and compositional changes that occur during stable 
integration of the U4/U6.U5 tri-snRNP and B complex formation, which is a prerequisite for the 
activation of the spliceosome. 
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2. Materials and methods 
2.1 Materials 
2.1.1 Chemicals 
Acetic acid        Merck, Germany 
Agarose (low melting point)     Invitrogen, Netherlands 
Agarose        Invitrogen, Netherlands 
Ammonium peroxidisulphate (APS)     Merck, Germany 
Ampicillin        Sigma-Aldrich, Germany 
AMT (4′-aminomethyl-4,5′,8-trimethylpsoralen hydrochloride) Sigma-Aldrich, Germany 
Boric acid        Merck, Germany 
Bovine serum albumin (BSA), acetylated   Sigma-Aldrich, Germany 
Bromphenol blue       Merck, Germany 
Coomassie brilliant blue G-250      Serva, Germany 
Creatine phosphate       Sigma-Aldrich, Germany 
Dimethylsulphoxide (DMSO)      Roth, Germany 
Dipotassiumhydrogenphosphate     Merck, Germany 
Dithiothreitol (DTT)       Roth, Germany 
DNA molecular weight marker      Gibco, New Zealand 
EDTA (Disodium salt dihydrate)     Roth, Germany 
Ethanol        Merck, Germany 
Ethidium bromide       Roche, Germany 
Ficoll        Sigma-Aldrich, Germany 
Fish sperm DNA (10 mg/ml)     Roche, Germany 
Formaldehyde        Merck, Germany 
Formamide        Merck, Germany 
Glutaraldehyde       Electron Microscopy Sciences, USA 
Glycerol        Merck, Germany 
Glycine        Merck, Germany 
Glycoblue        Ambion, USA 
Heparin (sodium salt)       Roth, Germany 
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HEPES (N-2-Hydroxyethylpiperazin-N-2-ethansulfonic acid)  Calbiochem, USA 
Imidazole        Merck, Germany 
IPTG        Merck, Germany 
Lithium chloride      Merck, Germany 
Maltose        Merck, Germany 
Magnesium acetate      Merck, Germany 
Magnesium chloride      Merck, Germany 
Methanol        Merck, Germany 
β-Mercaptoethanol      Roth, Germany 
Milk powder        Heirler, Germany 
MOPS        Invitrogen, Netherlands 
Nonidet P-40 (Igepal CA-630)      Sigma-Aldrich, Germany 
PMSF (Phenylmethylsulfonylfluoride)     Roche, Germany 
Polyvinylpyrrolidone      Sigma-Aldrich, Germany 
Potassium acetate      Merck, Germany 
Potassium chloride       Merck, Germany 
Potassium dihydrogen phosphate     Merck, Germany 
Pre-stained protein-molecular weight marker    Bio-Rad, Germany 
Roti phenol-chloroform-isoamyl alcohol (PCI)    Roth, Germany 
Rotiphorese gel 30 solution      Roth, Germany 
Rotiphorese gel 40 solution      Roth, Germany 
Silver nitrate        Merck, Germany 
Sodium acetate       Merck, Germany  
Sodium carbonate       Merck, Germany  
Sodium chloride      Merck, Germany 
Sodium dodecyl sulfate (SDS)      Serva, Germany 
Sodium thiosulfate      Merck, Germany 
Spermidine       Sigma-Aldrich, Germany 
TEMED (N, N, N’, N’-Tetramethylethylendiamine)   Sigma-Aldrich, Germany 
Tris [Tris-(hydroxymethyl)aminomethane]   Roth, Germany 
Triton X-100        Merck, Germany 
tRNA from E. coli       Boehringer, Germany 
Tween-20        Sigma-Aldrich, Germany 
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Uranyl formate       in-house 
Urea         Merck, Germany 
Xylene cyanol        Fluka, Switzerland 
2.1.2 Chromatography materials and consumables 
Amylose resin        New England Biolabs, Germany 
Cassettes for film exposure      Kodak, USA 
Centrifuge tubes       Beranek, Germany  
Chromatography columns      Bio-Rad, Germany 
Concentrator        Millipore, USA 
Dialysis membranes (MWCO 6000-8000 Da)    SpektraPor, USA 
HisTrap HP, Ni-NTA-Sepharose (5 ml)     GE Healthcare, UK 
NuPAGETM gels (1.5 mm, 4-12%)     Invitrogen, Netherlands 
Nylon membrane Hybond XL      GE Healthcare, UK 
Parafilm        Roth, Germany 
Poly-Prep columns       Bio-Rad, USA 
Protein A-Sepharose CL 4B0      GE Healthcare, UK 
Protran BA 83 nitrocellulose      Whatman, UK 
ProbeQuantTM G-25/ G-50 micro columns    GE Healthcare, UK 
Slide-A-Lyzer dialysis units (MWCO 6 kDa)    Pierce, USA 
Sterile filters (0.2 µm or 0.45 µm)     Sarstedt, Germany 
Superdex 200 (16/60) oder (10/30)     GE Healthcare, Germany 
Surgical blades        Martin, Germany 
Whatman 3MM paper       Whatman, UK 
X-ray films (BioMax MR)      Kodak, USA 
2.1.3 Commerical kits 
BCATM protein assay kit      Pierce, USA 
ECL Western Blot Detection Kit     GE Healthcare, USA 
Prime-It II Random Primer Labeling Kit    Stratagene, USA 
QIAGEN Plasmid Maxi Kit     Qiagen, Germany 
QIAquick® Gel Extraction Kit     Qiagen, Germany 
 




ÄKTA Explorer        GE Healthcare, UK 
ÄKTA Prime        GE Healthcare, UK 
Autoclaves        H+P Labortechnik, Germany 
Biofuge fresco        Kendro, USA 
Biofuge pico        Kendro, USA 
Gel documentation unit      Bio-Rad, Germany 
Gel electrophoresis apparatus      in-house 
Gel dryer model 583       Bio-Rad, Germany 
Gradient master model 106      BioComp Instruments, Canada 
Head-over-tail rotor       Cole-Parmer, USA 
Heating blocks        Eppendorf, Germany 
Hybridization oven      Hybaid Biometra, UK 
LTQ Orbitrap XL      Thermo Fisher Scientific, Germany 
Megafuge 1.0R        Kendro, USA 
Milli-Q-water supply apparatus     Millipore, USA 
PerfectBlue semi-dry electro blotter     PeqLab, Germany 
pH-Meter        Mettler Toledo, Switzerland 
Phosphorimager Typhoon 8600     Amersham Pharmacia, Germany 
Power supply EPS 2A200      Hoefer Pharmacia Biotech, USA 
Power supply EPS 3501/XL      Amersham Pharmacia, Germany 
Q-ToF Ultima mass spectrometer     Waters, USA 
Scintillation counter LS 1701      Packard, USA 
Sorvall HB-6 rotor       Kendro, USA  
Sorvall SA800 AT4 rotor      Kendro, USA 
Sorvall SS-34 rotor       Kendro, USA 
Sorvall TH660 rotor       Kendro, USA 
Sorvall TST41.14 rotor       Kendro, USA 
Speed Vac Konzentrator 5301      Eppendorf, Germany 
Spectrophotometer Nanodrop ND-1000    Thermo Fisher Scientific, Germany 
Spectrophotometer Ultrospec 3000 pro    Amersham Pharmacia, Germany 
SS-34 rotor        Kendro, USA 
Tabletop centrifuge 5415D      Eppendorf, Germany 
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Trans-Blot Cell        Bio-Rad, USA 
Ultracentrifuge Discovery 90      Sorvall/Kendro, USA 
Ultracentrifuge Discovery M150     Sorvall/Kendro, USA 
UV-Stratalinker 2400       Stratagene, USA 
UV lamps (365 nm)       Bachofer, Germany 
Vortex         Janke & Kunkel, Germany 
X-ray film developer X-Omat 2000     Kodak, USA 
2.1.5 Nucleotides 
Nucleoside-5’-triphosphate (100 mM):    Pharmacia, Germany 
ATP, CTP, UTP, GTP 
Deoxynucleoside-5’-triphsophate (100 mM):   Pharmacia, Germany 
dATP, dCTP, dTTP, dGTP 
7-monomethyl-diguanosine triphosphate   Kedar, Poland 
(m7G(5’)ppp(5’)G-cap) 
AMP-PNP       Sigma-Aldrich, Germany 
2.1.6 Radiolabeled nucleotides 
α-32P-UTP [10 µCI/µl, 3000 Ci/mmol]    Perkin-Elmer, Germany 
γ-32P-ATP [10 µCI/µl, 6000 Ci/mmol]    Perkin-Elmer, Germany 
α-32P-dATP [10 µCI/µl, 3000 Ci/mmol]    Perkin-Elmer, Germany 
2.1.7 RNA oligonucleotides 
RNA oligonucleotides were purchased from Eurofins MWG Operon or Sigma-Aldrich. Modifications 
are indicated by brackets. 
Name       Sequence 
5’ss oligonucleotide (wildtype)    AAGGUAAGUAU 
2’O-ribose methylated 5’ss oligonucleotide  [AAGGUAAGUAU]  
U5:5’ss       UUUGUAAGUAU  
U6:5’ss       AAGGUAACAUA  
U5:5’ss + U6:5’ss     UUUGUAACAUA  
-1G → A      AAAGUAAGUAU  
+1G → A      AAGAUAAGUAU  
+2U → A      AAGGAAAGUAU  
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GG → AA      AAAAUAAGUAU  
GU → AA      AAGAAAAGUAU       
GG → rIrI      AA[ribo-inosine][ribo-inosine]UAAGUA  
 (-1) 6-thio-G      AA[6-thio-G]GUAAGUAU    
(+1) 6-thio-G      AAG[6-thio-G]UAAGUAU   
(+2) 4-thio-U      AAGG[4-thio-U]AAGUAU    
2.1.8 Antibodies 
Anti-hPrp8      Dept. Lührmann [Lauber et al., 1996] 
Anti-hSnu66      Dept. Lührmann [Makarova et al., 2001] 
Anti-hPrp31, phospho-specific    Dept. Lührmann [Schneider et al., 2010b] 
Anti-RED      Dept. Lührmann 
Anti-MFAP1      Dept. Lührmann 
Anti-FBP21      Santa Cruz Biotechnology, USA 
Anti-hSmu-1      Santa Cruz Biotechnology, USA 
Anti-hPrp38      Dept. Lührmann 
Anti-hSnu23      Dept. Lührmann 
Anti-His6-tag      Abcam, UK 
Goat-anti-rabbit (horseradish peroxidase coupled) Jackson Immunoresearch, USA 
2.1.9 Enzymes 
Complete protease inhibitor, EDTA-free   Roche, Germany 
Klenow fragment of DNA polymerase I [5 U/µl]  New England Biolabs, Germany 
Proteinase K       Fluka, Switzerland 
Restriction endonucleases     New England Biolabs, Germany 
RNase A [1 mg/ml]     Ambion, USA 
RNase T1 [1 U/µl]     Ambion, USA 
RNasin (RNase inhibitor) [40 U/µl]    Promega, USA 
RQ1 DNase [1 U/µl]     Promega, USA 
T4 Polynucletide kinase (PNK) [10 U/µl]   New England Biolabs, Germany 
T7 RNA polymerase [20 U/µl]    New England Biolabs, Germany 
Yeast inorganic pyrophosphatase (YIPP) [0.1 U/µl] New England Biolabs, Germany 
 




pMINX U2-dependent pre-mRNA construct (MINX) in pSP65-vector under control of 
SP6 promoter, AmpR. [Zillman et al., 1988]. 
pMINX-exon MINX exon-RNA construct in pSP65-vector under control of T7 promoter, 
AmpR. [Schneider et al., 2010]. 
pMS2-MBP   MS2-MBP fusion protein in pMAL vector (NEB), AmpR. 
pET21a-hPrp28  His6-tagged hPrp28 wildtype protein in pET21a vector (S. Möhlmann). 
pET21a-hPrp28-AAAD His6-tagged hPrp28
AAAD protein in pET21a vector (S. Möhlmann). 
2.1.11 Bacteria strains 
E. coli DH5α      Novagen, Germany 
E. coli Rosetta 2 (DE3)     Novagen, Germany 
2.1.12 Cell line 
HeLa S3 cells (human cervical cancer cells)  GBF, Germany 
2.1.13 Buffers 
Commonly used media, buffers and solutions were prepared with deionized water (Millipore) and 
autoclaved if necessary (121 °C, 20 min, 1 bar). Solutions with heat-labile components were filter-
sterilized (0.22 µm). 
Coomassie staining solution: 100 µM Coomassie brilliant blue G-250 
    0.13 mM (v/v) HCl 
100x Denhardt’s solution: 2 % (w/v) Ficoll 400 
    2 % (w/v) Polyvinylpyrrolidone 
    2 % (w/v) BSA 
6x DNA loading dye:  60 % (v/v) glycerol 
10 mM Tris-HCl, pH 7.5 
    60 mM EDTA, pH 8.0 
0.05 % (w/v) bromphenol blue 
    0.05 % (w/v) xylene cyanol 
10x G-75 buffer:  200 mM HEPES 
    0.75 M KCl 
    15 mM MgCl2 
    adjust to pH 7.9 
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10x G-150 buffer:  200 mM HEPES 
    1.5 M KCl 
    15 mM MgCl2 
    adjust to pH 7.9 
1x MC buffer:   10 mM HEPES-KOH, pH 7.6 
    10 mM KOAc 
    0.5 mM MgOAc 
    5 mM DTT 
(add one Complete EDTA-free protease inhibitor cocktail tablet to    
50 ml of 1x MC buffer) 
5x Native gel loading dye: 90 mM Tris 
    90 mM boric acid 
2.5 mM EDTA, pH 8.0 
30 % (v/v) glycerol 
0.05 % (w/v) bromphenol blue 
10X PBS:   1.3 M NaCl 
    200 mM Na2HPO4 
    adjust to pH 7.4 or 8.0 
2x PK buffer:   200 mM Tris-HCl, pH 7.5 
    25 mM EDTA, pH 8.0 
    2 % (w/v) SDS 
Pre-/Hybridisationsbuffer: 25 mM Na2HPO4, pH 6.5 
(for Northern blot)  5x Denhardt’s solution 
    6x SSC 
    50 % (v/v) deionized formamide 
    0.5 % (w/v) SDS 
    100 µg/ml fish sperm DNA 
2x RNA loading dye:  80 % (v/v) formamide 
    1 mM EDTA, pH 8.0 
    0.05 % (w/v) bromphenol blue 
    0.05 % (w/v) xylene cyanol 
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1x Roeder C buffer:  25 % (v/v) glycerol 
    20 mM HEPES-KOH, pH 7.9 
    420 mM NaCl 
    1.5 mM MgCl2 
    0.2 mM EDTA, pH 8.0 
    0.5 mM DTT 
    0.5 mM PMSF 
1x Roeder D buffer:  10 % (v/v) glycerol 
    20 mM HEPES-KOH, pH 7.9 
    100 mM KCl 
    1.5 mM MgCl2 
    0.2 mM EDTA, pH 8.0 
    0.5 mM DTT 
    0.5 mM PMSF 
6x SDS loading dye:  750 mM Tris-HCl, pH 6.8 
    6 % (w/v) SDS 
    30 % (v/v) glycerol 
    0.03 % (w/v) bromophenol blue 
    60 mM DTT 
SDS-PAGE Running buffer: 25 mM Tris-HCl, pH 6.8 
    192 mM glycine 
    1 % (w/v) SDS 
4x Separating gel buffer: 1.5 M Tris 
    0.4 % (w/v) SDS 
    adjust to pH 8.8 
20x SSC:   3 M NaCl 
    0.3 M sodium citrate 
4x Stacking gel buffer:  0.5 M Tris 
    0.4 % (w/v) SDS 
    adjust to pH 6.8 
Stripping buffer:  62.5 mM Tris-HCl, pH 6.7 
100 mM β-mercaptoethanol 
2 % (w/v) SDS 
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10x TBE:   0.89 M Tris 
    0.89 M boric acid 
    25 mM EDTA, pH 8.0 
10x TBS:   200 mM Tris 
    1.37 M NaCl 
    adjust to pH 7.6 
10x TBS-T:   500 mM Tris 
    1.5 M NaCl 
1 % (v/v) Tween-20 
    adjust to pH 7.5 
TNES (RNA extraction buffer): 20 mM Tris-HCl pH 7.5 
    150 mM NaCl 
    0.2 mM EDTA, pH 8.0 
0.5 % (w/v) SDS 
5x TRO buffer:   1 M HEPES-KOH, pH 7.5 
    200 mM DTT 
    160 mM MgCl2 
    10 mM spermidine 
10x Western transfer buffer: 200 mM Tris 
    1.5 M glycine 
  




2.2.1 Molecular biology standard methods 
2.2.1.1 Nucleic acid quantification 
To determine the concentration of nucleic acids the extinction coefficient in an aqueous solution was 
measured at a wavelength of 260 nm and 280 nm in comparison to the corresponding buffer without 
nucleic acids. The ration of OD260/OD280 determined the purity of a nucleic acid solution: 2.0 
corresponded to pure RNA or oligonucleotides and 1.8 to pure DNA. The following equations were 
used to determine the concentrations: 
1 OD260: 50 µg/ml double-stranded DNA 
1 OD260: 33 µg/ml single-stranded DNA 
1 OD260: 40 µg/ml single-stranded RNA 
Lower ratios show contamination with proteins or phenol, which requires an additional PCI 
extraction (2.2.1.2). 
2.2.1.2 PCI extraction 
The phenol-chloroform-isoamyl alcohol (PCI) extraction was used to separate nucleic acids from 
proteins. Phenol and chloroform denature proteins and keep them in the organic phase, while 
nucleic acids stay in the aqueous phase. Reactions were first adjusted to 200 µl final volume. 
Subsequently an equal volume of PCI was added and samples were thoroughly mixed on a rotional 
shaker for 10 min at room temperature. To separate the aqueous from the organic phase, the 
suspension was centrifuged for 10 min at room temperature and 13000 rpm in a microfuge. The 
nucleic acids in the aqueous phase were precipitated by addition of 0.1 volume 3 M NaOAC pH 4.7 
and 3 volumes absolute ethanol. Samples were kept at -20 °C for at least 30 min and precipitates 
were sedimented by centrifugation for 30 min at 4 °C and 13000 rpm in a microfuge. The pellet was 
washed once with 70 % (v/v) ethanol, vacuum dried and finally resuspended in the desired solution.  
2.2.1.3 Proteinase K digestion 
To facilitate RNA recovery from protein rich samples, proteinase K treatment was performed prior to 
PCI extraction.  Samples were incubated in 1x PK buffer in the presence of 0.2 µg/µl proteinase K for 
45 min at 45 °C. The RNA was recovered by PCI extraction (2.2.1.2) followed by ethanol precipitation 
in the presence of 0.3 M NaOAc pH 4.7. The dried RNA pellet was subsequently resuspended in 
sterile water and stored at -20 °C. 
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2.2.1.4 Generation of templates for run-off in vitro transcriptions  
DNA plasmids encoding the MINX pre-mRNA or exon-RNA were extracted from E. coli DH5α cells 
using the QIAGEN Plasmid Maxi Kit (Qiagen) according to the manufacturer’s protocol. Plasmid DNA 
was eluted in ddH2O and used for restriction digestion to generate templates for run-off in vitro 
transcriptions. The reactions were performed with the respective restriction endonuclease (NEB) 
according to instruction of the manufacturer. Briefly, 10 units of enzyme were used to cut 1 μg of 
plasmid DNA for 1 h at 37 °C.  
Agarose gel-electrophoresis was then performed to purify preparative amounts of DNA fragments 
after restriction enzyme digestions. Samples were supplemented with 6x DNA loading dye. 
Depending on the length of linearized plasmids, gels were prepared using 1-2 % (w/v) agarose and 
0.4 μg/ml ethidium bromide in 1x TBE buffer. Gels were run at 100 V for approximately 1 h in 1x TBE 
buffer. 
In order to isolate DNA from agarose gels, DNA bands visualized with UV-light at a wavelength of 
365 nm were cut out from the gel using a sterile surigal blade. DNA was extracted using the 
QIAquick® Gel Extraction Kit (Qiagen) according to the manufacturer’s instructions. 
2.2.1.5 In vitro transcription 
RNA in vitro transcriptions were carried out using DNA templates derived from linearized plasmids 
(2.2.1.4). Uniformly 32P-labeled m7G(5’)ppp(5’)G-capped MINX pre-mRNA was synthesized in vitro by 
T7 run-off transcription. The composition of a standard reaction is shown in Table 2.1. For 
transcriptions of MINX exon-RNA, the m7G(5’)ppp(5’)G-cap was omitted and the final concentration 
of GTP was increased to 7.5 mM.  
Table 2.1: A standard in vitro transcription reaction 
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The transcription was carried out at 37 °C for 3 h. The DNA template was removed by addition of 2 µl 
RQ1 DNase (1U/µl, NEB) and further incubation at 37 °C for 30 min. In order to purify the pre-mRNA 
from unincorporated NTPs, the synthesized RNA was first separated by denaturing PAGE (2.2.1.6). 
The RNA bands were detected via autoradiography and cut out of the gel using a sterile razor blade. 
RNA was eluted from the gel pieces in TNES buffer overnight at 4 °C. Alternatively, the transcription 
reaction was passed through a ProbeQuant G-50 column (GE Healthcare) according to the 
manufacturer’s protocol to remove unincorporated nucleotides. 
2.2.1.6 Denaturing polyacrylamide gel-electrophoresis 
Denaturing polyacrylamide gel electrophoresis (PAGE) in the presence of 8 M urea was mainly used 
to separate snRNAs or intermediates and products of pre-mRNA in vitro splicing. Depending on the 
size of the RNAs, the gels contained 5-14 % (v/v) polyacrylamide, 8 M urea and 1x TBE. 
Polymerization of the gels was initiated by addition of 300 µl 10 % (w/v) APS and 30 µl TEMED to 
50 ml of gel solution. The RNA samples were dissolved in RNA loading dye, denatured for 5 min at 
96 °C and briefly chilled on ice before loading. The electrophoresis was performed at 15 W in 1x TBE 
buffer. The RNA was then visualized by Northern blotting, silver staining or autoradiography.   
2.2.1.7 Silver staining of RNA 
To stain RNA separated by denaturing PAGE (2.2.1.6), the gel was fixed in 10 % (v/v) acetic acid for 
30 min at room temperature. After fixation, the gel was washed three times with water for 5 min 
each and then treated with a 12 mM AgNO3 and 0.056 % (v/v) formaldehyde solution for 30 min at 
room temperature. Again, the gel was briefly washed three times with water for 30 seconds each. 
For development the gel was treated with a solution containing 280 mM Na2CO3, 0.056 % (v/v) 
formaldehyde and 2.5 nM Na2S2O3 until a clearly visible staining of the RNA was achieved. The 
staining was stopped by addition of 10 % (v/v) acetic acid solution.  
2.2.1.8 Northern blot 
Northern blot analyses were performed to detect specific RNAs via radiolabeled DNA probes 
complementary to the respective RNA. RNAs separated by denaturing PAGE (2.2.1.6) were 
transferred to a nylon membrane (Hybond XL) using a semi-dry electroblot apparatus. The transfer 
was carried out in 1x TBE at 2 mA/cm2 of the membrane for 2 h. After transfer the blot was UV-
irradiated (1200 mJ) using a UV-Stratalinker 2400 in order to crosslink the RNAs to the membrane. 
The membrane was incubated with pre-hybridization buffer at 42 °C for 2 h. The radiolabeled DNA 
probes were denatured by heating at 95 °C for 5 min and then added to the pre-hybridization buffer 
and the membrane was incubated overnight at 42 °C. After hybridization, the membrane was washed 
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twice with wash buffer 1 [2x SSC, 0.5 % (w/v) SDS] and twice with wash buffer 2 [2x SSC, 0.1 % (w/v) 
SDS] for 15 min each at room temperature. After washing, signals were detected by autoradiography.  
The radiolabeled DNA probes were generated from plasmids encoding the target sequence by using 
α-32P-dATP and a Prime It II Random Labeling Kit (Stratagene) according to the manufacturer’s 
protocol. 
2.2.1.9 Radioactive 5’-labeling of RNA oligonucleotides 
In order to detect protein-RNA crosslinks, 5’ss RNA oligonucleotides were radioactively labeled at 
their 5’-end using y-32P-ATP and T4 polynucleotide kinase (PNK). The concentration of RNA 
oligonucleotides were adjusted to 100 pmol/μl. A standard 25 µl reaction containing 1 µl of the RNA 
oligo, 2.5 µl of 10x PNK buffer (NEB), 2 µl of T4 PNK (10U/µl, NEB) and 10 µl of y-32P-ATP 
(6000 Ci/mmol, 10 µCi/µl) was incubated at 37 °C for 1 h. After incubation, the radiolabeled 
oligonucleotide was purified from unincorporated y-32P-ATP using ProbeQuant G-25 columns (GE 
Healthcare) according to the manufacturer’s protocol. 
2.2.2 Protein-biochemistry standard methods 
2.2.2.1 Protein quantification 
To measure the concentration of proteins, a BCATM Protein Assay Kit (Pierce) was used according to 
the manufacturer’s protocol. This assay is a detergent-compatible method based on bicinchoninic 
acid (BCA) for the colorimetric detection. Quantification of total protein was analyzed at an 
absorption maximum of 562 nm. 
2.2.2.2 Denaturing SDS polyacrylamide gel-electrophoresis (SDS-PAGE) 
Proteins were resolved by denaturing SDS-PAGE according to Laemmli [Laemmli, 1970]. Protein 
samples were dissolved in 6x SDS loading dye and denatured for 10 min at 70 °C, before loading onto 
a 10-13 % step polyacrylamide gel with a 5% stacking gel.  
Table 2.2: Compositions of SDS gels 
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The gel was run in 1x SDS running buffer at 30 mA until the samples entered the separating gel and 
then run at 50 mA until the bromphenol blue reached the bottom of the gel. Proteins were visualized 
by coomassie or silver staining. For mass spectrometry or western blot analysis, proteins were 
separated on 4-12 % NuPAGETM gradient gels (Invitrogen) run in 1x MOPS buffer (Invitrogen) 
according to the manufacturer’s protocol.  
2.2.2.3 Coomassie staining 
Coomassie staining of proteins was performed according to Sambrook et al. [Sambrook et al., 1989]. 
Proteins in denaturing SDS gels were stained with coomassie staining solution overnight at room 
temperature and were subsequently destained in water until protein bands were clearly visible.  
2.2.2.4 Silver staining of proteins 
Silver staining of proteins was performed as described in Blum et al., 1987. Protein gels were fixed in 
40 % (v/v) MeOH and 10 % (v/v) acetic acid over night at room temperature while gently shaking. 
After fixation, the gel was washed twice with 50 % (v/v) ethanol and once with 30 % (v/v) ethanol for 
20 min each. The gel was then washed with 0.8 mM Na2S2O3 for exactly 60 seconds, and immediately 
washed three times with water to remove excessive thiosulfate from the surface. After that, the gel 
was incubated with a 12 mM AgNO3, 0.026 % (v/v) formaldehyde solution for 20 min. Again, the gel 
was briefly washed with water, followed by the development step with 560 mM Na2CO3, 0.0185 % 
(v/v) formaldehyde and 16 μM Na2S2O3 until the desired visualization of protein bands was achieved. 
The staining was stopped by addition of a 10 % (v/v) acetic acid solution. For detection of radioactive 
signals by autoradiography the gel was dried at 80 °C for 1 h and exposed to a phosphoimager 
screen. 
2.2.2.5 Western blot 
Proteins separated by SDS-PAGE were transferred to a nitrocellulose membrane (Protan BA83 
nitrocellulose, 0.2 μm) using a wet electroblot procedure. Therefore, a sandwich of two layers of 
Whatman 3MM paper, SDS gel, nitrocellulose membrane and again two layers of Whatman 3MM 
paper were assembled in a Trans-Blot Cell (Biorad). After assembly of the blotting sandwich, the 
transfer was carried out in 1x western transfer buffer + 5 % (v/v) ethanol by applying a constant 
current of 65 V for 1 h at room temperature. Subsequently, the membrane was incubated with 
primary antibodies in 1x TBS-T + 5 % (w/v) milk overnight at 4 °C. Immunoblotting was performed 
with the antibodies specified in the figures. The membrane was then washed three times with 
1x TBS-T for 10 min each. Secondary antibodies (Horseradish peroxidase-conjugated anti-rabbit 
antibodies diluted 1:30000) were incubated for 1 h at room temperature and the blot washed again 
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three times with 1x TBS-T. Proteins were detected by enhanced chemiluminescence using an ECL 
Western Blot Detection Kit (GE Healthcare) according to the manufacturer’s instructions. 
For the sequential incubation of a membrane with different antibodies, the previous antibodies had 
to be removed from the blot. Therefore, the membrane was incubated with stripping buffer for 
30 min at 50 °C with constant shaking. Afterwards the membrane was washed twice in 1x TBS-T for 
15 min each at room temperature. 
2.2.2.6 Purification of MS2-MBP 
The fusion protein, which was used for affinity-purification of spliceosomal complexes was expressed 
in an E. coli strain containing the plasmid encoding the MS2-MBP protein. Cells were grown to an 
OD600 of 0.3-0.6 in LB medium supplemented with the respective antibiotics. The expression of the 
MS2-MBP protein was then induced by adding 0.1 M IPTG. The culture was further incubated for 
2.5 h at 37 °C. The cells were pelleted by centrifugation in a Cryofuge 6000i (Heraeus) for 10 min at 
2000 rpm. The supernatant was discarded and the cell pellet was washed with 40 ml of washing 
buffer (20 mM Tris-HCl pH 7.6, 0.2 M NaCl) supplemented with one complete EDTA-free protease 
inhibitor cocktail tablet. Then, the cells were resuspended in 25 ml of washing buffer and 
subsequently lysed by sonification. The lysate was centrifuged in a SS34 rotor for 30 min at 16000 g. 
The supernatant was transferred to 2 ml of amylose beads (NEB), which were equilibrated with 
MBP150 buffer (20 mM HEPES-KOH pH 7.9, 150 mM NaCl, 0.05 % (v/v) NP-40). Afterwards the 
mixture was incubated head-over-tail for 2 h at 4 °C. The suspension was transferred into a Bio-Spin 
chromatography column (Biorad) and the amylose resin was washed with 10 column volumes of 
MBP150 buffer followed by 5 column volumes of 5 mM Na2HPO4 pH 7.0. The MS2-MBP protein was 
then eluted with 5 mM Na2HPO4 pH 7.0 containing 20 mM maltose and the eluate was subsequently 
loaded onto a pre-equilibrated heparin agarose column. The column was washed with 10 volumes of 
5 mM Na2HPO4 pH 7.0 and the protein was eluted fraction-wise with elution buffer [20 mM HEPES-
KOH pH 7.9, 100 mM KCl, 15 % (v/v) glycerol, 0.5 mM DTT]. Peak fractions were pooled, shock frozen 
in liquid nitrogen and finally stored at -80 °C. The protein concentration was determined using the 
BCATM Protein Assay Kit (2.2.2.1). 
2.2.2.7 Purification of recombinant hPrp28 proteins 
To purify recombinant hPrp28 protein, E. coli strains containing the plasmids for His6-tagged hPrp28 
wildtype or AAAD mutant were grown in 2xYT medium [1.6 % (w/v) Tryptone, 0.5 % (w/v) NaCl, 1 % 
(w/v) Yeast extract] supplemented with the respective antibiotics. Cells were grown to an OD600 of 
0.4-0.8 at 30 °C and the expression of the recombinant protein was then induced by adding 0.3 mM 
IPTG. The culture was further incubated at 18 °C overnight and cells were harvested by centrifugation 
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in a Cryofuge 6000i (Heraeus) for 10 min at 2000 rpm and 4 °C. The cell pellet was resuspended in 20-
50 ml of lysis buffer [50 mM Tris-HCl pH 7.5, 2 M LiCl, 5 % (v/v) glycerol, 2 mM β-mercaptoethanol] 
and subsequently subjected to lysis by a microfluidizer (3-7 cycles at 80 psi). The lysate was 
centrifuged in a SS34 rotor for 30 min at 16000 g and 4 °C. The supernatant was supplemented with 
10 mM imidazole and subsequently applied to a pre-equilibrated Ni2+-NTA column (pre-packed 
columns with 5 ml column volume, GE Healthcare). The column was washed with 6 column volumes 
of buffer A [50 mM Tris-HCl pH 7.5, 500 mM NaCl, 5 % (v/v) glycerol, 2 mM β-mercaptoethanol] 
containing 5 % (v/v) of buffer B (buffer A + 300 mM imidazol). For elution of the His6-tagged proteins 
the column was washed with 6 column volumes of a linear gradient from 5-100 % (v/v) of buffer B. 
The elution was collected in 1 ml fractions and the fractions containing the recombinant hPrp28 
protein were pooled. The eluted sample was concentrated to approximately 10 mg/ml and subjected 
to a second purification step in order to remove remaining contaminating proteins. Therefore, this 
sample was loaded to a pre-equilibrated size-exclusion column (Superdex 200, GE Healthcare). Gel-
filtration was performed in the presence of a high-salt buffer [10 mM Tris-HCl pH 7.5, 500 mM NaCl, 
5 % (v/v) glycerol, 2 mM β-mercaptoethanol] to avoid aggregation of the recombinant protein on the 
column. The protein was then eluted with one volume of high-salt buffer. The eluted protein was 
concentrated to 1-5 mg/ml, shock frozen in liquid nitrogen and finally stored at -80 °C. 
2.2.2.8 Purification of antibodies 
For the purification of antibodies, a 1 ml aliquot of packed PAS beads (GE Healthcare) was washed 
twice with 10 ml 1x PBS pH 8.0. Then, 3 ml of sera were mixed with 7 ml of 1x PBS pH 8.0 and this 
mixture was passed through a 0.45 µm filter to remove particulate material. The filtrate was then 
incubated with the washed PAS beads for 2 h at RT head-over-tail. After antibody binding, the 
supernatant was removed and the beads were washed five times with 10 ml 1x PBS pH 8.0 each. 
Bound antibodies were then eluted via pH shock by successively adding 10 times 500 µl elution 
buffer (0.1 M glycine pH 2.7). The eluates were collected in separate fractions and the pH of each 
fraction was immediately neutralized by the addition of 30 µl of 1 M Tris pH 9.5. The protein 
concentration in each fraction was determined by BCATM Protein Assay and the peak fractions were 
pooled. The purified antibodies were dialyzed in a Slide-A-Lyzer (Pierce) against 500 ml 1x PBS pH 8.0 
for five hours with one change of buffer after 2.5 h. 
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2.2.3 Special methods 
2.2.3.1 Cell culture 
HeLa S3 cells (Computer Cell Culture Center, Belgium) were grown in suspension in S-MEM media 
supplemented with 5 % (v/v) newborn calf serum, 50 μg/ml penicillin and 100 μg/ml streptomycin to 
a density of 2.5-5x 105 cells/ml. Cultivation and harvesting of the cells was essentially done as 
previously described in Kastner, 1998, and Dignam et al., 1983. 
2.2.3.2 Preparation of splicing active HeLa nuclear extract 
Splicing active nuclear extract was prepared from HeLa cells as described in Dignam et al., 1983. Six 
to eight liters of HeLa cells were grown to a density of 2.5-5 x 105 cells/ml [Kastner, 1998]. The cells 
were pelleted by centrifugation in a Cryofuge 6000i (Heraeus) for 10 min at 2000 rpm. The 
supernatant was discarded and the cells were washed three times with ice-cold 1x PBS pH 7.4. Then, 
the cell pellet was resuspended in 1.25 volumes of 1x MC buffer supplemented with two complete 
EDTA-free protease inhibitor cocktail tablets per 50 ml of buffer. After an incubation of 5 min on ice 
the cells were lysed with 18 strokes of a Dounce homogenizer at 4 °C. The cell suspension was 
transferred to Corex tubes and the nuclei were pelleted by centrifugation in a SS34 rotor for 5 min at 
13000 g. Afterwards the supernatant was discarded and the nuclei were resuspended in 1.3 volumes 
of 1x Roeder C buffer containing 0.5 mM DTE and 0.5 mM PMSF. For lysis of the nuclei the 
suspension was again treated with 20 strokes of a Dounce homogenizer at 4 °C. The lysate was 
stirred for 40 min at 4 °C, followed by centrifugation in a SS34 rotor at 16000 rpm for 30 min to pellet 
particulate material. The supernatant was recovered and dialyzed against 50 volumes of 1x Roeder D 
buffer at 4 °C for five hours with one change of buffer after 2.5 h. The dialyzed nuclear extract was 
recovered and centrifuged in a HB6 rotor at 10000 rpm for 10 min at 4 °C. The supernatant was 
aliquoted, frozen in liquid nitrogen and stored at -80 °C. 
2.2.3.3 In vitro splicing reactions 
A typical splicing reaction was carried out in the presence of 10 nM MINX pre-mRNA or exon-RNA 
and 40 % (v/v) HeLa nuclear extract [Dignam et al., 1983] in a buffer containing 20 mM HEPES-KOH 
pH 7.9, 3 mM MgCl2, 65 mM KCl, 2 mM ATP and 20 mM creatine phosphate. Spliceosomal complexes 
were allowed to form at 30 °C for the times indicated in the respective figure (3. Results). 37S exon 
complexes were assembled on MINX exon-RNA by incubating at 30 °C for 6 min. 45S B-like complexes 
were formed by first incubation for 3 min and then adding a 100-fold excess of the 5’ss 
oligonucleotide or mutated oligonucleotide and incubating for an additional 3 min. After splicing, 
reactions were chilled on ice. 
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For complex assembly in the presence of recombinant hPrp28 protein, the splicing reaction was first 
supplemented with the indicated concentration of recombinant protein and was then pre-incubated 
for 30 min at 30 °C prior to the addition of the pre-mRNA. 
2.2.3.4 Analysis of splicing complexes by native agarose gel-electrophoresis 
The process of spliceosomal assembly in vitro can be analyzed by a mobility retardation assay. Briefly, 
spliceosomal complexes A, B and C form in a subsequent manner and show decreased mobility on a 
native agarose gel [Kent and MacMillan, 2002, Lamond et al., 1987]. 
To resolve spliceosomal complexes by native agarose gel-electrophoresis, 20 µl splicing reactions 
were incubated at 30 °C for the times indicated in the respective figure (3. Results). Heparin was 
added to a final concentration of 0.65 µg/µl and the mixtures were incubated for another 1 min at 
30 °C before addition of 6 µl of 5x native gel loading dye. The samples were immediately loaded onto 
a native gel containing 2 % (w/v) low melting point agarose in 0.5x TBE buffer. Electrophoresis was 
then performed at 50 V for 16 h at room temperature. The gels were dried at 60 °C for 5 h and 
exposed to a phosphoimager screen to visualize complex formation. 
2.2.3.5 MS2 affinity-selection of splicing complexes 
Spliceosomal complexes were isolated by MS2 affinity-selection as previously described in [Bessonov 
et al., 2010]. Pre-mRNA was incubated with 20 mM HEPES-KOH pH 7.9 and a 20-fold molar excess of 
purified MS2-MBP fusion protein for 30 min at 4 °C prior to splicing. Then, a 1 ml standard splicing 
reaction containing 20 mM HEPES-KOH pH 7.9, 3 mM MgCl2, 65 mM KCl, 2 mM ATP, 20 mM creatine 
phosphate and 10 nM of uniformly 32P-labeled MINX pre-mRNA or exon-RNA was incubated for 6 min 
at 30 °C. After 3 min of incubation the splicing reaction was supplemented with 1 µM of 5’ss 
oligonucleotides as indicated in the respective figure (3. Results). 
The splicing reaction was loaded onto a 14 ml linear 10-30 % (v/v) glycerol gradient containing G-150 
buffer. Gradients were centrifuged at 25000 rpm for 15 h at 4 °C in a Sorvall TST 41.14 rotor and 
harvested manually in 500 µl fractions from top to bottom. The distribution of 32P-labeled MINX pre-
mRNA or exon-RNA across the gradient was determined by Cherenkov counting. Peak fractions 
containing the spliceosomal complexes were pooled and loaded onto a pre-equilibrated column 
containing 300 µl of amylose beads (NEB). The matrix was then washed with four column volumes of 
G-75 washing buffer. Finally, spliceosomal complexes were eluted by adding 300 µl of G-75 washing 
buffer containing 20 mM maltose. 
To test the stabilization of the 37S exon or 37S cross-intron complexes, the respective elution 
fraction containing usually 2-3 pmol of affinity-purified complexes was supplemented with a 100-fold 
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excess of either the 5’ss oligonucleotide or the 2’O-ribose methylated 5’ss oligonucleotide. After an 
incubation of 15 min on ice, the reaction was loaded onto a linear 10-30 % (v/v) analytical glycerol 
gradient containing G-75 or G-150 buffer as specified in the respective figure (3. Results). Gradients 
were centrifuged at 60000 rpm for 135 min at 4 °C in a Sorvall TH660 rotor and harvested manually 
in 175 μl fractions from top to bottom.  
2.2.3.6 Psoralen-mediated RNA-RNA crosslinking 
Affinity-purified spliceosomal complexes were crosslinked with 4′-aminomethyl-4,5′,8-
trimethylpsoralen hydrochloride (AMT) to reveal RNA-RNA interactions [Hartmuth et al., 2002]. 
Crosslinking was initiated by adding 2 mg/ml AMT in DMSO to affinity-purified complexes to a final 
concentration of 20 μg/ml and incubating for 10 min on ice. Next, samples were irradiated with 
365 nm UV-light for 30 min at 4 °C with a distance of 4 cm between the samples and UV lamp. After 
proteinase K treatment of the samples (2.2.1.3), the RNA was recovered and resolved on a 5 % or 
10 % denaturing polyacrylamide gel (2.2.1.6) and analyzed by Northern blotting (2.2.1.8). 
2.2.3.7 UV crosslinking of spliceosomal complexes 
In order to induce site-specific protein-RNA crosslinks by UV-irradiation, spliceosomal complexes 
were affinity-purified as described in 2.2.3.5. The elution fraction was pipetted dropwise (30 µl each) 
onto a pre-cooled metal rack covered with Parafilm. The samples were irradiated at 365 nm for 
10 min with a distance of 4 cm between the metal rack and UV lamp. Afterwards, the drops were 
pooled and subsequently supplemented with 1 µl RNase A (1 mg/ml, Ambion). The crosslinked 
complexes were then incubated for 20 min at 37 °C to digest RNA. 
2.2.3.8 Immunoprecipitation of protein-RNA crosslinks 
For the enrichment of hPrp8-specific protein-RNA crosslinks, immunoprecipitation was performed. 
Purified antibodies were first coupled to PAS beads. For each assay, 20 µl packed PAS beads (GE 
Healthcare) were washed twice with PBS pH 8.0. Then, 500 µl of PBS pH 8.0 containing 0.5 mg/ml 
BSA, 0.05 mg/ml tRNA and 5 µg of purified anti-hPrp8 antibodies were added to the beads. In the 
negative control antibodies were omitted. The beads were then incubated for 1 h at room 
temperature while rotating head-over-tail. After centrifugation for 2 min at 3000 rpm in a microfuge, 
the supernatant was removed and the beads were washed twice with 500 µl of ice cold G-150 buffer 
containing 0.05 % SDS and 0.5 % Triton X-100. Then 250 µl of the elution fraction containing UV-
crosslinked spliceosomes disrupted by RNase digestion and treatment with detergent (2.2.3.7) were 
added and incubated with antibody coupled PAS beads, rotating head-over-tail at room temperature 
for 2 h. After centrifugation at 3000 rpm for 2 min in a microfuge and removal of the supernatant, 
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the beads were again washed two times with G-150 buffer containing 0.05 % SDS and 0.5 % Triton X-
100. Bound material was eluted by addition of 20 µl 6x SDS loading dye and incubation at 96 °C for 
10 min. Proteins were separated by SDS-PAGE (2.2.2.2) and finally analyzed by western blot (2.2.2.5) 
and autoradiography. 
2.2.3.9 Two-dimensional gel-electrophoresis of spliceosomal complexes 
Two-dimensional gel-electrophoresis of spliceosomal complexes was performed as described in 
[Agafonov et al., 2011]. Briefly, spliceosomal complexes were affinity-purified (2.2.3.5) and 
subsequently pelleted in a Sorvall SA800 AT400 rotor at 700000g at 4 °C for 6 h. The pellet was 
dissolved in G-1000 buffer (50 mM HEPES-KOH pH 7.9, 2 mM MgCl2, 1 M NaCl, 0.1 mM EDTA) and 
treated with RNase A and T1 (Ambion) under increasing urea concentrations. Then, the sample was 
dialyzed in a Slide-A-Lyzer (Pierce). Separation of proteins in the first dimension was carried out 
under very strong denaturing conditions at acidic pH in the extremely large pore matrix. In the 
second dimension proteins were separated on an 8 % acrylamide gel in the presence of SDS. Proteins 
were stained with SyproRuby (Life Science) according to the manufacturer’s protocol or with 
Coomassie. For identification of proteins, individual Coomassie-stained protein-spots were cut out 
from the gel and corresponding proteins were subsequently identified by mass spectrometry 
(2.2.3.11). 
2.2.3.10 Electron microscopy 
The structure of isolated spliceosomal complexes was analyzed by electron microscopy (EM). All EM 
experiments were performed in collaboration with Dr. Norbert Rigo and Dr. Berthold Kastner. For EM 
investigations, affinity-purified complexes were subjected to a second glycerol gradient 
centrifugation under mild-fixating GraFix conditions [Kastner et al., 2008]. Briefly, 6-8 pmol of 
spliceosomes were loaded onto a linear 10-30 % (v/v) glycerol and 0-0.1 % (v/v) glutaraldehyde 
gradient containing G-75 or G-150 buffer. Gradients were centrifuged at 60000 rpm for 2 h in a 
TH660 rotor at 4 °C and harvested manually in 175 µl fractions from top to bottom. The distribution 
of 32P-labeled RNA across the gradient was determined by Cherenkov counting and peak fractions 
were used for EM studies. The spliceosomal complexes from these fractions were allowed to adsorb 
to a thin carbon film for approximately 2 h. The carbon film was then transferred to a staining 
solution containing 2 % (w/v) uranyl formate and was stained for 2 min. After staining, the carbon 
film was applied to a copper EM grid and subsequently covered with a second carbon film.  
For visualization of structural features, images were recorded at a magnification of 88000x with a 
CM200 FEG electron microscope (Philips, Netherlands) equipped with a 4kx4k charge-coupled (CCD) 
camera (TVIPS) and a room temperature holder (Philips, Netherlands). For each data set 10000-
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15000 individual single-particle images were collected. Repeating rounds of image-processing of 
these images were performed using the software package IMAGIC-5 [van Heel et al., 1996]. After a 
reference-free alignment, images were subjected to multivariate statistical analysis and classification 
[Dube et al., 1993, van Heel and Frank, 1981, van Heel, 1989]. The resulting class averages were used 
as reference images in subsequent rounds of alignment until the class averages were stable. 
2.2.3.11 Mass spectrometry 
For protein identification via mass spectrometry, proteins recovered from affinity-purified 
spliceosomal complexes were first separated by 2D gel-electrophoresis as described in 2.2.3.10 and 
then stained with SyproRuby. Individual protein-spots were cut out and proteins were digested in-gel 
with trypsin and extracted as described by Shevchenko et al. [Shevchenko et al., 1996]. For mass 
spectrometry of the 37S cross-intron and B complex (approximately 1-2 pmol each), proteins 
recovered from the complexes were separated on 4-12 % NuPAGETM gradient gels (Invitrogen) and 
stained with Coomassie. Entire lanes were cut into 23 slices and proteins were digested in-gel with 
trypsin and extracted as described by Shevchenko et al. [Shevchenko et al., 1996]. The extracted 
peptides were analyzed in a liquid-chromatography coupled electrospray ionization quadropole time 
of flight (Q-ToF) or Orbitrap (LTQ Orbitrap XL) mass spectrometer under standard conditions. 
Proteins were identified by searching fragment spectra against the NCBI non-redundant (nr) 





Intron-defined spliceosome assembly occurs by the ordered interaction of spliceosomal components 
across an intron and proceeds sequentially with distinct intermediate stages. An alternative assembly 
pathway exists, in which the splicing complex first forms across an exon. This so-called exon 
definition is thought to be the prominent pathway for pre-mRNAs with long intronic sequences. 
However, the chemical steps of splicing can only occur across an intron, and therefore a 
rearrangement from exon-defined to an intron-defined organization must occur. Recent studies 
showed that exon-defined spliceosomes not only contain U1 and U2 snRNPs, but also the U4/U6.U5 
tri-snRNP, providing evidence that it is possible for a cross-exon complex to be converted directly 
into a cross-intron B complex via interaction with an upstream 5’ss [Schneider et al., 2010a]. Here I 
have investigated the requirements for stable integration of the U4/U6.U5 tri-snRNP during both 
exon- and intron-defined spliceosome assembly and factors contributing to this process, as this is a 
crucial step during which the two spliceosome assembly pathways converge and alternative splice 
site choices are made.  
3.1 A stable 45S B-like complex is formed upon addition of a 5’splice site-
containing RNA oligonucleotide 
To assemble exon-defined spliceosomes in a splicing reaction containing HeLa nuclear extract, I used 
a single exon RNA construct derived from the MINX pre-mRNA substrate (Figure 3.1A) [Schneider et 
al., 2010a]. This MINX exon-RNA contains a single exon flanked by intronic sequences containing an 
upstream branch site and polypyrimidine-tract, which is essential for U2 snRNP binding, and a 
downstream 5’ss with which the U1 snRNP interacts. Additionally, three MS2-aptamers are inserted 
at the 3’end to enable MS2 affinity-selection of splicing complexes as described in chapter 2.2.3.5. 
Incubation of this RNA substrate under splicing conditions results in the formation of an exon 
complex with a S-value of ~37S as determined by glycerol gradient centrifugation (Figure 3.1C). This 
37S exon complex contains all five snRNPs in stoichiometric amounts (Figure 3.1D). Previous 
investigation of the RNA-RNA network by psoralen-mediated crosslinking showed that the U1 snRNP 
is base paired with the downstream 5’splice site, while the U2 snRNP interacts with the upstream 
BPS [Schneider et al., 2010a]. The U4/U6.U5 tri-snRNP is associated with the 37S exon complex via 
base pairing with the U2 snRNA (U2/U6 helix II) and therefore the U2 snRNP establishes the 
connection between the MINX exon-RNA and the U4/U6.U5 tri-snRNP. But, in this 37S exon complex 
the U4/U6.U5 tri-snRNP is loosely-associated in a heparin-sensitive manner, as judged by native gels, 





Figure 3.1: Addition of a 5’ss RNA oligonucleotide leads to the formation of a stable 45S B-like complex 
(A) Schematic representation of the MINX exon-RNA [see Schneider et al. 2010a], which is used to assemble 
exon-defined spliceosomes and the sequence of the optimized 5’ss oligonucleotide that induces formation of 
the B-like complex. Exonic nucleotides are highlighted with a shaded box. (B) Exon-defined spliceosomes were 
assembled on uniformly 
32
P-labeled MINX exon-MS2 RNA and analyzed via native agarose gel-electrophoresis 
in the presence of heparin. The stabilization of U4/U6.U5 tri-snRNP binding was tested upon addition of a 100-
fold excess of a 5’ss RNA or 2’O-ribose methylated (2’O-me) 5’ss RNA oligonucleotide as indicated. The 
positions of A- and B-like complexes are indicated. (C) Glycerol gradient analysis of exon-defined spliceosome 
assembly. Splicing reactions were subjected to linear 10-30 % glycerol gradients containing 150 mM KCl. The 
percentage of total radioactivity in each gradient fraction is plotted. Sedimentation values were determined 
with prokaryotic ribosomal subunits. (D) Complexes in peak fractions of the gradients were purified by MS2 
affinity-selection. RNA was recovered from the eluates, separated by denaturing PAGE and visualized by silver 
staining. RNA identities are indicated on the right. 
 
Addition of 100-fold excess of a short RNA oligonucleotide containing an optimized 5’splice site 
sequence (Figure 3.1A) after 3 min of splicing, induces the formation of a B-like complex. During 
formation of this complex, the U4/U6.U5 tri-snRNP associates in a stable, heparin-resistant manner 




centrifugation showed that stable U4/U6.U5 tri-snRNP integration is accompanied by a change in the 
sedimentation behavior of the complex from ~37S for the exon to ~45S for the B-like complex (Figure 
3.1C). So, I set out to use this reductionist system to identify factors potentially contributing to the 
stabilization of U4/U6.U5 tri-snRNP binding. 
3.1.1 Stabilization of U4/U6.U5 tri-snRNP integration is not induced by 
removing U1 snRNP from the downstream 5’ss 
Due to the optimized complementarity of the 5’ss oligonucleotide with the 5’end of U1 snRNA, 
addition of the 100-fold excess of the 5’ss oligonucleotide should compete with the interaction 
between U1 snRNA and the downstream 5’ss of the MINX exon-RNA. Indeed, affinity-purified B-like 
complexes contain very little U1 snRNA, consistent with the 5’ss oligonucleotide outcompeting the 
bound U1 snRNP (Figure 3.1D, lane 2). Disrupting the U1:5’ss interaction could potentially allow the 
U6 snRNA to interact with the downstream 5’ss and lead thereby to stabilization of U4/U6.U5 tri-
snRNP binding during B-like complex formation. To test if this is indeed the case, we modified the 
5’ss RNA oligonucleotide by 2’O-ribose methylation (2’O-me), which still allows interaction with the 
U1 snRNP, but not other components of the 37S exon complex [Schneider et al., 2010a]. Addition of 
this modified 5’ss oligonucleotide to the splicing reaction did not support stable B-like formation on 
native gels (Figure 3.1B, lane 4), nor the shift to a 45S complex on a glycerol gradient (Figure 3.1C), 
even though the complexes formed in its presence did not contain the U1 snRNA (Figure 3.1D, 
lane 3). Thus, displacement of U1 snRNP by the 5’ss oligonucleotide does not support stable 
U4/U6.U5 tri-snRNP binding during 45S B-like complex formation. This suggests an essential role for a 
previously shown interaction of the 5’ss oligonucleotide with the U4/U6.U5 tri-snRNP, as opposed to 
U1 snRNP, for inducing stable integration of the U4/U6.U5 tri-snRNP within the 45S B-like complex. 
3.2 Formation of the 45S B-like complex is accompanied by the recruitment of 
B complex-specific proteins 
To identify factors that potentially contribute to stable U4/U6.U5 tri-snRNP binding, we set out to 
determine which proteins are abundant components of 37S exon and 45S B-like complexes. We thus 
made use of a novel 2D gel-electrophoresis technique developed in our laboratory that is optimized 
for the investigation of spliceosomal complexes and allows a quantitative assessment of the relative 
amounts of a given protein within a complex mixture [Agafonov et al., 2011]. However, due to the 
extremely large pore size of the gels used in this technique, visualization of proteins smaller than 




Thus, I purified 37S exon and 45S B-like complexes by gradient centrifugation and subsequent MS2 
affinity-selection under identical conditions to allow a direct comparison of the protein inventory of 
both complexes. In collaboration with Dr. Dmitry Agafonov, the proteins were separated via 2D gel-
electrophoresis, and visualized by staining with SyproRuby (Figure 3.2). The identity of each protein-
spot was subsequently confirmed by mass spectrometry. 
 
Figure 3.2: Identification of abundant proteins associated with 37S exon and 45S B-like complexes 
Analysis of the protein composition of MS2 affinity-purified 37S exon and 45S B-like complexes by 2D gel-
electrophoresis according to Agafonov et al. [Agafonov et al., 2011]. Proteins were stained with SyproRuby and 
the identities of protein-spots were determined by mass spectrometry. 
 
The protein-spots varied considerably in their intensities and proteins were classified as abundant 
based on a visual evaluation of these intensities (Figure 3.2, see also Agafonov et al., 2011). Proteins 
that were considered to be abundant in the 37S exon and 45S B-like complex are listed in Table 3.1. 
The evaluation of the protein pattern identified all U1, U2 and U4/U6.U5 tri-snRNP proteins to be 
abundant in the 37S exon complex, which is consistent with its snRNA composition. Further, the 
proteins BCLAF1, THRAP3, hnRNPA1b, hPrp4 kinase and SRSF1 were also classified as abundant 
based on their staining intensities. Additionally, the SR proteins SRSF7 and SRSF10 were also included 




SR proteins migrate not as a distinct, single spot but rather diffuse in this 2D gel-electrophoresis and 
furthermore this group of proteins is known to be heavily phosphorylated, which in combination 
results in a poor intensity of staining ([Agafonov et al., 2011], personal communication Dr. Agafonov).   
Protein MW 
gi l number 
37S exon 45S B-like S. cerevisiae 
name kDa complex complex gene name 
Sm proteins           
SmB/B' 24.6 gi|119631003     SMB1 
            
U1 snRNP           
U1-70K 51.6 gi|36100     SNP1 
U1-A 31.3 gi|189053747     MUD1 
            
U2 snRNP           
U2A' 28.4 gi|50593002     LEA1 
U2B'' 25.4 gi|119630691     MSL1 
SF3a120 88.9 gi|5032087     PRP21 
SF3a66 49.3 gi|116283242     PRP11 
SF3a60 58.5 gi|158255798     PRP9 
SF3b155 145.8 gi|54112117     HSH155 
SF3b145 100.2 gi|33875399     CUS1 
SF3b130 135.5 gi|54112121     RSE1 
SF3b49 44.4 gi|5032069     HSH49 
            
U5 snRNP           
hPrp8 273.7 gi|91208426     PRP8 
hBrr2 244.5 gi|40217847     BRR2 
hSnu114 109.4 gi|12803113     SNU114 
hPrp6 106.9 gi|189067252     PRP6 
hPrp28 95.6 gi|193785886     PRP28 
40K 39.3 gi|115298668       
            
U4/U6 snRNP           
hPrp3 77.6 gi|4758556     PRP3 
hPrp31 55.4 gi|221136939     PRP31 
hPrp4 58.4 gi|189053699     PRP4 
            
U4/U6.U5 snRNP           
hSnu66 90.2 gi|10863889     SNU66 
hSad1 65.4 gi|13926071     SAD1 
            
B complex-specific           
RED 65.6 gi|125988409       
MFAP1 51.9 gi|50726968       
hSmu-1 57.5 gi|84370185       
FBP21 42.5 gi|189069453       
hPrp38 37.5 gi|24762236     PRP38 
hSnu23 23.6 gi|13385046     SNU23 
hPrp4 kinase 117.1 gi|158255924       
            
SR proteins           
SRSF1 27.8 gi|296202382       
SRSF7 27.4 gi|72534660       
SRSF10 31.3 gi|5730079       
            
hnRNPs           
hnRNP A1 38.7 gi|119617171       
            
Miscelleneous           
THRAP3 108.6 gi|167234419       
BCLAF1 106 gi|219520423       
 
Table 3.1: Abundant proteins detected in 37S exon and 45S B-like complexes 
Overview of abundant proteins associated with 37S exon and 45S B-like complexes. Abundant proteins were 
identified by visual inspection and are indicated by a grey box. Proteins are grouped according to their 





In contrast, hPrp19 was not considered to be abundant despite a similar staining intensity as e.g. 61K, 
as it was shown that hPrp19 is recruited in multiple copies to the spliceosome [Grote et al., 2010]. 
Consistent with this finding other factors of the hPrp19 complex such as Cdc5L or Prl1 are also not 
abundant. For the same reason hSmu-1 was not classified as abundant within the 37S exon complex. 
Based on the increase in its staining intensity upon transition to the 45S B-like complex, we assume 
that additional copies of hSmu-1 are recruited to the complex upon interaction of the 5’ss 
oligonucleotide. The increase in staining intensity and previous investigations of Agafonov et al. 
suggest that hSmu-1 is present in multiple copies within the spliceosome ([Agafonov et al., 2011], 
personal communication Dr. Agafonov).Upon formation of a 45S B-like complex a distinct change in 
the protein composition was observed. First we detected a loss of the U1-specific proteins, which is 
consistent with the displacement of U1 snRNP from the complex upon addition of the 5’ss 
oligonucleotide to the splicing reaction. Additionally, all SR proteins as well as the hPrp4 kinase were 
displaced from the complex. In contrast, we detected a recruitment of MFAP1, FBP21, RED and 
hSmu-1 during the transition from a 37S exon to the 45S B-like complex (Figure 3.2, table 3.1). These 
B complex-specific proteins are stage-specifically recruited during formation of a stable, intron-
defined B complex and get already displaced during transition to a Bact complex [Agafonov et al., 
2011]. hPrp38 and hSnu23, which also belong to the group of B complex-specific proteins, were also 
classified as abundant in the 45S B-like complex despite showing a less intensive staining intensity. 
These two proteins migrate the longest distance in the first dimension of the two-dimensional gel, 
which results in the loss of material and therefore in a less intensive staining after separation in the 
second dimension ([Agafonov et al., 2011], personal communication with Dr. Dmitry Agafonov). 
hPrp38 was shown to be phosphorylated, which results in a reduction in its staining efficiency 
[Agafonov et al., 2011].  
In general, the 45S B-like complex shows essentially the same composition of abundant proteins as 
an intron-defined B complex, which was assembled on the MINX pre-mRNA [Agafonov et al., 2011] 
with the exception that the two proteins THRAP3 and BCLAF1 are not abundant in the intron-defined 
B complex. The presence of the B complex-specific proteins in spliceosomal complexes with a stably-
integrated U4/U6.U5 tri-snRNP, namely 45S B-like and B complex, suggests that the latter proteins 
could potentially be required for the stabilization of U4/U6.U5 tri-snRNP binding upon its interaction 
with a 5’splice site. Despite the change in the protein composition during the transition from the 37S 
exon to 45S B-like complex, the difference in the theoretical mass of the 37S exon (loss of proteins:  
~290 kDa) to a 45S B-like complex (recruitment of B complex-specific proteins: ~280 kDa) is 
negligible. Thus, the increased sedimentation value of the 45S B-like complex does not appear to be 
due to a higher mass of the complex, but rather suggests a structural rearrangement of the complex 




3.3 EM reveals a major structural difference between the 37S exon and the 
45S B-like complex 
To determine whether addition of the 5’ss oligonucleotide changes the morphology of the 37S exon 
complex, its structure was investigated in comparison to the 45S B-like complex via negative-stain 
electron microscopy (EM). All electron microscopy analyses were performed in collaboration with 
Dr. Berthold Kastner and Dr. Norbert Rigo (Department of Cellular Biochemistry, MPI-BPC). For this 
purpose, I separated 37S exon and 45S B-like complexes on a glycerol gradient and subjected the 
respective peak fractions to MS2 affinity-selection. The eluates were then fractionated on a second 
glycerol gradient containing 75 mM KCl under GraFix conditions [Kastner et al., 2008] and peak 
fractions were subsequently used for EM preparation. Figure 3.3 shows representative overviews of 
single particles of either the 37S exon or 45S B-like complex on the EM grid. To allow a structural 
comparison between 37S exon and 45S B-like complexes, we generated class averages from single 
particle images for both complexes. Therefore, we performed image processing of a dataset 
containing 12,000 and 10,400 individual raw images of the 37S exon and 45S B-like complex, 
respectively. Characteristic two-dimensional class averages of both complexes are shown in figure 
3.3 and the relative percentages of the respective appearances of the 37S exon complex are 
indicated below. Due to the similar appearance of the 45S B-like complex in nearly all class averages 
percentages were omitted. 
For the 37S exon and 45S B-like complexes clearly defined single particles are visible on the EM grid, 
showing that the increase in the sedimentation behavior during the transition is not due to an 
aggregation of the complexes (Figure 3.3, A & B). The 37S exon complex structures are characterized 
by an upper (head) and elongated lower (body) domain, which are connected via a slimmer neck 
domain (Figure 3.3D). The size and shape of the body domain are similar in most of the class 
averages, whereas the head domain displays more conformational heterogeneity.The head domain 
not only varies in its size, but it is also seen in different positions relative to the body domain (Figure 
3.3D, black, blue, red). The majority of the classes exhibit a clearly-defined, triangular-shaped head 
domain, which is located close to the body domain (Figure 3.3A, galleries 1 & 2). In the less abundant 
classes, the head appears more blurred and is composed of globular domains with either horizontally 
(Figure 3.3A, galleries 3 & 4) or vertically (Figure 3.3A, gallery 5) arranged protrusions. Thus, the head 
domain appears to have similar structural elements, which are flexibly connected by the neck domain 






Figure 3.3: Structural comparison of 37S exon and 45S B-like complexes by negative-stain electron 
microscopy 
An overview of negatively-stained 37S exon (A) and 45S B-like (B) complexes formed on MINX exon-RNA is 
shown on the left. Representative class averages of both complexes are shown in the galleries from most (1) to 
least (6) frequently observed classes on the right. The relative abundance of the different classes of the 37S 
exon complex is indicated. A small fraction (< 15 %) of images with a morphology typical for the 45S B-like 
complex was also detected in the preparation of the 37S exon complex (Gallery 6). The lower gallery (C) shows 
a selection of typical class averages of an intron-defined B complex formed on the MINX pre-mRNA. Scale bars 
correspond to 50 nm. (D) Schematic representation of the 37S exon complex including different orientations of 
the head domain characteristic for the galleries 1-2 (black), 3-4 (blue) and 5 (red). (E) Schematic representation 
of an intron-defined B complex. Main structural elements are labeled according to Boehringer et al. 




The class averages calculated from single particles of the 45S B-like complex appear structurally 
better defined and reveal more fine structural details in comparison to the 37S exon complex. The 
45S B-like complex exhibits a predominant orientation for the majority of the calculated class 
averages, based on the appearance of almost identical views in all class averages. The 45S B-like 
complex consists of a triangular body and a globular head domain, which are connected by a neck-
like structure. Interestingly, a small portion (< 15 %) of structures characteristic for the 45S B-like 
complex was also detectable in the preparation of the 37S exon complex (Figure 3.3, gallery 6). 
Overall the 45S B-like complex appears more compact and not as elongated as the 37S exon complex, 
which might explain the change in its sedimentation value. Surprisingly, the morphologies of the 
45S B-like complex are highly similar to those of an intron-defined B complex with stably associated 
U4/U6.U5 tri-snRNP (Figure 3.3C), despite the fact that these complexes were assembled on different 
substrates, namely MINX exon-RNA or MINX pre-RNA, respectively. This suggests that the relative 
orientation of snRNPs within the 45S B-like and B complex are highly similar or even identical. 
Immunolabeling studies of the human B complex could show that the head domain contains the 
A complex and the body is composed of the U4/U6.U5 tri-snRNP (Figure 3.3E) [Wolf et al., 2009]. 
Thus, the conformational change in the 37S exon complex triggered by its interaction with the 5’ss 
oligonucleotide, probably involves a rearrangement of the A complex domain with respect to the 
U4/U6.U5 tri-snRNP leading to more stable integration of the latter, which in turn may result in the 
stable integration of the U4/U6.U5 tri-snRNP within the complex. 
The comparison of the class averages generated for the 37S exon and 45S B-like complexes provide 
evidence that the stable integration of the U4/U6.U5 tri-snRNP during 45S B-like formation is 
accompanied by a major structural rearrangement in the complex organization. As the assembly of 
the 45S B-like complex is characterized by the recruitment of stoichiometric amounts of the 
B complex-specific proteins, this suggests a potential role of these proteins in the structural change 
occurring during stable association of the U4/U6.U5 tri-snRNP with the complex. 
3.4 Interaction of the 5’ss oligonucleotide with affinity-purified 37S exon 
complexes induces a structural change resulting in stable U4/U6.U5 tri-snRNP 
binding 
To test whether the recruitment of the B complex-specific proteins is a prerequisite for the structural 
reorganization of the complex during stabilization of U4/U6.U5 tri-snRNP binding, I assayed if this 
structural change also occurs in the absence of nuclear extract. Thus, 37S exon complexes were 
assembled in splicing reactions and subsequently purified by glycerol gradient centrifugation 




First, I monitored the stability of U4/U6.U5 tri-snRNP binding within the 37S exon complex upon 
addition of the 5’ss oligonucleotide via glycerol gradient centrifugation. Therefore, affinity-purified 
37S exon complexes were mixed with either a 5’ss oligonucleotide or a 2’O-me version thereof and 
subjected to a second glycerol gradient centrifugation containing 150 mM KCl. 
 
Figure 3.4: Addition of a 5’ss oligonucleotide to affinity-purified 37S exon complex stabilizes U4/U6.U5 tri-
snRNP binding 
(A) Analytical glycerol gradient centrifugation in the presence of 150 mM KCl of affinity-purified 37S exon 
complexes after addition of 5’ss oligonucleotide or 2’O-me 5’ss oligonucleotide. Purified 45S B-like complexes 
were run in parallel. (B) Peak fractions from the gradients were used for MS2 affinity-selection. RNA was 
recovered from the eluates, separated by denaturing PAGE and visualized by silver staining. Identities of 
snRNAs are indicated. 
 
The 37S exon complex without any added oligonucleotide showed only a single peak with an S-value 
< 30S (Figure 3.4A), and thus subjecting the purified 37S exon complex to 150 mM KCl resulted in a 
significant reduction in its S-value on a second glycerol gradient. Fractions 10-12 containing the 
majority of the 32P-labeled MINX exon-RNA were subsequently used for a second MS2 affinity-
selection to characterize the RNA composition of this slower migrating complex. RNA was recovered 
from the eluates and analyzed by denaturing PAGE with subsequent silver staining. The RNA analysis 
identified only the MINX exon-RNA and U2 snRNA in fractions 10-12 of the second gradient (Figure 
3.4B, lane 1), showing that under these conditions the U4/U6.U5 tri-snRNP as well as U1 snRNP 
dissociate from the 37S exon complex and only U2 snRNP stays bound at the MINX exon-RNA. 
Apparently, the 37S exon complex does not withstand salt concentrations of 150 mM KCl once it’s in 
a purified state. Upon addition of the 5’ss oligonucleotide, but not the 2’O-ribose methylated 
version, the majority of the exon complex is converted into a faster migrating (~45S) complex that 
sediments in the same fractions as affinity-purified B-like complexes, which were initially assembled 




second peak (fractions 15-17) also to MS2 affinity-selection. The RNA analysis of fractions 15-17 
showed that the complex in these fractions contains the U4/U6.U5 tri-snRNP in addition to the 
U2 snRNP and the MINX exon-RNA (Figure 3.4B, lane 2), showing that the complex stays intact upon 
addition of the 5’ss oligonucleotide. Further, the change in the migration behavior is not due to the 
loss of U1 snRNP, as judged by the fact that the 2’O-me oligonucleotide also displaces U1 snRNP from 
the 5’ss of the MINX exon-RNA, but does not induce a change in the sedimentation value of the 
complex.  
 
Figure 3.5: Addition of a 5’ss oligonucleotide to affinity-purified 37S exon complex induces the shift to a 45S 
complex 
(A) Analytical centrifugation on glycerol gradients containing 75 mM KCl of affinity-purified 37S exon complexes 
after addition of 5’ss oligonucleotides or 2’O-me 5’ss oligonucleotide. Purified 45S B-like complexes were run in 
parallel. Additionally 2 mM of the non-hydrolysable ATP-analog AMP-PNP was added to the washing buffer to 
remove any residual ATP (+AMP-PNP). (B) Peak fractions from the second gradient were used for western blot 
analysis. Proteins were separated by 4-12 % SDS-PAGE, transferred onto a nitrocellulose membrane and 
immuno-stained with antibodies against the phosphorylated form of hPrp31 (hPrp31 phos). Antibodies against 
the U4/U6.U5 tri-snRNP-specific protein hSnu66 were used to ensure equal loading.  
 
Thus, addition of solely the 5’ss oligonucleotide converts the exon complex into a complex exhibiting 
a higher S-value with stably-bound U4/U6.U5 tri-snRNP, consistent with it undergoing a structural 
rearrangement. Similar results were obtained when the second analytical centrifugation was 
performed with glycerol gradients containing only 75 mM KCl (Figure 3.5A). Under these conditions 
the 37S exon complex only partially dissociates, with ~50 % still migrating as a 37S complex. In 
presence of the 5’ss oligonucleotide, but not the 2’O-me form, nearly all of the exon complex was 
shifted to a complex with a higher S-value that co-migrated with a 45S B-like complex, which was 
initially generated by adding the 5’ss oligonucleotide to the splicing reaction. The addition of the 5’ss 




(data not shown), suggesting that the change in the S-value only occurs upon interaction of the 5’ss 
oligonucleotide with a 37S exon complex. 
Taken together, these data demonstrate that all of the factors required for the stable U4/U6.U5 tri-
snRNP binding and the shift from a 37S to 45S complex upon addition of the 5’ss oligonucleotide are 
already present in the affinity-purified 37S exon complex. Thus, B complex-specific proteins do not 
appear to play a major role in this process.  
3.4.1 ATP hydrolysis is not required for the shift in the S-value from 37S to 45S 
Assembly of the multi-megadalton spliceosome involves a series of structural rearrangements that 
are mainly driven by ATPases and helicases upon their hydrolysis of NTPs/ATP. As no additional ATP 
was added to the purified 37S exon complexes and the incubation steps were performed on ice, ATP 
hydrolysis does not appear to be required for the shift in its sedimentation value. However, at this 
point of our investigations it could not be excluded that ATP is bound by the purified complexes. 
The standard procedure to deplete splicing reactions from ATP is an incubation in the presence of 
glucose and hexokinase at 30 °C. But, in this case it was not possible to deplete ATP potentially 
retained by the 37S exon complexes by adding hexokinase and glucose due to the heat-sensitivity of 
the isolated complexes. Therefore, I set out to compete for ATP binding by supplementing the buffer 
that was used to wash the complexes while bound to the amylose beads with 2mM of the non-
hydrolysable ATP-analog AMP-PNP. These AMP-PNP treated 37S complexes were eluted from the 
column and the eluate was afterwards incubated with the 5’ss oligonucleotide. The glycerol gradient 
analysis of this reaction showed that the AMP-PNP washed 37S exon complexes also exhibited a 
faster migration behavior upon addition of the 5’ss oligonucleotide. These results strongly suggest 
that the increased sedimentation value of the 37S exon complex is ATP-independent and relies only 
on the presence of a 5’ss oligonucleotide. 
3.4.2 Phosphorylation of hPrp31 is not required for transforming the 37S exon complex 
into a 45S complex 
Previous studies showed that stable B complex formation when performed with nuclear extract 
depends on the phosphorylation of the U4/U6.U5 tri-snRNP-associated proteins hPrp31 and hPrp6 by 
the hPrp4 kinase [Schneider et al., 2010b]. Further, it was shown that these proteins can also be 
phosphorylated in purified 37S exon complexes upon addition of the 5’ss oligonucleotide and 
additional ATP and incubating at 30 °C [Schneider et al., 2010a]. This suggested that the site-specific 
phosphorylation of these factors might be necessary for the stable integration of U4/U6.U5 tri-snRNP 




prerequisite for the increased sedimentation value of the 37S exon complex upon addition of the 5’ss 
oligonucleotide, I monitored the phosphorylation-status of hPrp31 in peak fractions of the second 
gradient. Proteins from the peak fractions were precipitated and transferred to a nitrocellulose 
membrane. Then, the membrane was incubated with antibodies that specifically recognize the 
phosphorylated form of hPrp31 (Figure 3.5B). The phosphorylation of hPrp31 is strongly increased 
upon transition from the 37S exon to the 45S B-like complexes by addition of the 5’ss oligonucleotide 
to initial splicing reactions in nuclear extract (Figure 3.5B, lane 1 & 2). When 37S exon complexes 
were incubated with the 5’ss oligonucleotide after MS2 affinity-selection, no increase in hPrp31 
phosphorylation was observed despite the increase in their sedimentation value. 37S exon 
complexes that were additionally treated with AMP-PNP also showed no increased phosphorylation. 
These results show that the shift to a 45S complex does not dependent on the site-specific 
phosphorylation of hPrp31. 
3.5 EM reveals a structural change in the purified 37S exon complex after 
addition of the 5’ss oligonucleotide 
The shift in the migration behavior of purified 37S exon complexes after addition of the 5’ss 
oligonucleotide (stabilized exon complex) is likely due to a structural rearrangement in the complex. 
To identify potential structural changes, we subjected the stabilized exon complex to negative-stain 
EM. Therefore, affinity-purified 37S exon complexes were incubated with the 5’ss oligonucleotide 
and subsequently subjected to a second glycerol gradient under GraFix conditions. Complexes from 
the peak fractions of this fixating second gradient were then used for EM analysis with identical 
conditions as previously used for the 37S exon and 45S B-like complex (see figure 3.3). As judged by 
the appearance of single, clearly-defined particles on the EM grid (Figure 3.6A), we excluded an 
aggregation of the complex upon addition of the 5’ss oligonucleotide to be the reason for the 
increased sedimentation value. Subsequently, we generated class averages of the stabilized exon 
complex to allow a structural comparison with 37S exon and 45S B-like complexes, which were 
purified directly from splicing reactions. To generate representative class averages of the stabilized 
exon complex a total of 12000 raw images were subjected to image processing and characteristic 
class averages generated from these single particles are shown in the galleries 1-6 in figure 3.6A. The 
calculation of class averages resulted in similar structures in almost all classes, which might be 
explained by a predominant orientation of the complex on the EM grid, a feature also characteristic 
for the 45S B-like complex. The overall appearance of the stabilized exon complex was surprisingly 





Figure 3.6: EM analysis of affinity-purified 37S exon complexes after addition of 5’ss oligonucleotide 
(A) The overview on the left side shows negatively-stained particles of the stabilized exon complex on the EM 
grid. Representative class averages generated from single-particle images are shown in the galleries 1-6 on the 
right. Characteristic structural features within the body domain of the stabilized exon complex are indicated 
with red arrows. A selection of characteristic class averages of 45S B-like (B) and 37S exon (C) complexes is 
shown below. Scale bars correspond to 50 nm. 
 
The dimensions of the complexes and the relative orientation of the head domain with respect to the 
body domain appear to be nearly identical in the stabilized exon complex and the 45S B-like complex, 
which was initially formed in nuclear extract. However, the structure of the U4/U6.U5 tri-snRNP 
containing body domain is slightly different in the stabilized exon complex in comparison to the 
45S B-like complex. The majority of class averages calculated for the stabilized exon complex shows 
an additional belly-like protrusion in the center of the body domain, which is not present or 
significantly less pronounced in the structures of the 45S B-like complex. In contrast the stump of the 
body domain appears less pronounced in the class averages of the stabilized exon complex (Figure 
3.6A, indicated with red arrows). These differences in the morphology of the body domain might 
indicate a slightly different orientation of the U4/U6.U5 tri-snRNP in the stabilized exon complex, 
eventually due to the absence of the B complex-specific proteins. In contrast, we detected no class 
averages with a morphology like the purified 37S exon complex (Figure 3.6C), which was prepared in 
absence of any oligonucleotide. The results shown here strongly suggest that solely the interaction of 
a free 5’ss oligonucleotide with the 37S exon complex induces a major remodeling of the complex 
organization. The rearrangement results in a complex morphology, which is very similar to the 45S B-
like complex that was initially assembled in the splicing reaction. Apparently, the B complex-specific 




proteins are almost completely absent in the stabilized exon complex (see chapter 3.2). This provides 
strong evidence that the rearrangement of the complex is independent of protein factors not already 
found in the 37S exon complex or the activity of helicases or kinases since no ATP is required (see 
chapter 3.4.1). 
3.6 Sequence requirements of the 5’ss oligonucleotide for U4/U6.U5 tri-
snRNP stabilization during B-like complex formation  
The results above show that solely the addition of a 5’ss oligonucleotide to the 37S exon complex is 
sufficient to stably integrate the U4/U6.U5 tri-snRNP and adopt a structural organization 
characteristic for a 45S B-like complex. Previous studies indicated that the 5’ss oligonucleotide 
contacts the U6 ACAGAG box of the U4/U6.U5 tri-snRNP in the 45S B-like complex [Schneider et al., 
2010a]. But up to now it is not known, if the 5’ss/U6 base pairing and/or other interactions are 
essential to induce the structural rearrangement that is observed during formation of a 45S B-like 
complex. To assess the sequence requirements of the 5’splice site for transforming the 37S exon to a 
stable 45S B-like complex, we monitored the effects of different mutations within the oligonucleotide 
sequence on the formation of a stable B-like complex. 
3.6.1 The exon-intron junction of the 5’ss oligonucleotide interacts with the U5 protein 
hPrp8 in stably-assembled 45S B-like complexes 
Previous studies of the RNA-RNA network in pre-catalytic spliceosomes showed that exonic 
nucleotides of the 5’splice site base pair with loop I of U5 snRNA and intronic nucleotides with the 
ACAGAG box of U6 snRNA [Wassarmann and Steitz, 1992]. Furthermore, it was shown in a trans-
splicing assay using a radioactively-labeled 5’ss RNA oligonucleotide, that the conserved GU 
dinucleotide at the exon-intron junction is site-specifically crosslinked to the hPrp8 protein in stably-
assembled B complexes [Reyes et al., 1999] (Figure 3.7A). I first monitored whether hPrp8 also 
contacts this region of the 5’ss oligonucleotide in 45S B-like complexes, which were assembled on the 
MINX exon-RNA.  
To allow the identification of a site-specific protein-RNA interaction, I designed a 5’ss oligonucleotide 
containing a 6-thio-G substitution at position +1. Thio-modified oligos can be covalently crosslinked 
to proteins at a wavelength of 365 nm, which prevents unspecific crosslinks between RNA and 
proteins. The modification of the 5’ss oligonucleotide at position +1 with a 6-thio-G nucleotide does 
not impair B-like complex formation, as evidenced by native gel-electrophoresis (Figure 3.7B, lane 2) 





Figure 3.7: The exon-intron junction of the 5’ss oligonucleotide interacts with the U5 protein hPrp8 in stably-
assembled 45S B-like complexes 
(A) Scheme of the proposed interactions of a 5’splice site with the U5 snRNA, U6 snRNA and hPrp8 [adopted 
from Wassarmann and Steitz, 1992, Reyes et al., 1999]. The exonic part of the 5’splice site is represented by a 
shaded box. (B) B-like complex formation upon introduction of a (+1) 6-thio-G modification within the 5’ss 
oligonucleotide was tested by native gel analysis. (C) 45S B-like complexes were assembled in the presence of a 
5’-32P-labeled (+1) 6-thio-G modified 5’ss oligonucleotide and subjected to glycerol gradient centrifugation. 
After MS2 affinity-selection of peak fractions, purified complexes were irradiated at 365 nm (lanes 2, 3, 5, 6) to 
induce protein-RNA crosslinks and subsequently treated with RNase A (lanes 3 & 6). Proteins were separated 
on a 10-13 % polyacrylamide gel and visualized by silver staining (lanes 1-3). Crosslinked proteins were 
detected by exposure to a phosphoimager screen (lanes 4-6). *: Position of MINX exon-RNA. (D) Immuno-
precipitation of hPrp8 from denatured 45S B-like complexes after UV irradiation. Lanes 1 and 2 are controls 
without UV irradiation. Immunoprecipitation was performed using PAS-bound antibodies against hPrp8. The 
lanes 1 and 3 show negative controls, in which antibodies were omitted. The eluted proteins were separated by 
4-12 % SDS-PAGE and blotted onto a nitrocellulose membrane. Western blotting was performed with hPrp8-





Irradiation of affinity-purified 45S B-like complexes assembled in the presence of a 32P-labeled (+1) 6-
thio-G oligonucleotide at 365 nm generated a highly-specific protein-RNA crosslink, which is resistant 
to RNase A treatment (Figure 3.7C, lane 6). The first cleavage site of RNase A, which cleaves after 
pyrimidines, is downstream of the exon-intron junction, so that the 5’-32P-label and the (+1) 6-thio-G 
crosslink are included within the same cleavage fragment. The crosslinked protein migrates in the 
range of ~250 kDa and co-migrates with the silver stained hPrp8 band (Figure 3.7C, lane 3). 
Immunoprecipitation with hPrp8-specific antibodies demonstrated that this crosslinked protein is 
indeed hPrp8 (Figure 3.7D). The same result was achieved using (-1) 6-thio-G or (+2) 4-thio-U 
modified 5’ss oligonucleotides (data not shown), showing that hPrp8 contacts nucleotides across the 
exon-intron boundary. 
3.6.2 Base pairing interactions between 5’ss and U6 ACAGAG box are not absolutely 
required for stable B-like complex formation 
To determine the sequence requirements for inducing stable integration of the U4/U6.U5 tri-snRNP 
during B-like formation, we introduced a variety of mutations into the 5’ss oligonucleotide sequence 
and analyzed their effects on B-like complex formation (Figure 3.8A). The stability of U4/U6.U5 tri-
snRNP binding was assayed by native gel-electrophoresis in the presence of heparin. 
First, I disrupted the Watson-Crick base pairing between loop I of U5 snRNA and the 5’ss 
oligonucleotide by mutating all three exonic nucleotides to uridines (U5:5’ss). This resulted in 
reduced formation of B-like complexes in comparison to the optimized wildtype sequence as assayed 
by native gel-electrophoresis (Figure 3.8B, lanes 3 & 4), but had little or no effect when assayed by 
the less stringent glycerol gradient centrifugation (Figure 3.8C). Next, I mutated intron nucleotides 
+5 to +8 of the 5’ss oligonucleotide to abolish Watson-Crick base pairing with the ACAGAG box of 
U6 snRNA (U6:5’ss). This mutation also impaired, but did not abolish formation of B-like complexes 
on native gels (Figure 3.8B, lane 5) and had no effect when assayed by glycerol gradient 
centrifugation (Figure 3.8C). Thus, neither the U5:5’ss nor the U6:5’ss interaction is absolutely 
necessary for stable B-like formation. But, when both mutations were introduced within the same 
oligonucleotide (U5:5’ss + U6:5’ss) B-like complex formation was completely abolished both on a 
native gel (Figure 3.8B, lane 6) and glycerol gradients (Figure 3.8C). These results show that individual 
disruption of either U5/5’ss or U6/5’ss base pairing has a moderate effect on B-like formation, but 





Figure 3.8: Effect of disruption of U5 and U6 interactions with the 5’ss oligonucleotide on B-like complex 
formation 
(A) Overview of mutations introduced within the 5’ss oligonucleotide sequence to abolish Watson-Crick base 
pairing with U5 or/and U6 snRNA, respectively. Exonic nucleotides are highlighted by a blue box and mutations 
are labeled in red. (B) Native gel analysis of B-like complex assembly upon addition of mutated 5’ss 
oligonucleotides to the splicing reaction. Samples were analyzed on a 2 % (w/v) LMP agarose gel in the 
presence of heparin and visualized by autoradiography. The identities of the spliceosomal complexes are 
indicated. (C) Analytical glycerol gradient centrifugation of cross-exon complexes formed in splicing reactions 






3.6.3 Mutations of nucleotides at the exon-intron junction that contact hPrp8 abolish 
formation of a stable 45S B-like complex 
Next, I investigated the role of the exon-intron junction of the 5’ss oligonucleotide, which is 
contacted by hPrp8, in formation of a stable B-like complex. Thus, I monitored the impact of 
mutations within the conserved G/GU nucleotides that define the exon-intron junction (Figure 3.9A).  
 
Figure 3.9: Mutations within the exon-intron junction of the 5’ss oligonucleotide abolish formation of a 
stable 45S B-like complex 
(A) Schematic of interactions between the 5’ss oligonucleotide and U5 snRNA, U6 snRNA and hPrp8. (B) Native 
gel analysis of B-like formation with 5’ss oligonucleotides containing mutations within the G/GU triplet at the 
exon-intron junction. Mutations are indicated above the respective lane. Positions of the spliceosomal 
complexes are indicated. rI: ribo-inosine modification. (C) Schematic representation of guanosine and inosine 
base. (D) Analytical glycerol gradient centrifugation of complexes formed in extracts upon addition of the 





Oligonucleotides containing single point mutations of -1G → A or +2U → A support B-like formation 
as efficiently as the wildtype sequence (Figure 3.9B, lanes 3, 4 & 6). The mutation of +1G → A 
strongly impaired the formation of a stable B-like complex in presence of heparin (Figure 3.9B, 
lane 5), but had only little effect when assayed by glycerol gradient centrifugation (Figure 3.9C). 
However, the mutation of two neighboring nucleotides within the exon-intron junction, either GG → 
AA or GU → AA, resulted in a complete inhibition of B-like formation as judged by native gel analysis 
(Figure 3.9B, lanes 7 & 8) and glycerol gradient centrifugation (Figure 3.9C). Thus, a single point 
mutation at position +1G strongly impairs B-like formation and mutation of a second neighboring 
nucleotide completely abolishes stable U4/U6.U5 tri-snRNP binding. Interestingly, the mutation of 
the GG dinucleotide to ribo-inosines also inhibited the stable integration of the U4/U6.U5 tri-snRNP 
(Figure 3.9B, lane 9) as well as the transition to a 45S complex (data not shown). As guanosine and 
ribo-inosine differ only by an amino group in the exocyclic group of the nucleotide (Figure 3.9D), this 
points to a very specific and functionally important recognition of guanosine-nucleotides at the exon-
intron junction probably via interaction with hPrp8. 
3.6.4 Double mutations at the intron-exon boundary abolish binding of 5’ss 
oligonucleotide to the exon complex 
The mutations with the strongest impact on B-like formation are located in the region of the 
hPrp8:5’ss interaction and should have little or no affect on the RNA-RNA interactions between U5 or 
U6 snRNA and the 5’ss oligonucleotide. Since these 5’ss oligonucleotide mutants still have 
complementarity to the U5 snRNA and U6 snRNA, I tested if these RNA-RNA interactions are 
sufficient to stably bind the different oligonucleotides to the 37S exon complex.  
Thus, 5’ss oligonucleotides containing mutations of a single nucleotide (+1G → A) or two neighboring 
nucleotides (GG → AA and GU → AA) were first 5’-32P-labeled in order to detect them by denaturing 
PAGE after affinity-purification of the 37S exon or 45S B-like complexes, respectively. Then, 
spliceosomal complexes were assembled in presence of either labeled or unlabeled 5’ss 
oligonucleotides and subjected to glycerol gradient centrifugation. The peak fractions of these 
gradients, 45S peak for the wildtype and +1G → A, and 37S peak for the GG → AA and GU → AA 
oligonucleotide (see figure 3.9D), were subjected to MS2 affinity-selection. RNA was recovered from 
the eluates, separated on a denaturing PAGE and 32P-labeled RNA species were detected by 
autoradiography. After affinity-purification, I detected in all lanes similar amounts of 32P-labeled 
MINX exon-RNA, which was used to assemble and purify the complexes (Figure 3.10). Additionally, 
I detected signals for the wildtype and +1G → A oligonucleotide upon 5’-32P-labeling (Figure 3.10, 





Figure 3.10: Double mutations within the exon-intron junction inhibit the integration of the 5’ss 
oligonucleotide 
Spliceosomal complexes were assembled in the presence of the wildtype or mutated 5’-
32
P-labeled 5’ss 
oligonucleotides, and subsequently subjected to glycerol gradient centrifugation. After MS2 affinity-selection of 
the respective peak fractions, RNA was recovered from the eluates, separated by denaturing PAGE and 
visualized by autoradiography. The positions of MINX exon-RNA and 5’labeled oligonucleotide are indicated. 
 
This was not the case for the 5’-32P-labeled oligonucleotides containing mutations GG → AA and GU 
→ AA (Figure 3.10, lanes 6 & 8) showing that these oligonucleotides were not co-purified with the 
respective complex despite their complementarities to U5 and U6 snRNA. These results provide 
evidence that not only RNA-RNA interactions between the 5’ss oligonucleotide and the U5 snRNA 
and U6 snRNA are necessary for the physical association of the 5’ss with the complex, but also 
additional protein-RNA interactions are required for stable binding of the 5’ss oligonucleotide. This 
points to a crucial role for the hPrp8:5’ss interaction in binding of the 5’ss and further in mediating 
the structural change that leads then to stable integration of the U4/U6.U5 tri-snRNP. 
I went on to test the co-purification of 5’-32P-labeled 5’ss oligonucleotides mutants described in 
chapter 3.6.2 and 3.6.3 as well as the 2’O-me 5’ss oligonucleotide. A summary of the results is listed 
in Table 3.2. Interestingly, the 2’O-me 5’ss oligonucleotide was not co-purified with the complex, 
suggesting that the physical association of the 5’ss oligonucleotide with the 37S exon complex does 
not only depend on a specific interaction of hPrp8 with guanosine nucleotides at the exon-intron 
boundary, but also involves a recognition of the ribose-backbone of the RNA oligonucleotide. In 
addition, I could show that all 5’ss oligonucleotides that induce the transition to a 45S complex were 




32P-labeled MINX exon-RNA and the 5’-labeled 5’ss oligonucleotides, we determined that 




  B-like formation 
S-value 
co- 
    on native gel purification 
                                    
  wildtype   A A G G U A A G U A U   +++ 50S + 
                                    
  2'O-me   A A G G U A A G U A U   - 37S - 
                                    
  U5:5'ss   U U U G U A A G U A U   ++ 50S + 
                                    
  U6:5'ss   A A G G U A A C A U A   ++ 50S + 
                                    
  U5:5'ss + U6:5'ss   U U U G U A A C A U A   - 37S - 
                                    
  -1G → A   A A A G U A A G U A U   +++ 50S + 
                                    
  +1G → A   A A G A U A A G U A U   + 50S + 
                                    
  +2U → A   A A G G A A A G U A U   +++ 50S + 
                                    
  GU → AA   A A G A A A A G U A U   - 37S - 
                                    
  GG → AA   A A A A U A A G U A U   - 37S - 
                                    
  GU → rIrI   A A rI rI U A A G U A U   - 37S - 
                                    
      -3 -2 -1 +1 +2 +3 +4 +5 +6 +7 +8         
 
Table 3.2: Summary of the effects of the 5’ss oligonucleotide mutations on the 45S B-like complex formation 
Overview of 5’ss oligonucleotide mutants and their effect on the formation of a 45S B-like complex. Exonic 
nucleotides are represented by a shaded box and mutations are labeled in red. The effect of mutations on B-
like complex formation assayed by native gel analysis was classified in not reduced (+++), reduced (++), strongly 
reduced (+) and complete inhibition (-). Sedimentation values of the spliceosomal complexes were determined 
by glycerol gradient centrifugation and co-purification of 5’-
32
P-labeled 5’ss oligonucleotides was detected by 
MS2 affinity-selection followed by denaturing PAGE.  
3.6.5 Recruitment of B complex-specific proteins is independent of complex stability in 
presence of heparin 
In the presence of certain mutated 5’ss oligonucleotides, namely U5:5’ss, U6:5’ss and +1G → A, the 
formation of a B-like complex was reduced in the presence of heparin during native gel-
electrophoresis, but not under the less stringent conditions used for glycerol gradient centrifugation. 
However, these 5’ss oligonucleotide mutants still bind to the cross-exon complex resulting in a 
quantitative shift to a 45S complex (Table 3.2), but the U4/U6.U5 tri-snRNP appears to be slightly less 
stably associated, i.e. sensitive to heparin. The formation of a stable 45S B-like complex in splicing 
reactions is not only characterized by an increased sedimentation value, but also by a site-specific 
phosphorylation of hPrp31 and strongly enriched amounts of the B complex-specific proteins. These 
characteristics of the B-like complex could potentially be involved in the stabilization of U4/U6.U5 tri-





Figure 3.11: Western blot analysis of 45S B-like complexes assembled in presence of mutated 5’ss 
oligonucleotides 
Affinity-purified 37S exon or 45S B-like complexes formed after addition of the indicated 5’ss oligonucleotide 
were separated on a 4-12 % SDS-PAGE, transferred to a nitrocellulose membrane and sequentially 
immunoblotted with the antibodies indicated on the right. Antibodies against the U4/U6.U5-specific protein 
hSnu66 were used to control for equal loading. 
 
Therefore, I monitored the recruitment of B complex-specific proteins and the site-specific 
phosphorylation of hPrp31 in B-like complexes that were assembled by addition of the 5’ss 
oligonucleotide mutants U5:5’ss, U6:5’ss and +1G → A to the splicing reaction. These splicing 
reactions were then subjected to glycerol gradient centrifugation and the 45S peak fractions (see 
figures 3.8C & 3.9D) were used for MS2 affinity-selection. Finally, the recruitment of B complex-
specific proteins and the site-specific phosphorylation of hPrp31 within the purified complexes were 
investigated via immunoblotting with the respective antibodies.Western blot analysis showed the 
same amount of site-specific phosphorylation of hPrp31 in the B-like complexes that were assembled 
in presence of the U5:5’ss, U6:5’ss or +1G → A oligonucleotide mutants as for the wildtype 5’ss 
oligonucleotide (Figure 3.11, lanes 2-5). Further, the amount of B complex-specific proteins was also 
nearly identical in all of the B-like complexes analyzed, despite their difference in heparin-resistance. 
These results show that the apparent difference in complex stability is independent of hPrp31 




3.7 A dominant-negative mutant of the DEAD-box helicase hPrp28 stalls 
spliceosome assembly prior to stable B complex formation 
Next I set out to investigate the requirements for the stable integration of the U4/U6.U5 tri-snRNP 
during formation of a pre-catalytic B complex that is assembled across an intron. A prerequisite for 
these studies was the isolation of an intron-defined splicing complex containing all five snRNPs, but 
in which the U4/U6.U5 tri-snRNP had not yet been stably-integrated.  
During the initial steps of spliceosome assembly the 5’splice site of a pre-mRNA base pairs with the 
5’end of the U1 snRNA. The DEAD-box helicase Prp28 disrupts this U1:5’ss interaction during 
formation of a stable pre-catalytic B complex and previous studies suggested that in yeast the 
U4/U6.U5 tri-snRNP initially associates with the spliceosome prior to the action of Prp28 [Staley and 
Guthrie, 1999, Chen et al., 2001]. Therefore, we chose hPrp28 as a target to inhibit splicing prior to 
formation of an intron-defined B complex. The aim was to induce a retention of U1 snRNP at the 
5’splice site of the pre-mRNA to impair its interaction with the U4/U6.U5 tri-snRNP. Thus, I used a 
His6-tagged version of the human ortholog of Prp28 (hPrp28), in which the DEAD motif was mutated 
to AAAD, thereby abolishing its ATPase activity (kindly provided by Prof. Dr. Ralf Ficner, Department 
for Molecular Structural Biology, Georg-August-Universität Göttingen). This ATPase-deficient hPrp28 
is further designated as hPrp28AAAD. First, I tested if this ATPase-deficient protein is a suitable tool to 
stall spliceosome formation prior to B complex formation. Therefore, increasing amounts of 
recombinant hPrp28 wildtype or the hPrp28AAAD protein were added to a splicing reaction containing 
a MINX pre-mRNA to investigate its effect on in vitro splicing. A pre-incubation in the absence of the 
pre-mRNA substrate was first carried out to allow an exchange of the endogenous hPrp28, which is 
an integral component of the U4/U6.U5 tri-snRNP, with the recombinant protein, and the splicing 
reaction was subsequently started by addition of the MINX pre-mRNA. The reaction was stopped 
after 30 min of incubation and the RNA was recovered and separated on a 14 % denaturing 
polyacrylamide gel. The formation of splicing intermediates and products was detected by 
autoradiography. The addition of recombinantly-expressed hPrp28 wildtype protein had little or no 
effect on splicing as judged by the amounts of splicing intermediates and products formed relative to 
the control without any recombinant protein (Figure 3.12, compare lane 2 with lanes 3-6). Addition 
of increasing concentrations of hPrp28AAAD impaired pre-mRNA splicing (Figure 3.12, lane 7 & 8), and 
at a final concentration of 50 ng/µl hPrp28AAAD a complete inhibition of in vitro splicing was observed 
(Figure 3.12, lane 9). In vitro splicing was blocked prior to the first catalytic step, as neither 
intermediates nor products of the splicing reaction were detected. These results show that pre-




protein. Thus, the recombinant hPrp28AAAD acts as a dominant-negative mutant during in vitro 
splicing.  
 
Figure 3.12: Recombinant hPrp28
AAAD
 protein inhibits splicing prior to the first catalytic step 
In vitro splicing of uniformly 
32
P-labeled MINX pre-mRNA was carried out in HeLa nuclear extract. Prior to 
addition of pre-mRNA, the splicing reaction was supplemented with recombinant wildtype hPrp28 or an AAAD 
mutant version of the protein to the final concentrations as indicated. RNA was analyzed on a 14 % 
polyacrylamide gel and visualized by autoradiography. The positions of the pre-mRNA, splicing intermediates 
and products are indicated on the right. 
 
To identify which step of splicing is blocked by recombinant hPrp28AAAD, I analyzed spliceosome 
assembly in the presence of the dominant-negative mutant by native gel-electrophoresis. Splicing 
reactions were performed in the presence of inhibitory concentrations of hPrp28AAAD protein for the 
times indicated. Afterwards the samples were subjected to native gel-electrophoresis in the presence 
of heparin and complex formation was visualized by autoradiography.   
The native gel analysis showed a sequential formation of A, B and Bact/C complexes in reactions 
without any recombinant protein (Figure 3.13, lanes 1-4) and in samples with the recombinant 
hPrp28 wildtype protein (Figure 3.13, lanes 5 & 6). In the presence of the hPrp28AAAD mutant, 
B complex assembly was severely reduced and predominantly formation of A complex was observed 
(Figure 3.13, lane 7 & 8). These results show that the presence of hPrp28AAAD blocks spliceosome 
assembly after A complex but prior to stable B complex formation. In summary, the use of the 
dominant-negative hPrp28AAAD is an efficient and powerful tool to stall spliceosome assembly prior to 







 stalls spliceosome assembly prior to B complex formation 
Spliceosome assembly was investigated in the presence of 50 ng/µl of recombinant hPrp28 wildtype or AAAD 
protein. Spliceosomal complexes were formed under splicing conditions in HeLa nuclear extract for the times 
indicated, subsequently analyzed on a 2 % (w/v) LMP agarose gel in the presence of heparin, and visualized by 
autoradiography. The positions of H, A, B and B
act
/C complexes are indicated. 
 
3.8 Isolation and characterization of a novel intron-defined spliceosome 
assembly intermediate 
The presence of hPrp28AAAD resulted in an inhibition of B complex formation and in native gel 
analyses mainly A complex assembly was detected. At this point it was not clear if the inhibition of 
spliceosome assembly occurs prior to recruitment of the U4/U6.U5 tri-snRNP or after association of 
the U4/U6.U5 tri-snRNP with the complex, but prior to its stable integration. Thus, I set out to 
characterize the effect of the hPrp28AAAD on spliceosome assembly in greater detail. For this purpose 
I performed splicing reactions either in presence or absence of the hPrp28AAAD mutant and separated 
the complexes by glycerol gradient ultracentrifugation. The gradient profile shows that spliceosomal 
complexes assembled in the presence of hPrp28AAAD peaked in the region of ~37-40S (designated 
37S cross-intron complex), while the kinetically-assembled B complex, which is formed after 6 min of 
in vitro splicing, peaked at ~45S (Figure 3.14A). To further characterize this 37S cross-intron complex 
I performed MS2 affinity-selection of the peak fractions. RNA was recovered from the eluates, 





Figure 3.14: Addition of hPrp28
AAAD
 stalls spliceosome assembly after recruitment of the U4/U6.U5 tri-snRNP 
(A) Analysis of spliceosomal complexes assembled in the presence of inhibitory concentrations of the 
recombinant hPrp28
AAAD
 by centrifugation on glycerol gradients containing 150 mM KCl. Sedimentation values 
were determined with prokaryotic ribosomal subunits. (B) Peak fractions were subjected to MS2 affinity-
selection. RNA was recovered from the eluted complexes, separated by denaturing PAGE and visualized with 
silver staining. snRNA identities are indicated on the right. 
 
The RNA analysis showed that the hPrp28AAAD stalled 37S cross-intron complex contains 
stoichiometric amounts of all five snRNAs (Figure 3.14B, lane 1). In contrast, U1 snRNA is significantly 
underrepresented in stably assembled B complexes (Figure 3.14B, lane 2). These results suggest that 
in presence of the hPrp28AAAD a spliceosomal complex is formed, in which the U4/U6.U5 tri-snRNP is 
already recruited, but not yet stably bound such that it does not withstand the presence of heparin 
during native gel-electrophoresis. An intermediate with these characteristics has not yet been 
described for the human spliceosome assembly pathway. Thus, it represents a novel assembly 
intermediate that is formed prior to the action of hPrp28 and stable B complex formation. 
Consequently, I set out to identify the protein composition of this 37S cross-intron complex by mass 
spectrometry in order to characterize the change in the protein composition that occurs during 
formation of an intron-defined B complex. To identify proteins associated with the 37S cross-intron 
complex and compare them with the protein inventory of a kinetically-assembled B complex, affinity-
purified complexes were separated on a 4-12 % SDS-PAGE and proteins were identified by LC-
MS/MS. The identified proteins and their respective peptide counts are shown in Table 3.3. The 
MS analysis identified all proteins associated with the 17S U2 snRNP, as well as a number of 17S U2-




specific proteins including the Sm and LSm proteins were identified. This includes also the hPrp28 
protein, which suggested that the recombinant hPrp28AAAD is integrated in the 37S cross-intron 
complex. We subsequently confirmed the presence of the hPrp28AAAD protein via western blot 
analysis with antibodies against the His6-tag of the recombinant protein (data not shown). The 37S 
cross-intron complex contains also U1 snRNP-associated proteins, while in the B complex the 
U1 proteins are less abundant compared to the U2, U5 and U4/U6 associated proteins. This is 
consistent with the lower abundance of U1 snRNA in the B complex shown in figure 3.14B. 
Moreover the B complex shows higher peptide counts for the B complex-specific proteins RED, 
MFAP1, FBP-21, hSmu-1, hPrp38 and hSnu23 in comparison to the 37S cross-intron complex. 
Proteins associated with the hPrp19 complex and hPrp19 complex-related proteins were identified in 
the B complex, while these proteins were nearly absent in the 37S cross-intron complex. Further, 
proteins of the RES complex are also underrepresented in the 37S cross-intron complex in 
comparison to the B complex. The MS analysis shows that the protein inventory of the 37S cross-
intron complex consists mainly of U1, U2, U2-related and U4/U6.U5 tri-snRNP associated proteins, 
whereas the B complex additionally contains B complex-specific proteins and factors that are related 
to the hPrp19 and RES complex. Interestingly, the protein composition of the 37S cross-intron 
complex appears to be astonishingly similar to the 37S exon complex, which was previously 
investigated by mass spectrometry under comparable conditions [Schneider et al., 2010a]. We thus 
set out to compare the protein composition of the 37S cross-intron and 37S exon complexes with a 
more quantitative approach using 2D gel-electrophoresis followed by MS identification, which also 




















    
          
 preparation gi number MW   #1 #2 #3   #1 #2 #3   S. cerevisiae 
pmol   0.9 0.9 2.0   0.9 0.9 2.0   gene name 
                          
Sm                         
Sm B/B' gi|119631003 24 kDa   43 35 62   52 55 94   SMB1 
Sm D1 gi|5902102 13 kDa   12 15 38   18 17 62   SMD1 
SmD2 gi|4759158 14 kDa   22 39 51   26 42 72   SMD2 
SmD3 gi|4759160 14 kDa   25 36 57   34 45 59   SMD3 
Sm E gi|4507129 11 kDa   18 25 65   17 31 70   SME1 
Sm F gi|4507131 10 kDa   11 - 10   7 - 12   SMX3 
Sm G gi|4507133 8 kDa   4 - 9   5 - 12   SMX2 
                          
U1                         
U1-70K gi|36100 52 kDa   23 19 38   7 11 13   SNP1 
U1-A gi|189053747 31 kDa   24 29 35   10 14 13   MUD1 
U1-C gi|119624201 20 kDa   4 - 7   3 - 3   YHC1 
                          
U2                         
U2 A' gi|50593002 28 kDa   65 47 66   65 59 82   LEA1 
U2B'' gi|119630691 28 kDa   27 21 39   24 25 45   MSL1 
SF3a120 gi|5032087 89 kDa   75 70 185   63 88 213   PRP21 
SF3a66 gi|116283242 51 kDa   15 17 32   13 20 40   PRP11 
SF3a60 gi|158255798 59 kDa   50 42 98   45 63 120   PRP9 
SF3b155 gi|54112117 146 kDa   188 206 559   215 222 740   HSH155 
SF3b145 gi|33875399 100 kDa   63 65 205   71 80 299   CUS1 
SF3b130 gi|54112121 136 kDa   232 216 833   236 255 950   RSE1 
SF3b49 gi|5032069 44 kDa   13 14 43   12 16 43   HSH49 
SF3B14a / p14 gi|7706326 15 kDa   22 21 40   29 18 48     
SF3b14b gi|14249398 12 kDa   10 6 12   13 11 21   RDS3 
SF3b10 gi|13775200 10 kDa   5 - 16   4 - 21   YSF3 
 
                        
U2-related                         
hPrp43 gi|68509926 91 kDa   52 44 130   60 46 142   Prp43 
U2AF65 gi|228543 53 kDa   14 20 45   8 19 36     
U2AF35 gi|5803207 28 kDa   7 9 14   7 6 18     
SPF45 gi|14249678 45 kDa   15 14 18   11 10 20     
SPF30 gi|189054204 27 kDa   12 19 35   7 16 21     
CHERP gi|119226260 104 kDa   20 16 23   12 10 20     
SR140 gi|122937227 118 kDa   25 21 67   20 19 67     
PUF60 gi|109087698 54 kDa   1 8 4   - 7 1     
 
                        
U5                         
hPrp8 gi|91208426 274 kDa   257 271 1048   392 450 1601   PRP8 
hBrr2 gi|40217847 245 kDa   343 307 1316   519 521 1925   BRR2 
hSnu114 gi|12803113 109 kDa   141 150 545   223 228 788   SNU114 
hPrp6 gi|189067252 107 kDa   109 98 301   105 141 441   PRP6 
hPrp28 gi|193785886 93 kDa   101 110 217   76 75 157   PRP28 
40K gi|115298668 39 kDa   46 63 141   70 75 237     
hDib1 gi|5729802 17 kDa   22 - 28   20 - 31     
hLin1 gi|5174409 38 kDa   8 5 4   10 18 28   Lin1 
 
                        
LSm                         
LSm2 gi|10863977 11 kDa   13 11 23   13 14 25   LSM2 
LSm3 gi|189053316 12 kDa   4 4 1   2 6 2   LSM3 
LSm4 gi|6912486 15 kDa   5 10 14   5 13 22   LSM4 
LSm5 gi|195222722 7 kDa   3 - 4   1 - 5   LSM5 
LSm6 gi|5901998 9 kDa   3 3 6   1 6 10   LSM6 
LSm7 gi|119589795 15 kDa   5 - 6   7 - 7   LSM7 
LSm8 gi|7706425 10 kDa   12 11 13   10 7 23   LSM8 
 
                        
U4/U6                         
hPrp3 gi|4758556 78 kDa   77 97 186   85 116 255   PRP3 
hPrp31 gi|221136939 55 kDa   44 39 99   33 62 122   PRP31 
hPrp4 gi|189053699 58 kDa   72 80 229   51 90 272   PRP4 
Cyp-H gi|119627556 17 kDa   17 26 57   23 27 68   CPRS / CPR3 
15.5K gi|145580328 14 kDa   7 6 13   6 11 12   SNU13 
 
                        
U4/U6.U5                         
hSnu66 gi|10863889 90 kDa   125 73 365   101 115 395   SNU66 
hSad1 gi|13926071 65 kDa   42 37 82   31 45 66   SAD1 
27K gi|24307919 19 kDa   12 11 14   5 9 12     
                          
A complex                         
RBM10 gi|20127479 104 kDa   9 14 40   14 8 14   MSL5 / BBP1 
RBM5 / LUCA15 gi|5032031 92 kDa   13 8 30   14 10 26     
S164 (fSAP94) gi|118196855 100 kDa   1 11 6   1 9 3     
 
                        
B complex-specific                         
MFAP1 gi|50726968 52 kDa   7 5 7   15 18 62     
RED gi|125988409 66 kDa   15 14 34   42 68 152     
hSmu-1 gi|84370185 58 kDa   18 24 58   53 75 234     
hPrp38 gi|24762236 37 kDa   11 9 10   32 40 83   PRP38 
hSnu23 gi|13385046 24 kDa   1 1 -   10 11 -   SNU23 










    
            
preparation 
gi number MW 
  #1 #2 #3   #1 #2 #3   S. cerevisiae 
pmol   0.9 0.9 2.0   0.9 0.9 2.0   gene name 
                          
B complex                         
TCERG1 gi|21327715 124 kDa   1 1 1   26 40 32   YPR152C / URN1 
FBP11 gi|34222504 109 kDa   - 9 3   - 6 2     
DDX9 gi|100913206 141 kDa   16 44 150   15 27 89     
DDX17 / p72 gi|148613856 80 kDa   - 6 12   - - 0   DBP2 
CAPER / RNPC2 gi|194384132 58 kDa   12 22 35   10 23 25     
hsp27 gi|4504517 23 kDa   4 - 5   4 - 6     
UBL5 gi|13236510 9 kDa   1 - 2   2 - 8   HUB1 
hPrp4 kinase gi|158255924 117 kDa   65 66 185   40 28 86   YAK1 
KIN17 / BTCD gi|13124883 45 kDa   2 1 2   21 25 59   RTS2 
BCLAF1 gi|219520423 106 kDa   2 - 6   1 - 4     
SKIV2L2 gi|193211480 118 kDa   16 14 30   13 7 14   MTR4 
THRAP3 gi|167234419 109 kDa   2 - 18   2 - 14     
TFIP11 gi|21619831 97 kDa   18 10 9   35 36 54   NTR1 
                          
hPrp19                         
hPrp19 gi|7657381 55 kDa   12 13 36   46 50 196   PRP19 
Cdc5L gi|11067747 92 kDa   18 14 27   63 66 189   CEF1 
SPF27 gi|5031653 26 kDa   2 4 6   20 31 37   SNT309 
hPrl1 gi|4505895 57 kDa   12 14 14   27 41 155   PRP46 
CCAP1 (hsp73) gi|5729877 71 kDa   13 17 -   9 27 -   Ssa/Ssb families 
CCAP2 (AD002) gi|116812573 27 kDa   1 1 -   6 6 -   CWC15 
CTNNBL1 (catenin, β-like 1) gi|111306496 65 kDa   3 1 -   21 13 -     
NPW38BP gi|194378864 67 kDa   2 5 -   36 36 -     
                          
hPrp19-related                         
RBM22 gi|119582116 47 kDa   - 2 1     16 41   CWC2 + ECM2 
hSyf1 gi|10566459 100 kDa   9 1 1   47 36 151   SYF1 
hSyf3 gi|119630613 99 kDa   8 9 18   55 38 107   CLF1 
hIsy1 gi|20149304 33 kDa   2 4 5   16 9 29   ISY1 
SKIP gi|34783485 61 kDa   13 7 9   37 35 69   PRP45 
Cyp-E gi|2828149 33 kDa   3 - 5   18 - 42     
PPIL1 gi|258588180 22 kDa   1 - 3   10 - 24     
KIAA0560 / fSAP164 gi|38788372 171 kDa   25 14 9   91 66 307   SEN1 
G10 gi|32171175 17 kDa   1 3 4   21 22 28   BUD31 / CWC14 
                          
Bact                         
KIAA1604 gi|119631401 106 kDa   3 1 -   21 10 -   CWC22 
hPrp17 gi|62897001 66 kDa   6 8 7   33 33 85   CDC40 
                          
RES complex                         
MGC13125 gi|14249338 71 kDa   4 2 3   25 19 56   BUD13 
CGI-79 gi|4929627 40 kDa   4 2 2   14 10 16   IST3 / SNU17 
                          
EJC/mRNP                         
Pinin gi|158258595 82 kDa   5 - 3   6 - 3     
RNPS1 gi|3253165 34 kDa   1 - 5   2 - 4     
ACINUS gi|259906018 151 kDa   16 23 16   15 20 10     
SAP18 gi|6648547 18 kDa   2 - 3   2 - 6     
ALY / REF gi|238776833 28 kDa   5 12 11   7 16 10   YRA1 
UAP56 / Bat1 gi|114306812 51 kDa   6 16 21   8 11 15     
ELG / C17orf85 gi|166295179 71 kDa   4 7 6   6 5 5     
DDX3 / HLP2 gi|197692141 73 kDa   7 14 9   4 14 5     
                          
cap binding complex                         
CBP80 gi|4505343 92 kDa   62 76 149   78 74 209   STO1 
CBP20 gi|1060899 18 kDa   3 8 12   4 7 16   CBC2 
                          
mRNA binding proteins                         
PABP4 gi|119627667 71 kDa   15 21 31   5 20 12     
PABP1 gi|41386798 71 kDa   18 33 40   14 22 20   PAB1 
YB-1 gi|181486 40 kDa   40 12 82   31 24 118     
ASR2, SRRT gi|119596872 102 kDa   54 62 154   33 33 94     
DDX5 gi|197692465 69 kDa   9 14 17   8 15 12   DBP2 
ELAV / HuR gi|119589356 50 kDa   3 5 11   4 2 3     
NF45 / Ilf2 gi|13385872 43 kDa   11 19 46   14 17 38     
                          
SR proteins                         
SRSF1 / ASF/SF2 gi|296202382 32 kDa   21 24 27   28 15 29     
SRSF3 gi|119624305 15 kDa   6 - 14   7 - 8     
SRSF5 gi|119601416 24 kDa   11 17 15   10 16 12     
SRSF6 gi|1049086 38 kDa   8 - 11   7 - 9     
SRSF7 gi|119389969 11 kDa   13 14 28   17 9 20     
SRSF9 gi|4506903 26 kDa   7 9 16   10 15 12     
SRSF10 gi|16905517 31 kDa   12 6 13   9 6 10     
hTra2-α gi|194385084 21 kDa   4 - 5   4 - 3     
hTra2-β gi|119598613 34 kDa   8 9 16   9 7 17     
                          
SR-related proteins                         
SRm300 gi|118572613 300 kDa   32 69 66   71 91 162   CWC21 











    
        
preparation 
gi number MW 
  #1 #2 #3   #1 #2 #3   S. cerevisiae 
pmol   0.9 0.9 2.0   0.9 0.9 2.0   gene name 
                          
hnRNP                         
hnRNP A0 gi|5803036 31 kDa   3 14 31   3 12 31     
hnRNP-A1 gi|119617171 34 kDa   8 34 43   23 50 77     
hnRNP-A2/B1 gi|14043072 37 kDa   21 33 28   30 36 31     
hnRNP-A3 gi|119631468 37 kDa   4 14 25   9 25 30     
hnRNP-C1/C2 gi|117190174 32 kDa   18 21 73   18 20 40     
hnRNP-D gi|119626284 30 kDa   - 4 7   - 7 4     
hnRNP-E1 gi|460771 38 kDa   5 4 13   8 7 14     
hnRNP F gi|16876910 46 kDa   3 - 4   4 - 6     
hnRNP-G gi|3256007 42 kDa   4 7 13   5 7 19     
hnRNP-H1 gi|48145673 49 kDa   4 5 14   3 9 13     
hnRNP-H3 gi|14141157 37 kDa   2 5 -   3 6 -     
hnRNP K gi|119583080 51 kDa   5 7 -   - 1 -     
hnRNP M gi|187281 78 kDa   10 10 15   9 12 13     
hnRNP Q gi|119569012 66 kDa   7 18 49   5 19 10     
hnRNP-R gi|5031755 71 kDa   13 28 84   13 30 31     
hnRNP-U gi|14141161 89 kDa   4 14 25   2 11 3     
hnRNP U-like1 gi|3319956 96 kDa   2 1 -   5 6 -     
RALY gi|119596694 32 kDa   4 5 -   5 2 -     
                          
TREX                         
THOC1 gi|154448890 76 kDa   4 8 7   6 9 4   HPR1 
THOC2 gi|125656165 183 kDa   11 9 20   6 7 9   RLR1 
THOC6 gi|31543164 38 kDa   4 11 12   6 6 5     
THOC7  gi|34783006 23 kDa   3 - 4   4 - 8     
                          
MISC                         
hUBA3 gi|126031226 89 kDa   159 199 403   173 207 451     
TUBB gi|18088719 50 kDa   29 47 97   27 60 99     
ZC3H18 gi|194390520 109 kDa   45 39 68   23 23 36     
PAXBP1 / GCFC gi|22035565 105 kDa   15 15 11   39 37 71     
DSP gi|58530840 332 kDa   7 8 26   6 25 49     
IGF2BP3 / KOC / IMP gi|2105469 64 kDa   17 17 33   11 19 27     
eIF3A gi|4503509 167 kDa   3 7 5   2 13 3     
GNB2L1 / RACK1 gi|5174447 35 kDa   13 17 28   11 12 10     
ZCCHC8 gi|14042579 78 kDa   9 14 28   17 15 24     
RBM42 gi|114676748 47 kDa   12 21 47   3 9 20     
SETD2 gi|197313748 288 kDa   6 14 -   - 5 -     
JUP gi|15080189 82 kDa   5 5 20   4 14 31     
SON3 gi|119630222 270 kDa   18 12 17   26 9 18     
eEF1A1 gi|62896589 50 kDa   6 9 10   6 12 12     
RSRC1 gi|332818209 32 kDa   6 7 4   13 12 18     
MATR3 gi|21626466 95 kDa   6 4 17   5 8 12     
CPSF1 gi|1045574 161 kDa   2 7 -   - 6 -     
MSI2 gi|119614912 37 kDa   8 12 14   5 5 16     
IGF2BP1 / IMP1 gi|56237027 63 kDa   11 7 16   5 9 13     
RBM4 / LARK gi|93277122 40 kDa   9 5 13   9 5 12     
CFAP20 / fSAP23 gi|8392875 23 kDa   1 4 1   5 9 4     
eIF3E gi|17389740 52 kDa   2 8 6   2 5 6     
OTT-MAL gi|14041646 206 kDa   1 3 3   1 3 -     
RBM7 gi|119587652 31 kDa   4 6 9   6 7 11     
eIF3L gi|193786348 71 kDa   - 6 5   - 5 2     
eIF3F gi|119589043 39 kDa   3 6 -   2 5 -     
MEPCE gi|158256168 74 kDa   - 2 2   - 7 -     
KIAA1429 / fSAP121 gi|119612122 202 kDa   1 7 -   1 1 -     
TOE1 gi|10436256 57 kDa   - 5 5   - 4 6     
CPSF3 gi|62898706 77 kDa   3 5 -   - 1 -     
ZC3H13 gi|119629156 197 kDa   1 7 -   - 1 -     
WTAP gi|10334526 43 kDa   2 4 -   - 1 -     
eIF3I gi|4503513 37 kDa   2 3 -   - 2 -     
FLG2 gi|62122917 248 kDa   6 - 9   3 - 3     
RPSA gi|34272 33 kDa   5 - 27   5 - 10     
GPANK1 / Bat4 gi|15042961 39 kDa   1 - 1   9 - 6     
DSG gi|119703744 114 kDa   5 - 13   1 - 21     
TUBA1B gi|193786502 46 kDa   19 - 76   23 - 89     
NKTR gi|6631100 166 kDa   4 - 1   15 - 20     
RBBP6 / PACT  gi|33620769 202 kDa   1 - 8   6 - 2     
ZC3HAV1 gi|158259083 101 kDa   5 - 8   6 - 10     
ANXA2 gi|4757756 39 kDa   3 - 8   4 - 16     
EXOSC10 gi|50301240 101 kDa   6 - 11   3 - 5     
YBX3 / CSDA gi|14250672 40 kDa   28 - 67   23 - 90     
S100A8 gi|21614544 11 kDa   5 - 8   5 - 7     
EXOSC7 gi|15215485 32 kDa   3 - 11   4 - 6     
AHNAK gi|61743954 629 kDa   1 - 5   1 - 8     
ERH gi|4758302 12 kDa   3 - 2   1 - 2     
EXOSC3 gi|122920913 31 kDa   2 - 2   3 - 4     
EXOSC9 gi|119625657 47 kDa   6 - 13   4 - 11     
GPATCH8 gi|119571978 155 kDa   2 - 4   - - -     
HBB gi|229752 16 kDa   1 - 8   11 - -     
TUBB4B gi|23958133 50 kDa   26 - 87   26 - 83     
Mtr3 / EXOSC6 gi|17402904 28 kDa   3 - 6   3 - 5     





Table 3.3: Protein compositions of the 37S cross-intron and B complex were identified by mass spectrometry 
Proteins of the indicated affinity-purified complexes were identified by LC-MS/MS after separation by 4-12 % 
SDS-PAGE. Proteins that were identified in at least two out of three independent preparations (#1-#3) are 
shown. Proteins not reproducibly detected or proteins generally considered to be common contaminants, such 
as ribosomal proteins, are omitted. Shown are the total spectral counts for each protein. Proteins are grouped 
according to function or stage of recruitment. 
 
3.9 The 37S cross-intron and 37S exon complexes have nearly identical 
protein compositions 
To directly compare the protein composition of the 37S cross-intron and 37S exon complexes, 
affinity-purified complexes were separated via 2D gel-electrophoresis and all visible protein-spots 
were subsequently identified by mass spectrometry.  
The direct comparison of affinity-purified 37S cross-intron and 37S exon complexes by 2D gel-
electrophoresis showed an almost identical protein pattern for both complexes, despite the fact that 
these complexes were assembled on different RNA substrates, namely MINX pre-mRNA and MINX 
exon-RNA. Like the 37S exon complex, nearly all U1, U2 and U4/U6.U5 tri-snRNP proteins were 
abundant in the 37S cross-intron complex (Figure 3.15). The B complex-specific proteins were absent 
or underrepresented in both complexes. 
The comparison of both complexes side by side allowed not only a qualitative but also a semi-
quantitative comparison of abundant proteins associated with the 37S cross-intron and 37S exon 
complex, respectively. The evaluation of the staining intensities showed lower amounts of hnRNPA1b 
and BCLAF1 (red dots) in the 37S cross-intron complex so that these proteins were not considered to 
be abundant in the 37S cross-intron complex. Additionally, the two proteins THRAP3 and SRSF10 
(blue dots) are abundant in the 37S exon complex, while they are completely absent in the 37S cross-
intron complex. The cap binding protein CBP80 is the only factor that was abundant in the 37S cross-
intron complex, while not being abundant in the 37S exon complex (green dot). This is likely due to 
the fact that the MINX pre-mRNA, which was used to assemble the 37S cross-intron complex, 
contains a 5’-cap, while the MINX exon-RNA is synthesized in the absence of a 5’-cap. The very 
similar protein compositions of both 37S complexes suggest that these complexes are similar 





Figure 3.15: 2D gel-electrophoresis of affinity-purified 37S exon and 37S cross-intron complexes 
Affinity-purified complexes were analyzed by 2D gel-electrophoresis and individual protein-spots were 
identified by mass spectrometry. The abundance of individual proteins was determined by visual inspections 
and differences in the relative abundance of single proteins between both complexes are indicated by green 
(abundant) or red (not abundant) dots, respectively. Proteins that are exclusively abundant within a particular 
complex are marked with blue dots.  
 
Interestingly, the proteins THRAP3 and BCLAF1 are abundant in the 37S exon complex not in the 
37S cross-intron complex. This is consistent with the results shown in chapter 3.2 and data from 
Agafonov et al. [Agafonov et al., 2011], which indicate that the protein compositions of the 45S B-like 
and the intron-defined B complex differ only in abundance of these two proteins. This suggests that 
THRAP3 and BCLAF1 might be involved in the formation of exon-defined spliceosomes or the process 





3.10 Analysis of the RNA-RNA network in the 37S cross-intron complex 
Next I performed psoralen-mediated RNA-RNA crosslinking to investigate RNA-RNA interactions 
within the 37S cross-intron, as well as in the B complex. Thus, affinity-purified complexes were UV-
irradiated at 365 nm in presence of psoralen (AMT) to induce RNA-RNA crosslinks. The crosslinked 
RNAs were separated on a denaturing 5 % polyacrylamide-gel and transferred to a nitrocellulose 
membrane, which was then sequentially incubated with 32P-labeled probes against the pre-mRNA, 
U1, U2, U4, U5 and U6 snRNAs. The identities of crosslinked RNAs can be deduced by comparison of 
the migration behavior of various bands in the denaturing PAGE. Radioactive signals by two or more 
probes at the same position indicate the formation of a crosslink of the respective RNAs. 
No signals of cross-linked RNAs were detected with any of the probes in the absence of psoralen 
(Figure 3.16A, lanes 1, 3, 5, 7, 9, 11, 13, 15, 17 & 19). After incubation with a probe specific for the 
MINX pre-mRNA, we detected signals of slower migrating bands upon addition of AMT (Figure 3.16A, 
lanes 2 & 4). Next, we incubated the membrane with an U1-specific probe and detected a signal at 
the same position as the pre-mRNA in the lane of the 37S cross-intron complex (Figure 3.16A, 
lanes 2 & 6). This crosslinking product was almost absent in the B complex (Figure 3.16A, lanes 4 & 8) 
consistent with lower amounts of U1 snRNA in affinity-purified B complexes as seen in figure 3.14B. 
This indicates that the U1 snRNA is still base paired with the pre-mRNA in the 37S cross-intron 
complex, but not anymore or at least to a significantly reduced extend in the B complex (U1/5’ss). 
Then, we sequentially incubated the membrane with probes specific for the U2, U4 and U6 snRNA. 
During these investigations, we identified a signal at the same position using probes against U2 and 
U6 snRNA (Figure 3.16A, lanes 10 & 18, 12 & 20). Based on the migration behavior of this crosslinking 
product, we conclude that it represents a crosslink in U2/U6 helix II (U2/U6) suggesting that the 
U4/U6.U5 tri-snRNP is associated via U2/U6 helix II to the 37S cross-intron and B complex, 
respectively (Figure 3.16B). The incubation with a U4-specific probe identified a crosslink between 
U4 and U6 at the same position within both complexes (Figure 3.16A, lanes 14 & 18, 16 & 20), 
showing that U4 and U6 snRNA are still base paired (U4/U6), even after stable integration of the 
U4/U6.U5 tri-snRNP within the B complex (Figure 3.16B). These results show clearly that stable 
integration of the U4/U6.U5 tri-snRNP and B complex formation occur prior to disruption of the 
U4/U6 base pairing. Additionally, several crosslinks between U2, U4 and U6 were identified in the 
B complex (Figure 3.16A, lanes 12, 16 & 20), which are significantly weaker or absent in the 37S exon 





Figure 3.16: Investigation of RNA-RNA base pairing interactions in the 37S cross-intron complex 
(A) Affinity-purified 37S cross-intron and B complexes were UV-irradiated in presence of psoralen (AMT) to 
induce RNA-RNA crosslinks (even-numbered lanes). As a negative control, AMT was omitted (odd-numbered 
lanes). RNA was recovered, separated on a denaturing 5 % polyacrylamide gel and transferred to a 
nitrocellulose membrane. The membrane was sequentially incubated with 
32
P-labeled probes against the pre-
mRNA, U1, U2, U4 and U6 snRNAs. The positions of crosslinked products are indicated on the right side. 
(B) Schematic representation of the RNA-RNA networks in the 37S cross-intron, B and 37S exon complexes. The 
U1 snRNP is still base paired with the 5’ss of the pre-mRNA, whereas the U4/U6.U5 tri-snRNP is bound to the 
U2 snRNP via U2/U6 helix II.  
 
The fastest migrating species of this U2/U4/U6 triple-crosslink shows a dominant signal within in the 
B complex and is significantly weaker in the 37S cross-intron complex. Since the pre-mRNA-specific 
probe showed no or only weak signals at this position, we concluded that this crosslinking product 
resembles a triple crosslink between the U2 snRNA and the base paired U4/U6 di-snRNA (U2/U4/U6) 




might indicate that the association between the U2 snRNP and the U4/U6.U5 tri-snRNP is somehow 
weaker or less optimal to generate RNA-RNA crosslinks. The second slowest migrating crosslinking 
product showed nearly the same signal intensities for the pre-mRNA, U2, U4 and U6 snRNA, 
suggesting that the U2-associated U4/U6 di-snRNA was additinally crosslinked to the pre-mRNA 
(U2/U4/U6/BPS). Since we detected faint signals of this crosslink also in the 37S cross-intron 
complex, we conclude that the pre-mRNA crosslink occurred at the BPS sequence of the pre-mRNA 
via interaction with the U2 snRNA. The slowest migrating crosslinking product between the pre-
mRNA and the U2, U4 and U6 snRNA was only detected in the B complex (Figure 3.16, lanes 4, 12, 16 
& 24) suggesting that in this RNA species the U6 snRNA was crosslinked to the pre-mRNA at the 
5’splice site (U2/U4/U6/5’ss). Hybridization of the membrane with a U5-specific probe showed no 
signals for both complexes (data not shown). 
In summary, the analyses of the RNA-RNA interactions within the 37S cross-intron showed that 
U1 snRNP is still base paired with the 5’ss of the pre-mRNA, while the U4/U6.U5 tri-snRNP associates 
via the U2/U6 helix II to the pre-mRNA bound U2 snRNA (Figure 3.16B). Previous investigations of the 
RNA-RNA network of the 37S exon complex showed a similar pattern of RNA-RNA interactions 
[Schneider et al., 2010a], with the difference that the U1 snRNP base pairs with the downstream 5’ss 
of the MINX exon-RNA. Notably, the interaction between the U4/U6.U5 tri-snRNP and the pre-mRNA 
bound U2 snRNA appears to be stronger or more suitable for RNA-RNA crosslinking in the B complex 
in comparison to the 37S cross-intron complex. Additionally, we detected a crosslinking product 
exclusively in the B complex, in which the U6 snRNA potentially contact the pre-mRNA at its 5’splice 
site.  
3.11 Electron microscopy investigation of the 37S cross-intron complex 
Next we set out to determine structural features of the 37S cross-intron complex via negative-stain 
EM. Additionally, we also investigated a kinetically-assembled B complex via electron-microscopy 
under exactly the same conditions. The direct comparison of the 37S cross-intron to an intron-
defined B complex should give insights into potential structural rearrangements during stable 
U4/U6.U5 tri-snRNP integration in the intron-defined spliceosome assembly pathway. 
To characterize the novel intermediate structurewise, we subjected purified 37S cross-intron 
complexes to a second glycerol gradient under GraFix conditions and investigated the peak fractions 
by negative-stain EM. A gallery of individual class averages of the 37S cross-intron complex obtained 
by averaging approximately 10300 individual raw images is shown in figure 3.17. In parallel, a total of 
9300 raw images of the kinetically-assembled B complex were subjected to image processing to allow 





Figure 3.17: Negative-stain electron microscopy of the 37S cross-intron complex 
Overviews of negatively-stained 37S cross-intron (A) and kinetically-assembled B complexes (B), i.e. 6 min 
incubation of splicing, are shown on the left. On the right representative class averages of the complexes are 
shown in the galleries 1-6 starting with the most frequently observed class. A small fraction (< 10 %) of images 
typical for the B complex was also detected in the preparation of the 37S cross-intron complex. Scale bars 
correspond to 50 nm. (C) Typical class averages of the 37S exon complex are shown in the gallery. 
(D) Schematic representation of the 37S cross-intron complex. The flexible and structurally heterogeneous 
region of the complex is shown as a grey circle. The circle indicates the maximal dimension of this domain, 
while the actual size of this domain may vary in the respective class averages. (E) Schematic representation of 






The class averages of the 37S cross-intron complex are shown in figure 3.17A and the relative 
abundance of the respective structures is shown below. The upper domain of the particle, 
designated head, exhibits a triangular structure and appears similar in all classes, while the lower 
body domain shows significant differences in its structure. The lower left domain of the body appears 
diffuse or blurred without many structural details. Further, this domain varies in size and form in 
almost all class averages suggesting that this region of the complex is flexible or structurally 
heterogeneous (Figure 3.17A & D). In the majority of the classes the flexible region accounts for a 
substantial part of the body domain (Galleries 1 & 2), but in the less frequently observed classes this 
domain appears smaller (Gallery 3) or is not visible at all (Galleries 4 & 5). The head and body 
domains are connected by a hook-like neck domain. At this point, we can’t determine if the 
structural diversity of the 37S cross-intron complex is based on a conformational heterogeneity 
potentially by movements of the domains relative to each other or if the different structures reflect 
different orientations of the complex on the EM grid.  
In contrast, the kinetically-assembled B complex appears structurally homogenous with a 
characteristic orientation in almost all class averages. Further, the B complex reveals more structural 
details in the class averages in comparison with the 37S cross-intron complex, what supports the 
assumption that the splicesome adopts a structurally homogenous appearance upon formation of a 
stable B complex (Figure 3.17B). A small fraction (< 10 %) of B complex structures is also present in 
the 37S preparation. The appearance of the B complex generated in this preparation is consistent 
with previous structural investigations of the intron-defined B complexes [Deckert et al., 2006, Wolf 
et al., 2009]. These results show that the transition from a 37S cross-intron to a B complex, and 
consequently stable integration of the U4/U6.U5 tri-snRNP, is accompanied by a dramatic change in 
the structure of the complex. Potentially, the relative orientation of the U4/U6.U tri-snRNP with 
respect to the U2 snRNP rearranges to a more favorable orientation during the stabilization of the 
U4/U6.U5 tri-snRNP binding (see chapter 3.3). However, at this level of the structural investigations it 
is not possible to conclude, how these domains are rearranged. 
Interestingly, no structures similar to that of the 37S exon complex were identified in the class 
averages of the 37S cross-intron complex (Figure 3.17A & C). Actually, the structural investigation of 
the 37S cross-intron and 37S exon complex identified significantly different structures for these 
complexes, despite their nearly identical protein composition. The different appearance of these two 
complexes might reflect the difference in the location of U1 snRNP, which is base paired with the 
upstream 5’ss in the 37S cross-intron and with the downstream 5’ss in the 37S exon complex, 
respectively. Additionally, the presence of 5’-cap bound by CBP80 may influence the appearance of 




formed of CBP80 and CBP20 interact with various proteins associated with the U4/U6.U5 tri-snRNP 
[Pabis et al., 2013] and these additional protein-protein interactions may alter the structure or 
organization of the complex. 
3.12 The 37S cross-intron complex is converted into a stable B complex in 
presence of a 5’ss oligonucleotide 
The characterization of the RNA-RNA network of the 37S cross-intron complex suggests that this 
assembly intermediate is formed upon association of the U4/U6.U5 tri-snRNP with the U2 snRNA via 
U2/U6 helix II. But, native gel analysis showed that the U4/U6.U5 tri-snRNP is not yet stably-
integrated within the complex. In the exon-defined system, the interaction of a 5’ss oligonucleotide 
with the exon complex bound U4/U6.U5 tri-snRNP results in its stable integration and changes the 
morphology of the complex so that it looks very similar to a B complex. But, despite the nearly 
identical protein composition and a similar RNA-RNA network of the 37S exon and 37S cross-intron 
complex, the structure of both complexes differs quite significantly as judged by a comparison of 
their appearance via negative-stain EM.  
Thus, I tested if the addition of a 5’ss oligonucleotide also induces the stable integration of the 
U4/U6.U5 tri-snRNP within the 37S cross-intron complex, which should finally result in B complex 
formation. Therefore, I assembled spliceosomes in the presence of inhibitory concentrations of 
hPrp28AAAD and added either the 5’ss oligonucleotide or the 2’O-me oligonucleotide after 3 min of 
incubation to the splicing reaction. The formation of a stable B complex was then monitored by 
native gel-electrophoresis in the presence of heparin. 
As described above, the addition of 50 ng/µl hPrp28AAAD protein to the splicing reaction results in 
assembly of a complex with loosely-bound U4/U6.U5 tri-snRNP. Upon treatment with heparin the 
U4/U6.U5 tri-snRNP dissociates and only an A complex signal is visible in the native gel (Figure 3.18, 
lane 3). The addition of 100-fold excess of the 5’ss oligonucleotide, but not a 2’O-me form, to the 
splicing reaction, induced the stable integration of the U4/U6.U5 tri-snRNP as judged by the 
appearance of a B complex signal in the native gel (Figure 3.18, lane 4 & 5). These results show that 
the 37S cross-intron complex is competent for B complex formation, despite the absence of hPrp28 
action. As the 2’O-ribose methylated oligonucleotide competes for U1 snRNP binding and releases 
U1 snRNP from the 5’ss of the MINX pre-mRNA, a free 5’ss is apparently not sufficient to induce 







Figure 3.18: A stable B complex is formed upon addition of a 5’ss oligonucleotide to the splicing reaction 





P-labeled MINX pre-mRNA was incubated under splicing conditions in the absence (lanes 1 & 2) or 
presence (lanes 3-5) of inhibitory concentrations of recombinant hPrp28
AAAD
 protein for the times indicated. 
Either the 5’ss oligonucleotide or 2’O-me 5’ss oligonucleotide was added in a 100-fold excess after three 
minutes of incubation. Spliceosome assembly was analyzed on a 2 % (w/v) LMP agarose gel in presence of 
heparin and visualized by autoradiography. The positions of H, A, B and B
act
/C complexes are indicated. 
 
The stabilization of U4/U6.U5 tri-snRNP binding within the hPrp28AAAD stalled 37S cross-intron 
complex was tested in splicing reactions, which contain all proteins required for splicing. To exclude 
any secondary or passive effects of the 5’ss oligonucleotide in inducing the stable U4/U6.U5 tri-
snRNP binding, I set out to investigate the requirements of stabilization under more defined 
conditions. Subsequently, I tested if the stable association of the U4/U6.U5 tri-snRNP also occurs 
upon addition of the 5’ss oligonucleotide to affinity-purified 37S cross-intron complexes. Thus, 
affinitiy-purified 37S cross-intron complexes were mixed with either the 5’ss oligonucleotide or the 
2’O-me form and the U4/U6.U5 tri-snRNP binding was then analyzed by centrifugation on a second 
glycerol gradient containing 150 mM KCl, at which a loosely-associated U4/U6.U5 tri-snRNP 
dissociates from the complex. In absence of any added oligonucleotide the majority of the 37S cross-
intron complexes localize in fractions with an S-value < 30S, which is consistent with the dissociation 
of the U4/U6.U5 tri-snRNP from the complex (Figure 3.19A). Addition of the 5’ss oligonucleotide, but 
not the 2’O-methylated form led to the formation of a complex that co-migrated with purified 
B complexes. I pooled fractions 15-17 from this gradient and subjected them to MS2 affinity-






Figure 3.19: Addition of a 5’ss RNA oligonucleotide to affinity-purified 37S cross-intron complex induces 
stabilization of U4/U6.U5 tri-snRNP binding 
(A) Affinity-purified 37S cross-intron complexes were incubated with either 5’ss oligonucleotide or 2’O-me 5’ss 
oligonucleotide and subsequently subjected to a second analytical centrifugation on a glycerol gradient 
containing 150 mM KCl. A kinetically-assembled B complex was run in parallel. (B) Peak fractions from the 
gradients were used for MS2 affinity-selection. RNA was recovered from the eluates, separated by denaturing 
PAGE and visualized by silver staining. Identities of snRNAs are indicated. 
 
The RNA analysis showed that the complex, which peaks in fraction 15-17, contains the U2 snRNP 
and U4/U6.U5 snRNP as well as the MINX pre-mRNA (Figure 3.19B). This demonstrates that the in 
presence of a 5’ss oligonucleotide the U4/U6.U5 tri-snRNP gets stably-integrated within the 
37S cross-intron complex without the requirement of any proteins, which are not associated with 
this complex. Interestingly, the presence of the 2’O-me 5’ss oligonucleotide does not induce the 
stabilization, despite it displaces U1 snRNP from the 5’ss of the pre-mRNA (data not shown). This 
supports the results of the native gel analyses, in which a free 5’ss of the pre-mRNA was not 
sufficient for stable U4/U6.U5 tri-snRNP binding in absence of hPrp28 function (Figure 3.18). 
Taken together, these results are consistent with the idea that the 37S complexes with loosely-
associated U4/U6.U5 tri-snRNP represent a very similar intermediate in both cross-exon and cross-
intron spliceosome assembly pathways and that stable integration of the U4/U6.U5 tri-snRNP is 
triggered solely by its interaction with the 5’ss oligonucleotide. Further, these results also support 





3.13 EM reveals that the purified 37S cross-intron complexes adopt a B 
complex appearance after incubation with the 5’ss oligonucleotide 
Finally, we set out to structurally investigate the 5’ss oligonucleotide induced shift of the 37S intron 
complex by negative-stain EM. Therefore, I performed MS2 affinity-selection of 37S cross-intron 
complexes assembled in the presence of inhibitory concentrations of hPrp28AAAD. Subsequently, the 
purified complexes were supplemented with the 5’ss oligonucleotide and the reaction was separated 
on a second glycerol gradient under GraFix conditions. Particles in the peak fractions were stained 
with uranyl formate and subsequently analyzed by negative-stain EM. The overview shows clearly 
defined, single particles on the EM grid (Figure 3.20A), which were used to calculated class averages.  
 
Figure 3.20: EM analysis after addition of the 5’ss oligonucleotide to purified 37S cross-intron complexes 
Affinity-purified 37S cross-intron complexes were mixed with 5’ss oligonucleotide and subjected to a second 
glycerol gradient under GraFix conditions. Complexes from the peak fraction were used for negative-stain EM. 
(A) Raw images of affinity-purified 37S cross-intron complex after addition of 5’ss oligonucleotide are shown on 
the left. The galleries on the right side show representative class averages generated from single particle 
images. Typical class averages of the intron-defined B (B), the 37S cross-intron (C) and the stabilized exon (D) 
complex are shown below. Characteristic structural features within the body domain of the stabilized cross-





Based on the appearance of single particles on the EM grid, we excluded an aggregation to be the 
reason for the increased S-value of the 37S cross-intron complex after addition of the 5’ss 
oligonucleotide. To generate representative class averages of the stabilized cross-intron complex a 
total of 11000 raw images were subjected to image processing. The most frequently observed classes 
(Figure 3.20A, galleries 1-6) of the stabilized cross-intron complex are very similar and show only a 
low degree of structural heterogeneity, which is highlighted by the fact that in each class average 
complexes in structurally nearly identical states were obtained. The evaluation of the generated class 
averages showed that the stabilized cross-intron complex adopts a structure almost identical to class 
averages of a kinetically-assembled intron-defined B complex (Figure 3.20B), but shows nearly no 
similarities to the structure of the 37S cross-intron in the absence of any added oligonucleotide 
(Figure 3.20C). Strikingly, no classes characteristic for the 37S cross-intron complex are detectable in 
this preparation. These results show that the addition of a 5’ss oligonucleotide induces a significant 
change in the structure of the 37S cross-intron complex and rearranges the structure of the complex 
in such a way that it adopts an organization characteristic for a stably-assembled B complex. 
Astonishingly, the stabilized cross-intron complex shows an appearance that is also very similar to 
the 37S exon complex after addition of the 5’ss oligonucleotide (Figure 3.20D). Especially, the body 
domain of the stabilized cross-intron complex exhibit similar features, which are also characteristic 
for the stabilized exon complex, namely the belly-like protrusion in the center of the body as well as 
slimmer stump (Figure 3.20A & D, indicated by red arrows). This supports the idea that these 





In eukaryotes, most protein-coding genes contain coding exons and non-coding sequences known as 
introns. The splicing of pre-mRNA introns is catalyzed by the spliceosome, which assembles by the 
interaction of five snRNPs and numerous splicing factors with the pre-mRNA across an intron 
sequence (intron definition). An alternative assembly pathway exists, in which the spliceosome first 
forms across an exon (exon definition). As the chemical steps of splicing can only occur across an 
intron, a rearrangement from the exon-defined to an intron-defined organization must occur to allow 
generation of mature mRNAs. Previously it was shown that exon-defined spliceosomes not only 
contain U1 and U2 snRNPs, but also the U4/U6.U5 tri-snRNP (37S exon complex), providing evidence 
that it is possible for an exon-defined complex to be converted directly into a intron-defined 
B complex via interaction with an upstream 5’ss. During my studies I have investigated the 
requirements for stable B complex formation and factors contributing to this process, as this is a 
crucial step in which these two spliceosome assembly pathways converge. My data reveal that 
interaction of the 37S exon complex with solely a 5’ss oligonucleotide triggers a major 
conformational change that is visible by EM and accompanies stable integration of the U4/U6.U5 tri-
snRNP within the spliceosome. This conformational change is triggered by the interaction of 
U4/U6.U5 tri-snRNP components with the 5’ss sequence, most importantly hPrp8, but does not 
require the B complex-specific proteins RED, MFAP1, FBP21, hSmu-1, hPrp38 and hSnu23, which are 
recruited during this stabilization process. Using an ATPase-deficient mutant of the DEAD-box 
helicase hPrp28, I was able to identify and characterize a novel intermediate of the intron-defined 
spliceosome assembly pathway (37S cross-intron complex) that is formed prior to stable B complex 
formation. This 37S cross-intron complex contains all of the snRNPs, but the U4/U6.U5 tri-snRNP is 
only loosely-associated. Characterization of its protein composition by mass spectrometry showed 
distinct differences in the composition of this novel intermediate in comparison to an intron-defined 
B complex, which helps to extend our understanding of how the protein inventory of the 
spliceosome changes during formation of a stable, pre-catalytic B complex. Interestingly, the intron- 
and exon-defined 37S assembly intermediates show a nearly identical RNA and protein composition, 
but their structures differ significantly. However, upon stable integration of the U4/U6.U5 tri-snRNP 
within the complexes induced by its interaction with a 5’ss sequence, their appearances become 
almost identical. Thus, the data presented here suggest that the exon- and intron-defined 
spliceosome assembly pathways converge at the stage, when the U4/U6.U5 tri-snRNP interacts with 





4.1 Addition of a 5’ss-containing RNA oligonucleotide transforms the 37S 
exon complex into a 45S B-like complex with stably-integrated U4/U6.U5 tri-
snRNP 
To investigate the requirements for stable integration of the U4/U6.U5 tri-snRNP within the 
spliceosome, I used an established system to assemble exon-defined spliceosomes on a single exon 
pre-mRNA substrate in HeLa nuclear extract [Schneider et al., 2010a]. Although this 37S exon 
complex contains all five snRNAs, the U4/U6.U5 tri-snRNP is only loosely-associated and sensitive to 
the presence of heparin. The addition of an RNA oligonucleotide containing an optimized 5’ss 
sequence induces the formation of a 45S B-like complex, in which the U4/U6.U5 tri-snRNP is now 
stably-integrated. During this stabilization process, the sedimentation value increases from 37S for 
the exon complex to 45S for the B-like complex and the U4/U6.U5 tri-snRNP binding becomes 
resistant against heparin (Figure 3.1). As the optimized 5’ss oligonucleotide is added in excess to the 
splicing reaction, it competes with the downstream 5’ss of the MINX exon-RNA for U1 snRNP binding, 
and consistent with this, the RNA composition of affinity-purified 45S B-like complexes shows a loss 
of U1 snRNP. Upon 2’O-ribose methylation of the 5’ss oligonucleotide, it no longer interacts with the 
U4/U6.U5 tri-snRNP but still binds to U1 snRNA. Addition of this modified 5’ss oligonucleotide did not 
support stable B-like formation on native gels, nor the shift to a 45S complex on a glycerol gradient, 
even though the complexes formed in its presence did not contain U1 snRNP. These data rule out 
that the loss of U1 snRNP alone induces stable U4/U6.U5 tri-snRNP binding and suggest an essential 
role for a previously shown interaction of the 5’ss oligonucleotide with the ACAGAG motif of 
U6 snRNA [Schneider et al., 2010a], as opposed to U1 snRNP, for inducing stable integration of the 
U4/U6.U5 tri-snRNP within the 45S B-like complex. 
4.2 B complex-specific proteins are recruited upon formation of the 45S B-like 
complex, but are not required for stable integration of the U4/U6.U5 tri-
snRNP 
To identify factors that potentially contribute to stable U4/U6.U5 tri-snRNP binding, we characterized 
abundant factors associated with affinity-purified 37S exon and 45S B-like complexes by 2D gel-
electrophoresis. These analyses allowed a direct comparison of their protein compositions with each 
other, as well as with previously characterized spliceosomal complexes of the intron-defined 
assembly pathway [Agafonov et al., 2011]. The comparison of abundant factors in the 37S exon and 
45S B-like complex revealed that proteins associated with the U1 snRNP and SR proteins are lost 




the formation of a 45S B-like complex was accompanied by the recruitment of the B complex-specific 
proteins RED, MFAP1, FBP21, hSmu-1, hPrp38 and hSnu23 to the complex. These proteins are also 
recruited first during formation of an intron-defined B complex [Agafonov et al., 2011]. In general, 
the 45S B-like complex shows the same composition of abundant proteins as an intron-defined 
B complex, which was assembled on the MINX pre-mRNA [Agafonov et al., 2011]. The 45S B-like 
complex contains additionally abundant amounts of the two proteins THRAP3 and BCLAF1.  
The presence of the B complex-specific proteins in spliceosomal complexes with a stably-integrated 
U4/U6.U5 tri-snRNP, namely the 45S B-like and intron-defined B complex, suggested that these 
proteins could potentially be required for the stabilization of U4/U6.U5 tri-snRNP binding upon its 
interaction with a 5’splice site. To test whether the recruitment of the B complex-specific proteins is 
required for the increased stability of the complex, I subsequently assayed if the addition of the 5’ss 
oligonucleotide to the 37S exon complex in the absence of nuclear extract also results in stronger 
U4/U6.U5 tri-snRNP binding. Surprisingly, addition of the 5’ss oligonucleotide alone to affinity-
purified 37S exon complexes induced the formation of a 45S complex with stably-integrated 
U4/U6.U5 tri-snRNP (Figure 3.4 & 3.5). Thus, all factors required for stable U4/U6.U5 tri-snRNP 
binding upon interaction with the 5’ss oligonucleotide are already present in the 37S exon complex. 
As the B complex-specific proteins are for the most part absent from the 37S exon complex, these 
results show that the B complex-specific proteins are not essential for stable binding of the U4/U6.U5 
tri-snRNP in vitro. 
The B complex-specific proteins were shown to be abundant in the intron-defined B complex, but are 
already displaced during the transition to a Bact complex [Agafonov et al., 2011]. As it was shown that 
these proteins are not essential for transition to a 45S complex, this suggests a role for these proteins 
after B complex and prior to or during Bact complex formation. Consistent with this result, the Prp38 
protein was shown not to be required for assembly of a B complex in yeast and has a proposed 
function in promoting U4/U6 unwinding [Xie et al., 1998]. Yeast-2-hybrid experiments showed that 
certain B complex-specific proteins interact with factors of the U4/U6.U5 tri-snRNP, as well as with 
proteins of the hPrp19 complex [Hegele et al., 2012]. Therefore, the B complex-specific proteins 
might be involved in the recruitment of factors that are necessary for Bact formation, e.g. as binding 
partners for the hPrp19 complex. But, while the B complex-specific proteins are conserved in 
C. elegans and D. melanogaster, only hSnu23 and hPrp38 have homologues in S. cerevisiae, which 
suggests a role of these proteins in spliceosome function restricted to higher eukaryotes, e. g. in 
alternative splicing. However, Prp38 and Snu23 are components of the U4/U6.U5 tri-snRNP in 
S. cerevisiae but not in human, and may therefore play a different role in yeast [Gottschalk et al., 




4.3 Stable binding of the U4/U6.U5 tri-snRNP likely depends on the 
interactions with U2 snRNP proteins 
The characterization of abundant factors in the 45S B-like complex showed that the complex is 
mainly composed of proteins associated with the U2 snRNP and U4/U6.U5 tri-snRNP and just a small 
number of additional factors. As we showed that the B complex-specific proteins are not essential to 
stabilize the interaction of the U4/U6.U5 tri-snRNP, its stable binding within the complex must 
depend on interactions with other factors that are also abundant in the 45S B-like complex. The 
2D analysis of the protein inventory of the 45S B-like complex suggests that the stable association of 
the U4/U6.U5 tri-snRNP likely relies on proteins associated with the U2 snRNP, since these proteins 
are the only abundant ones present. Yeast-2-hybrid experiments identified interactions between U2-
associated SF3b proteins and U5-specific proteins, especially hPrp8, hBrr2 and hSnu114, in the 
intron-defined B complex [Hegele et al., 2012]. Therefore, interactions between these proteins likely 
play a role in stable binding of the U4/U6.U5 tri-snRNP. The interaction of the 5’ss oligonucleotide 
with the U4/U6.U5 tri-snRNP, in particular hPrp8, may trigger the formation of new interactions, e.g. 
between U2 and U5 proteins, or stabilize existing ones.  
The factor SPF30 was shown to be important for association of the U4/U6.U5 tri-snRNP with the 
A complex [Rappsilber et al., 2001, Meister et al., 2001], but neither the 37S exon nor the 45S B-like 
complex contain abundant amounts of this protein, showing that the stable integration of the 
U4/U6.U5 tri-snRNP does not depend on the presence of this factor. SPF30 could play a transient role 
in U4/U6.U5 tri-snRNP stabilization, but nevertheless its presence apparently is not required to 
maintain the stable binding of the U4/U6.U5 tri-snRNP. Further, previous studies suggested 
SR proteins to be important for integration of the U4/U6.U5 tri-snRNP and stable B complex 
formation [Roscigno and Garcia-Blanco, 1995]. However, the SR proteins SRSF1, SRSF7 and SRSF10, 
which are abundant in the 37S exon complex, are displaced upon formation of the 45S B-like complex 
and therefore do not contribute to the increased stability of U4/U6.U5 tri-snRNP binding in the 
45S B-like complex. SR proteins have an important role in exon recognition and establish protein-
protein interactions with the general splicing machinery, which is supported by the presence of SR 
proteins in the 37S exon complex. But upon commitment of the spliceosome to a 5’ss, these 
interactions might be disrupted in order to establish new ones. 
4.4 The hPrp4 kinase is abundant solely in the 37S exon complex 
Interestingly, the hPrp4 kinase was shown to be abundant in the 37S exon but not in the 45S B-like 
complex. Previous studies showed that this protein is neither abundant in the intron-defined 




specifically recruited upon association of the U4/U6.U5 tri-snRNP with the A-like complex during 
formation of the 37S exon complex. It was shown that the hPrp4 kinase phosphorylates the 
U4/U6.U5 tri-snRNP-associated factors hPrp31 and hPrp6 during formation of a stable, intron-
defined B and 45S B-like complex [Schneider et al., 2010a, b]. Although the hPrp4 kinase is present in 
the 37S complex, it does not phosphorylate its target proteins as seen by the very low 
phosphorylation levels of hPrp31 in the 37S exon complex (Figure 3.5). The addition of the 5’ss 
oligonucleotide to purified 37S exon complexes induces stable binding of the U4/U6.U5 tri-snRNP, 
but the phosphorylation of hPrp31 does not increase as compared to the level of its phosphorylation 
within the 37S exon complex. The fact that no additional ATP was required for stable U4/U6.U5 tri-
snRNP integration and that the incubation with the 5’ss oligonucleotide was performed at 4 °C 
supports the idea that no enzymatic activity is required or involved in the stabilization process. These 
results show that the transition to a 45S complex is not dependent on the site-specific 
phosphorylation of hPrp31 and presumably also hPrp6. The phosphorylation of hPrp31 and hPrp6 
observed in nuclear extract occurs after interaction of the 5’ss oligonucleotide with the 37S exon 
complex and consequently after transition to a 45S complex. Thus, the activation of hPrp4 kinase 
might even rely on the structural change accompanying 45S complex formation, i.e. a B complex 
structure, e.g. by inducing the accessibility of the phosphorylation sites or establishing new protein-
protein interactions. However, this conformational rearrangement appears to induce changes in 
protein-protein interactions that result in the release of hPrp4 kinase upon transition to a 45S B-like 
complex. 
4.5 The proteins THRAP3 and BCLAF1 are abundant in exon-defined 
spliceosomes 
Notably, the proteins THRAP3 and BCLAF1 are abundant in the exon-defined 37S exon and 45S B-like 
complexes, but not in the intron-defined B complex, which was assembled on the MINX pre-mRNA. 
The MINX exon-RNA construct was derived from the MINX pre-mRNA and contains very few 
nucleotides not found in the MINX pre-mRNA sequence. Therefore, a sequence-specific recruitment 
of BCLAF1 and THRAP3 appears unlikely and the recruitment of these factors would favor a model in 
which both proteins are associated in the exon-defined complexes due to the presence of a 
downstream located 5’ss or the formation of an exon-defined spliceosomal complex. THRAP3 and 
BCLAF1 have a function in the subcellular distribution and stability of mRNAs in human cells and 
interact with components of the EJC [Varia et al., 2013]. Further, THRAP3 was shown to activate pre-
mRNA splicing in vivo and an interaction with ongoing transcription and early stages of splicing was 
proposed [Lee et al., 2010]. Thus, these proteins might play a role in formation of exon-defined 




4.6 The 37S exon complex undergoes a major structural change upon 
interaction with the 5‘ss oligonucleotide and adopts the appearance of a 
cross-intron B complex 
To determine whether addition of the 5'ss oligonucleotide changes the morphology of the 37S exon 
complex as suggested by the increase in its S-value, we investigated the structures of the 37S exon 
and 45S B-like complexes via electron microscopy. Class averages generated from single-particle 
images revealed that the 37S exon complex exhibits an elongated structure, in which the body 
domain appears similar in all classes, whereas the head domain shows a high degree of flexibility 
(Figure 4.1A). In contrast, the 45S B-like complex appears more compact, consistent with a change in 
its sedimentation behavior. Moreover the 45S B-like complex exhibits a predominant structure in the 
vast majority of all classes, in which the head and body domain of the complex are almost in the 
same orientation with respect to each other. The comparison of the class averages generated for the 
37S exon and 45S B-like complexes provides evidence that the stable integration of the U4/U6.U5 tri-
snRNP during 45S B-like formation is accompanied by a major rearrangement in the structure of the 
complex. Strikingly, the 45S B-like complex has an almost identical morphology as the intron-defined 
B complex, indicating that in B and B-like complexes similar interactions may occur. This assumption 
is supported by the fact that these two complexes share almost the same set of abundant factors as 
judged by mass spectrometry and 2D gel-electrophoresis. Previous studies used immunolabeling in 
combination with negative-stain EM to determine the localization of the pre-mRNA and the 
U2 snRNP-associated protein SF3b155. In this way, the U2 snRNP could be mapped to the head 
domain of an intron-defined B complex [Wolf et al., 2009] (Figure 4.1B). A similar approach with 
B complexes of S. cerevisiae indicated that U5-associated proteins are located in the body domain, 
while the neck domain is mainly composed of U4/U6 di-snRNP-specific proteins (personal 
communication Dr. Norbert Rigo and Dr. Berthold Kastner). A comparison of the EM structures of the 
37S exon complex with the 45S B-like complex suggests that the position of the head domain relative 
to the body is the main structural difference between these complexes. Thus, the conformational 
change triggered by the interaction with the 5'ss oligonucleotide, probably involves a rearrangement 
of the U4/U6.U5 tri-snRNP (body) with respect to the pre-mRNA bound U2 snRNP (head), leading 
then to the stable integration of the U4/U6.U5 tri-snRNP within the complex.  
Structure probing of 37S exon and 45S B-like complexes showed no significant changes in the snRNA 
structures aside from the accessibility of the ACAGAG box of U6 snRNA [Schneider et al., 2010a], 
which is apparently necessary to induce the structural change upon interaction of the 5’ss 
oligonucleotide with the 37S exon complex. Importantly, in the 37S exon complex the U4/U6.U5 tri-




directly interact with the pre-mRNA, at least not by RNA-RNA interactions [Schneider et al., 2010a]. 
Thus, the interaction of the 5’ss oligonucleotide probably enables the transition to a more favorable 
orientation between U2 snRNP and the U4/U6.U5 tri-snRNP based on changes in protein-protein 
interactions. Previous studies showed that the addition of a 5’ss oligonucleotide to HeLa extract 
results in formation of a U2/U4/U6/U5 tetra-snRNP [Konforti and Konarska, 1994] suggesting that 
the interaction of a 5’ss oligonucleotide with the U4/U6.U5 tri-snRNP induces or stabilizes 
interactions between U2 snRNP and the U4/U6.U5 tri-snRNP already in the absence of a pre-mRNA. 
Since the formation of the 45S B-like complex is accompanied by the recruitment of stoichiometric 
amounts of the B complex-specific proteins, we also tested if these proteins have a potential role in 
the structural change occurring during stable association of the U4/U6.U5 tri-snRNP with the 
complex. 
 
Figure 4.1: Comparison of class averages generated from exon-defined spliceosomes 
(A) The most abundant structures of the indicated complex are shown. Characteristic structural features within 
the body domain of the stabilized exon complex are indicated with red arrows. Scale bars correspond to 50 nm. 
(B) Schematic representation of an intron-defined B complex and localization of snRNPs within the structure as 
determined by immunolabeling with subsequent negative-stain EM. 
 
We could show that solely the addition of the 5’ss oligonucleotide to affinity-purified 37S exon 
complexes not only induced the stable integration of the U4/U6.U5 tri-snRNP, but also resulted in an 
increase in its S-value (Figure 3.4 and 3.5). The increased S-value indicates a remodeling in the 
complex during the stabilization process, similar to what was seen with the 45S B-like complex in the 
presence of nuclear extract. EM analyses of this stabilized exon complex revealed structural features 
highly similar to those observed with the 45S B-like complex formed in nuclear extract (Figure 4.1A). 
Further, the stabilized exon complex shows a predominant structure in the majority of all classes, 




These results demonstrate that binding of the 5’ss oligonucleotide alone triggers a conformational 
change in the structural organization of the exon complex, which potentially leads to stable 
integration of the U4/U6.U5 tri-snRNP. This provides strong evidence that the significant 
conformational rearrangement of the complex is independent of protein factors not already found in 
the 37S exon complex and occurs even in the absence of additional ATP (see chapter 3.4). The data 
presented here indicate that the conformational changes observed upon binding of the 5’ss 
oligonucleotide occur prior to the recruitment of the B complex-specific proteins and might even be 
a prerequisite for their interaction with the spliceosomal complexes. This suggests that these 
proteins are recruited to the spliceosome after it adopts a structure characteristic for a B complex. 
But despite the structural similarities of the stabilized exon complex and the 45S B-like complex 
formed in nuclear extract, we identified differences in the morphologies of their body domains. The 
body domain of the stabilized exon complex contains an additional belly-like protrusion and exhibits 
a slimmer stump (Figure 4.1A, indicated with red arrows), whereas the body of the 45S B-like 
complex appears broader and lacks this additional protrusion. Since the differential appearance of 
the body domain is observed in the majority of all classes, we assume that the U4/U6.U5 tri-snRNP 
containing part of the complex might have a slightly different orientation with respect to the head 
domain, which appears similar to the 45S B-like complex formed in nuclear extract. Alternatively, this 
difference might be due to the absence of the B complex-specific proteins in the stabilized exon 
complex. However, whether these proteins contribute directly to the mass of the body domain or 
alternatively whether the lack of these proteins alters the orientation of the body domain is 
presently unclear.  
4.7 Sequence requirements for the 5’splice site to induce stable U4/U6.U5 tri-
snRNP binding  
The drastic changes in composition, structure and stability, which occur during formation of a 45S B-
like complex, are solely induced by addition of the 5’ss oligonucleotide to the splicing reaction. To 
better understand the mechanism underlying this transition, I assessed the 5’ss oligonucleotide 
sequence requirements for transforming the 37S exon complex into a stable 45S B-like complex, by 
monitoring the effect of different mutations within the 5’ss oligonucleotide on the stabilization of 
U4/U6.U5 tri-snRNP binding and formation of a 45S complex. Nucleotides in the exonic part of the 
5’ss oligonucleotide can base pair with loop I of U5 snRNA and intronic nucleotides with the ACAGAG 
box of U6 as evidenced by psoralen crosslinking [Sontheimer and Steitz, 1993]. Additionally, a highly-
specific crosslink of the 5’ss at position +2 to the RNase H domain of hPrp8 was identified, which 




that hPrp8 not only contacts intronic nucleotides of a 5’ss, but also makes contacts with nucleotides 
in the 5’exon [Sha et al., 1998]. Consistent with this result, site-specific protein-RNA crosslinking in 
stably-assembled 45S B-like complexes showed that the 5’ss oligonucleotide is directly contacted by 
hPrp8, at the G/GU nucleotides defining the exon-intron junction (see chapter 3.6). Consequently, 
I introduced mutations in the 5’ss oligonucleotide sequence to potentially disrupt its interaction with 
the U5 or U6 snRNAs, or with hPrp8.  
When the potential for Watson-Crick base pairing between loop I of U5 snRNA and the 5’ss 
oligonucleotide was disrupted, the formation of B-like complexes in the presence of heparin was 
reduced. Similar results were achieved when mutations were introduced that disrupt base pairing 
with the ACAGAG box of U6 snRNA. However, no inhibitory effect of these mutations was detected 
when the transition to a 45S complex was assayed by glycerol gradient centrifugation. As no effect on 
the formation of a 45S complex was observed, we conclude that the interaction of the 5’ss 
oligonucleotide with either loop I of U5 snRNA or the ACAGAG box of U6 is not required to induce 
the structural change in the complex. Apparently, introduction of mutations within the 5’ss 
oligonucleotide influences the U4/U6.U5 tri-snRNP interaction such that it is sensitive to the 
presence of heparin, but the structural change as indicated by the increased S-value still occurs as 
assayed by the less stringent glycerol gradient analysis. Thus, the conformational change of the 
complex to a 45S complex does not necessarily translate into an increased heparin resistance. 
Further, western blot analysis showed that the apparent difference in complex stability is 
independent of hPrp31 phosphorylation and recruitment of the B complex-specific proteins (Figure 
3.11). I could show that all 5’ss oligonucleotides that induce the transition to a 45S complex were 
also co-purified with the respective complex suggesting that the interaction between the 5’ss 
oligonucleotide and the U4/U6.U5 tri-snRNP must be maintained in order to stabilize the complex 
and also to support the conformational change to a 45S complex. 
However, if both base pairing interactions between the 5’ss oligonucleotide and the U5 and 
U6 snRNAs were disrupted simultaneously, B-like formation was abolished in the presence (native 
gels) and absence (glycerol gradient) of heparin. These results show that individual disruption of 
either U5/5’ss or U6/5’ss base pairing has a moderate effect on B-like formation, but the disruption 
of both interactions abolishes the stable integration of the U4/U6.U5 tri-snRNP. The former result is 
consistent with previous results showing that the loop I of U5 snRNA is not essential for efficient pre-
mRNA splicing in HeLa nuclear extract [Segault et al., 1999]. The base pairing interactions between 
the U5 and U6 snRNA, and the 5’ss oligonucleotide, thus appear to be redundant and might 




Next, I assayed the effect of single point mutations in the G/GU triplet, which defines the exon-intron 
junction and is directly contacted by hPrp8. While mutations of -1G → A and +2U → A had no effect 
on B-like formation, the G → A transition at position +1 reduced stable U4/U6.U5 tri-snRNP binding 
in the presence of heparin significantly. Nevertheless, glycerol gradient and western blot analysis 
showed an efficient transition to a 45S complex and the recruitment of the B complex-specific 
proteins as well as phosphorylation of hPrp31. This underlines that the structural change and 
recruitment of B complex-specific proteins does not always translate into resistance against heparin. 
Thus, suboptimal 5’ss sequences are also competent for the formation of a B-like complex, but the 
interaction with hPrp8 might be less stable and therefore lead to destabilization of the complex in 
the presence of heparin. However, in all cases tested here, a structural rearrangement, i.e. 
45S complex formation, appears to be a prerequisite for heparin stability and also the resistance 
against increased salt concentrations during glycerol gradient centrifugation. 
The mutation of two neighboring nucleotides within the exon-intron junction abolished the potential 
for formation of a B-like complex completely. Copurification studies showed that upon mutation of 
GU → AA, as well as GG → AA (or rIrI), the 5’ss oligonucleotide not only loses the potential to induce 
45S B-like complex formation, but also its physical interaction with the 37S exon complex is 
abolished. The fact that the most severe impairment of B-like formation was observed upon 
mutations within the exon-intron junction, which should not contribute to base pairing with U5 or 
U6 snRNA, provides evidence that not only RNA-RNA interactions between the 5’ss oligonucleotide 
and the snRNAs are necessary for the physical association of the 5’ss with the complex, but also 
additional protein-RNA interactions are required for stable binding of the 5’ss oligonucleotide. This 
points to a crucial role for the hPrp8:5’ss interaction in stable binding of the 5’ss and further in 
discrimination between suitable and aberrant 5’ss sequences. The data presented here suggest that 
recognition of a suitable 5’ss sequence by hPrp8 triggers the structural rearrangement that leads 
then to stable integration of the U4/U6.U5 tri-snRNP and consequently to B-like complex formation.  
Apparently, the recognition of a suitable 5’ss substrate by hPrp8 involves also the exocyclic part of 
the GG dinucleotide at the exon-intron junction, because mutation to ribo-inosine nucleotides inhibit 
B-like complex formation (Table 3.2). This points to a very specific and functionally important 
recognition of guanosine nucleotides at the exon-intron junction. Additionally, binding of the 5’ss 
oligonucleotide within in the complex and consequently the transition to a 45S complex also involves 
the recognition of the ribose backbone, as judged by the fact that 2’O-ribose methylation of the RNA 
oligonucleotide abolishes the formation of a B-like complex. This is in line with previous results, 
which showed that especially modifications of the ribose backbone at position -2 to +3 of a 5’ss 




physical association of the 5’ss oligonucleotide with the 37S exon complex does not only depend on a 
specific interaction of hPrp8 with guanosine nucleotides at the exon-intron boundary, but also 
involves the recognition of the ribose-backbone of the RNA strand. In summary, base pairing with the 
U6 ACAGAG box is not required to trigger the observed structural rearrangement during transition to 
a 45S B-like complex, but instead the latter likely requires a highly specific interaction of the 
U5 snRNP protein hPrp8 with the exon-intron junction. These results were observed during exon-
defined formation of a 45S B-like complex. But given the compositional, structural and functional 
similarities between the B-like and the intron-defined B complex, they likely also hold true for the 
formation of an intron-defined B complex. Although the 5’ss oligonucleotide represents a 5’splice 
site in trans, one can extrapolate to the situation with a 5’splice site in cis, i.e. the 5’ss present in the 
MINX pre-mRNA. Thus, the observed sequence requirements for the 5’ss sequence probably also 
hold true for the stable formation of an intron-defined B complex. 
4.8 Structural implications for the stabilizing effect of a 5’ss sequence on 
stable U4/U6.U5 tri-snRNP binding 
Structural investigations of the RNase H domain of Prp8 showed that it adopts an RNase H fold even 
in absence of a substrate [Pena et al., 2008, Ritchie et al., 2008, Schellenberg et al., 2013]. In previous 
studies it was shown that residues 1894-1898 of the RNase H domain of hPrp8 crosslink with the 
+2 position of a 5’ss in stably-assembled B complexes [Reyes et al., 1996, Reyes et al., 1999]. By 
superimposing the hPrp8 crystal structure with an RNA oligonucleotide mimicking a 5’ss sequence, it 
was shown that the 5’ss fits in a positively-charged cleft of the hPrp8 structure, which would favor 
interaction with the negatively-charged sugar-phosphate backbone of the RNA [Pena et al., 2008]. 
During this superimposition the conserved GU dinucleotide at position +1 and +2 of the 5’ss is 
located directly next to the five amino acid peptide, which was cross-linked in stably-assembled 
B complexes [Reyes et al., 1999]. We detected crosslinks between the nucleotides -1 to +2 of the 5’ss 
oligonucleotide and hPrp8 in stably-assembled 45S B-like complex and it is likely that the crosslink is 
also located in the RNase H domain of hPrp8 (Figure 3.7).  
Recently it was shown that the RNase H domain of Prp8 can adopt alternatively an open and a closed 
conformation [Schellenberg et al., 2013]. In the closed conformation a two-stranded antiparallel β-
hairpin (thumb) is formed, whereas in the open conformation this hairpin is disrupted. This thumb is 
in direct proximity of the positively-charged cleft, which is proposed to interact with the ribose 
backbone of the 5’ss RNA strand, and in the closed state the thumb is ideally positioned to interact 
with bound RNA [Pena et al., 2008]. Structural investigation of a C-terminal part of Prp8 comprising 




of Prp8 revealed considerable interdomain movements of the RNase H domain with respect to the RT 
and En domains [Galej et al., 2013]. It was proposed that the alternative positions of the RNase H 
domain may transmit conformational changes of the RNA network after each transesterification 
reaction. These studies show that the RNase H domain can adopt alternative conformations and that 
these changes may also influence the interactions with other domains of hPrp8. 
During the structural investigation of the 37S exon complex by negative-stain EM we could show that 
solely the presence of a 5’ss oligonucleotide induces a significant change in the organization of the 
complex (Figure 3.6). Further, we provided evidence that the stable binding of the 5’ss 
oligonucleotide within the spliceosome likely requires interactions with hPrp8 (see chapter 3.6). The 
binding of the 5’ss oligonucleotide by hPrp8 might induce a conformational change in the RNase H 
domain of hPrp8 and also in other domains of this protein. These rearrangements in the hPrp8 
protein might subsequently induce changes in protein-protein interactions between proteins of the 
U4/U6.U5 tri-snRNP and the U2 snRNP, and as a consequence, result in the structural transition to a 
complex with stably bound U4/U6.U5 tri-snRNP. This mode of action could also explain the 
difference in complex stability regarding heparin and glycerol gradients. It is known that in the 
presence of heparin less stable protein-RNA interactions are disrupted. Thus, heparin might interfere 
with the interaction between the 5’ss oligonucleotide and the RNase H domain of hPrp8 when the 
former is mutated to a less optimal sequence. As soon as the hPrp8:5’ss interaction is disrupted, the 
stabilizing effect on the U4/U6.U6 tri-snRNP binding is reversed or abolished.  
4.9 A dominant-negative mutant of the DEAD-box helicase hPrp28 inhibits 
stable B complex formation 
Next I investigated the requirements for stable B complex formation in the intron-defined assembly 
pathway. To learn more about factors contributing to stable B complex formation, I set out to isolate 
splicing complexes formed after the A complex but prior to a stable B complex. In S. cerevisiae the 
DEAD-box helicase Prp28 is necessary for B complex formation, and it was shown to destabilize the 
U1:5’ss interaction [Staley and Guthrie, 1999]. The ATP-dependent activity of Prp28 is required for 
dissociation of U1 snRNP from the 5’ss of the pre-mRNA, but there are indications that the U4/U6.U5 
tri-snRNP can associate with the spliceosome prior to the action of Prp28 [Staley and Guthrie, 1999]. 
The U5-specific protein hPrp28 is the human homolog of Prp28 and is an integral component of the 
U5 snRNP and U4/U6.U5 tri-snRNP [Teigelkamp et al., 1997]. The integration of hPrp28 within the 
U4/U6.U5 tri-snRNP depends on its phosphorylation by SRPK2 and only a U4/U6.U5 tri-snRNP 
containing hPrp28 is competent for productive B complex formation [Mathew et al., 2008]. Based on 




investigations. As it was shown that Prp28 and ATP are required for B complex formation, I used an 
ATPase-deficient version of hPrp28, in which the DEAD motif was mutated to AAAD (hPrp28AAAD). 
In vitro splicing assays and native gel analysis showed that hPrp28AAAD is a dominant-negative 
inhibitor of splicing that stalls intron-defined spliceosome assembly after A but prior to stable 
B complex formation. 
4.10 Identification of a novel cross-intron assembly intermediate that is 
formed prior to hPrp28 action 
Analysis of spliceosome assembly on glycerol gradients revealed that in the presence of the 
dominant-negative mutant hPrp28AAAD, a 37S cross-intron complex is formed that contains 
stoichiometric amounts of all five snRNAs (Figure 3.14). These results show that association of the 
U4/U6.U5 tri-snRNP occurs prior to the action of hPrp28, but it is not yet stably-integrated in the 
complex as judged by native gel-electrophoresis in the presence of heparin (Figure 3.13). This 
complex thus represents a novel intermediate stage of spliceosome assembly, which is formed after 
U4/U6.U5 tri-snRNP recruitment, but prior to its stable integration within the spliceosome. Thus, 
initial association of the U4/U6.U5 tri-snRNP does not require the removal of the U1 snRNA from the 
5’ss. Further, the presence of stoichiometric amounts of U1 snRNA in the 37S cross-intron complex is 
consistent with a function of hPrp28 in destabilizing the interaction between U1 snRNP and the 
5’splice site of the pre-mRNA, since the U1 snRNA is significantly underrepresented in stably-
assembled B complexes. These results are consistent with the known function of Prp28 in 
S. cerevisiae. In summary, these data indicate that in the absence of hPrp28 action, U1 snRNP 
remains base paired to the 5’ss, which was additionally supported by the detection of a prominent 
crosslink between U1 snRNA and the pre-mRNA in the 37S cross-intron complex (Figure 3.16). In the 
B complex the U1 snRNA is no longer base paired with the pre-mRNA and we detected additional 
RNA-RNA interactions between the U4/U6.U5 tri-snRNP and the pre-mRNA. Thus, in the 37S cross-
intron complex the 5’ss sequence is not available for interaction with the U4/U6.U5 tri-snRNP and 
consequently the transition to a pre-catalytic B complex is inhibited.  
Characterization of the protein composition of the 37S cross-intron complex revealed the presence 
of all U1, U2 and U4/U6.U5 tri-snRNP proteins. However, unlike the cross-intron B complex, the 
37S cross-intron complex contains only very low levels of the B complex-specific proteins RED, 
MFAP1, FBP21, hSmu-1, hPrp38 and hSnu23. Further, proteins associated or related to the hPrp19 
complex, as well as factors of the RES complex were also significantly underrepresented in the 37S 
cross-intron complex, consistent with the idea that these subcomplexes are recruited first upon/after 




incorporated in the 37S cross-intron complex, i.e. the defect in splicing is not due to absence of 
hPrp28, but lack of its activity. Interestingly, the protein composition of the 37S cross-intron complex 
is astonishingly similar to that of the 37S exon complex, which was previously investigated by mass 
spectrometry under comparable conditions [Schneider et al., 2010a]. Based on the same snRNA 
composition and the very similar protein compositions of these 37S complexes, they appear to 
resemble similar spliceosome assembly intermediates. Consequently, we determined abundant 
factors associated with the 37S cross-intron complex via 2D gel-electrophoresis and compared them 
directly with the protein composition of the 37S exon complex. The comparison of their compositions 
on a semi-quantitative level showed also a very similar inventory of abundant proteins. Interestingly, 
the hPrp4 kinase is also abundant in the 37S cross-intron complex, which supports the idea that this 
kinase is stage-specifically recruited to the spliceosome after/upon association of the U4/U6.U5 tri-
snRNP, but prior to its stable integration (see chapter 4.4). Only the THRAP3 protein was absent, and 
BCLAF1 significantly underrepresented, in the 37S cross-intron complex, while being abundant in the 
37S exon complex. These factors are also abundant in the exon-defined 45S B-like complex, but they 
are absent or underrepresented in B complexes assembled across an intron (see 4.5), supporting the 
idea that THRAP3 and BCLAF1 might have a role solely in the assembly of exon-defined spliceosomes. 
In contrast, the 37S cross-intron complex contains abundant amounts of the cap-binding protein 
CBP80, whereas the 37S exon complex shows only low amounts of this protein. This is likely due to 
the fact that the MINX pre-mRNA, which was used to assemble intron-defined spliceosomes, 
contains a 5’cap, while the MINX exon-RNA does not contain a 5’cap. 
4.11 The 37S cross-intron complex can be converted into a stable B complex 
via addition of a 5‘ss oligonucleotide 
The 37S cross-intron complex represents an intermediate stage of spliceosomal assembly, which is 
formed after initial A complex assembly and prior to stable pre-catalytic B complex formation. Our 
data suggest that due to the retention of U1 snRNP at the 5’ss of the pre-mRNA, this sequence is not 
available for interaction with the U4/U6.U5 tri-snRNP and thus the transition to a pre-catalytic 
B complex is inhibited. At this point, it was not clear whether the 37S cross-intron complex resembles 
a functional intermediate of intron-defined spliceosome assembly or whether it is a dead-end 
product that is not competent to proceed to subsequent steps of splicing. Therefore, I tested 
whether the 37S cross-intron complex could be chased into a stable B complex via addition of an 
accessible 5’splice site in trans, in form of an oligonucleotide. Indeed, the addition of a 5'ss 
oligonucleotide to a splicing reaction containing inhibitory concentrations of hPrp28AAAD resulted in 
formation of a heparin-resistant B complex as assayed by native gel analysis (Figure 3.18). This shows 




assembly. However, as the stabilization was tested in total nuclear extract, I next tested whether the 
stabilization of the complex also occurs under more defined conditions, namely if an affinity-purified 
37S cross-intron complex is also competent for stable U4/U6.U5 tri-snRNP binding, as shown for the 
37S exon complex (Figure 3.4). The addition of the 5'ss oligonucleotide to affinity-purified 37S cross-
intron complexes led to the formation of a complex with stably associated U4/U6.U5 tri-snRNP, as 
evidenced by the shift in its migration behavior on glycerol gradients containing 150 mM KCl, which 
are restrictive conditions for loosely-associated U4/U6.U5 tri-snRNPs (Figure 3.19). A second affinity-
selection followed by analysis of the RNA composition verified that this stabilized cross-intron 
complex contains stoichiometric amounts of the U4, U5 and U6 snRNA, and thus the U4/U6.U5 tri-
snRNP. Therefore, addition of solely a 5’ss oligonucleotide to the 37S cross-intron complex increases 
dramatically the stability of the complex, in particular the binding of the U4/U6.U5 tri-snRNP, even in 
the absence of hPrp28 action. These results show that the 37S cross-intron complex is competent for 
B complex formation, despite the absence of hPrp28 activity, and contains all factors required for 
stable U4/U6.U5 tri-snRNP binding. This is consistent with the idea that the 37S complexes with 
loosely-associated U4/U6.U5 tri-snRNP represent a very similar intermediate in both exon-defined 
and intron-defined spliceosome assembly pathways and that stable integration of the U4/U6.U5 tri-
snRNP is triggered solely by its interaction with the 5’ss. In summary, hPrp28 ATPase activity is not 
required for initial binding of the U4/U6.U5 tri-snRNP, but action of hPrp28 destabilizes the U1:5’ss 
interaction, which makes the 5’ss accessible for interaction with the U4/U6.U5 tri-snRNP. Further, we 
conclude that the B complex-specific proteins are not essential for the stable integration of the 
U4/U6.U5 tri-snRNP within the 37S exon complex (3.4) or formation of an intron-defined B complex 
(Figure 3.19). 
4.12 The 37S cross-intron and 37S exon complex adopt an almost identical 
appearance upon interaction with a 5’ss oligonucleotide 
Based on the identical snRNA and a very similar protein composition of the 37S cross-intron and 
37S exon complex, we investigated the EM structure of the 37S cross-intron complex to see if the 
almost identical compositions of the complexes also result in a similar appearance. Surprisingly, EM 
analysis of the 37S cross-intron complex revealed that despite the similarities in their compositions, 
the structures of the 37S cross-intron and 37S exon complex differ quite significantly (Figure 4.2B). 
The 37S cross-intron complex exhibit areas of structural heterogeneity in its body domain, whereas 
the 37S exon complex showed the most structural heterogeneity in its head domain. The differences 
in the appearance of these complexes might be due to the different localization of the 5’ss-bound 
U1 snRNP, which is upstream of the BPS in the 37S cross-intron and downstream of the BPS in the 




the presence of the cap binding complex, i.e. CBP80 and CBP20, might influence the structure of the 
37S cross-intron complex, since it was shown that the cap binding complex interacts with proteins of 
the U4/U6.U5 tri-snRNP [Pabis et al., 2013]. These additional protein-protein interactions may alter 
the relative orientation of the U4/U6.U5 tri-snRNP within the complex or its absorption behavior on 
the EM grid and result thereby in a different appearance in comparison to the 37S exon complex, 
which lacks this 5’cap.   
 
Figure 4.2: Comparison of class averages generated from exon- and intron-defined spliceosomes  
(A) Schematic representation of the relative orientation of snRNPs in the 37S cross-intron and 37S exon 
complex. The arrow indicates interaction between the cap binding complex bound to the 5’cap and the 
U4/U6.U5 tri-snRNP. (B) The most abundant structures of the indicated complex are shown. Characteristic 
structural features within the body domain of the stabilized cross-intron and exon complex are indicated with 
red arrows. Scale bars correspond to 50 nm. 
 
Finally, we investigated the structure of the affinity-purified 37S cross-intron complex after addition 
of the 5’ss oligonucleotide, since this stabilized cross-intron complex showed an increased S-value 
presumably due to a change in its structure. The EM analysis revealed that the addition of a 5’ss 
oligonucleotide induces a significant change in the structure of the 37S cross-intron complex and 
rearranges its organization in such a way that it adopts an organization more characteristic for a 
stably-assembled B complex. Astonishingly, the stabilized cross-intron complex appears very similar 




body domain of both 37S complexes share structural features, namely the belly-like protrusion in the 
center of the body and the slimmer stump (Figure 4.2B, indicated with red arrows), after addition of 
the 5’ss oligonucleotide to the purified complexes. Based on the comparison of RNA and protein 
compositions, we suggest that the 37S cross-intron and 37S exon complex might resemble similar 
assembly intermediates of spliceosome formation. Upon interaction with the 5’ss oligonucleotide 
also their structure and presumably the organization of U2 snRNP with respect to the U4/U6.U5 tri-
snRNP is rearranged in such a way that these complexes adopt a very similar appearance. Taken 
together, these results are consistent with the idea that the 37S complexes with loosely-associated 
U4/U6.U5 tri-snRNP represent a very similar intermediate in both exon- and intron-defined 
spliceosome assembly pathways. Further, our data suggest that these alternative assembly pathways 
converge at the stage where the spliceosome is committed to using a particular 5’ss sequence via its 
interaction with the U4/U6.U5 tri-snRNP. 
4.13 Changes in the RNA-RNA network during spliceosome assembly prior to 
the first catalytic step 
The characterization of the RNA-RNA interactions within the 37S cross-intron complex extend our 
understanding of rearrangements within the RNA network during formation of a catalytically 
activated spliceosome and how helicases are involved in this process (Figure 4.3). In the A complex 
U1 snRNP is base paired with the 5’ss of the pre-mRNA (blue), whereas the U2 snRNP interacts with 
the branch point sequence (turquoise). Then the pre-assembled U4/U6.U5 tri-snRNP associates via 
U2/U6 helix II (purple) to the A complex resulting in formation of the 37S cross-intron complex. At 
this stage the U4/U6.U5 tri-snRNP is only loosely-associated with the complex and U1 snRNP is still 
occupying the 5’ss sequence. The results provided in this study suggest that the action of hPrp28 
leads then to a destabilization of the U1 snRNP:5’ss interaction resulting finally in the displacement 
of U1 snRNP from the complex, which is consistent with the function of its ortholog in yeast [Staley 
and Guthrie, 1999]. This enables an interaction of the U4/U6.U5 tri-snRNP with the now accessible 
5’ss, probably via a highly-specific recognition by hPrp8, resulting in the stronger binding of the 
U4/U6.U5 tri-snRNP and formation of a stable B complex. Base pairing interactions between the 5’ss 
and the ACAGAG box of U6 snRNAs (orange) might be necessary to stabilize the transition during 
exchange of U1:5’ss to hPrp8:5’ss interaction (see chapter 4.7). Thus, in a stably-assembled 
B complex U1 snRNA is not base paired with the pre-mRNA anymore, while new RNA-RNA 
interactions between the 5’ss and the U6 snRNA are established. Importantly, the U4 and U6 snRNAs 
are still base paired within in the pre-catalytic B complex to keep the U6 snRNA in an inactive state 
[Brow and Guthrie, 1998]. These results show that the displacement of U1 and U4 snRNA occur 




of the spliceosome the action of the U5-protein hBrr2 leads to disruption of the U4/U6 base pairing 
and extensive interactions between U2 and U6 snRNA are established resulting in formation of 
U2/U6 helix Ia and Ib (red) as well as the U6 internal-stem loop (green) [Yean et al., 2000, Anokhina 
et al., 2013]. 
 
Figure 4.3: Changes in the RNA-RNA network during stable integration of the U4/U6.U5 tri-snRNP within the 
spliceosome and its activation. 
 
4.14 The role of hPrp28 in formation of a stable B complex 
The results of my studies show that the 37S cross-intron complex already contains all factors that are 
required for stable binding of the U4/U6.U5 tri-snRNP even in absence of the ATPase-activity of 
hPrp28 and only depend on an interaction with a 5’ss sequence (Figure 3.19). This points to a role of 
hPrp28 in generating an accessible 5’ss, rather than stable U4/U6.U5 tri-snRNP binding per se. 
Interestingly, the addition of the 2’O-ribose methylated 5’ss oligonucleotide to the splicing reaction, 
which contains inhibitory amounts of hPrp28AAAD, does not support B complex formation (Figure 
3.18), even though it displaces U1 snRNP from the 5’ss of the pre-mRNA (Figure 3.1, 3.19 and data 
not shown). We could show that this oligonucleotide only interacts with the U1 snRNP, but does not 




U6 snRNA (Table 3.2). Thus, addition of the 2’O-ribose methylated 5’ss oligonucleotide displaces 
U1 snRNP from the 5’ss of the MINX pre-mRNA and thus creates an accessible 5’ss, which is 
competent to induce stable integration of the U4/U6.U5 tri-snRNP. But apparently, additional 
interactions are necessary to facilitate an interaction between the U4/U6.U5 tri-snRNP and the 
accessible 5’ss that is present in cis, i.e. in the pre-mRNA, since the 37S cross-intron complex is not 
stabilized. In contrast, the stabilization of the 37S cross-intron complex upon addition of an 
unmodified 5’ss oligonucleotide in trans is likely due to the fact that a 100-fold excess of the 5’ss 
oligonucleotide is added to the purified complexes. Previous studies provide evidence that hPrp28 
might not only displaces U1 snRNP from the 5’ss but also have a role in mediating the interaction 
between the 5’ss and the U4/U6.U5 tri-snRNP during stable B complex formation. Site-specific 
crosslinking studies showed that upon B complex formation the ATP-binding site of hPrp28 is in close 
proximity to the 5’ss, just a few nucleotides downstream of the exon-intron junction [Ismaili et al., 
2001], which is contacted by hPrp8. Further, it was shown that not only the presence of ATP is 
required for hPrp28 interaction with the 5’ss, but rather its hydrolysis, as no crosslink was detected 
in presence of a non-hydrolysable ATP-analog [Ismaili et al., 2001]. The hPrp28:5’ss crosslink 
correlates with an interaction of the 5’ss with the U6 snRNA at the same intron position, which 
suggest that interaction between the 5’ss and hPrp28, as well as U6 snRNA, are established in the 
same complex upon hydrolysis of ATP [Ismaili et al., 2001]. This suggests that the hPrp28 driven 
displacement of U1 snRNP from the 5’ss of a pre-mRNA generates a close proximity of the U6 snRNA 
and hPrp8 to the 5’ss. It is likely that at this stage, RNA-RNA interactions between the U6 snRNA and 
the 5’ss are established. However, we showed that the Watson-Crick base pairing between U6 and 
the 5’ss is not essential for stable B-like complex formation, as long as sequence complementarities 
between U5 loop I and the 5’ss exist (Figure 3.8). Either of these base pairing interactions might keep 
the 5’ss in close proximity to the U4/U6.U5 tri-snRNP until hPrp8 can engage interactions with the 
exon-intron junction. Such a coordinated handover of the 5’ss to hPrp8 might also explain how the 
spliceosome achieves the high accuracy of splice site recognition and identify bona fide 5’ss from the 
numerous pseudo sites found in any pre-mRNA. Consequently, a 5’ss has first to be recognized by the 
U1 snRNP to avoid that a wrong 5’ss interacts with the U4/U6.U5 tri-snRNP. The recently identified 
crystal structure of hPrp28 showed that the RecA domains of the DEAD box-helicase are not 
competent for ATP binding [Möhlmann et al., 2014] and that conformational changes within the 
protein have to occur in order for it to bind and hydrolyze ATP. Further, it was shown that hPrp28 is 
only able to bind ATP in the presence of a pre-mRNA under splicing conditions and not within the 
U4/U6.U5 tri-snRNP, suggesting that ATP binding by hPrp28 requires the formation of a spliceosomal 
complex [Möhlmann et al., 2014, Laggerbauer et al., 1996]. The results of this study suggest that in 




between U1 snRNP and the 5’ss of the pre-mRNA in order to allow B complex formation (Figure 
3.13), which is consistent with its function in yeast [Staley and Guthrie, 1999]. We would propose 
that hPrp28 action takes place only upon assembly of the spliceosome and does not occur in the 
context of a U4/U6.U5 tri-snRNP. After hPrp28-mediated displacement of U1 snRNP, the 5’ss 
sequence is integrated within the U4/U6.U5 tri-snRNP and a reorganization in the complex occurs, 
which finally results in stable U4/U6.U5 tri-snRNP binding and B complex formation. 
4.15 Perspectives 
The aim of this thesis was to elucidate the requirements for B complex formation and in particular 
the prerequisites for stable integration of the U4/U6.U5 tri-snRNP during this process. Strikingly, the 
results of my studies show that solely the interaction of a 5’ss sequence with a 37S complex is 
sufficient to stably integrate the U4/U6.U5 tri-snRNP within the complex. Here I have presented 
biochemical and biophysical data that shed light on the nature of the conformational change that 
occurs upon interaction of the U4/U6.U5 tri-snRNP with a 5’ss sequence and accompanies its stable 
integration within the spliceosome. Remarkably, the functional interaction of the 5’ss with the 
spliceosome, in particular with hPrp8, depends on a highly-specific recognition of conserved 
nucleotides at the exon-intron junction. These extensive changes in stability and morphology of the 
spliceosome occur without requirement for additional factors or ATP suggesting that changes in 
protein-protein interactions between factors already present in the complex, presumably U2 and 
U4/U6.U5 tri-snRNP proteins, account for the dramatic rearrangement of the complex. However, it is 
still unclear which protein-protein interactions are changed or established during B complex 
stabilization. Thus, further studies are needed to identify these interactions and how they are 
established or changed in order to support stable U4/U6.U5 tri-snRNP binding. A promising approach 
towards a comprehensive identification of protein-protein interactions in complex and protein-rich 
samples is the implementation of a technique in which protein-protein crosslinks are identified via 
mass spectrometry. This method is currently established in the Lührmann laboratory, together with 
Prof. Dr. Henning Urlaub’s group, to detect interactions between spliceosomal proteins in purified 
and subsequently crosslinked spliceosomes. Recent progress in the sensitivity and reproducibility of 
the detection of protein-protein crosslinks are auspicious, such that by using this approach it is now 
possible to detect also the dynamics of interactions by comparing distinct assembly intermediates. 
Therefore, we will apply this technique to identify protein-protein interactions within spliceosomes 
before and after stable integration of the U4/U6.U5 tri-snRNP to determine how the spatial 
organization of the U4/U6.U5 tri-snRNP with respect to the U2 snRNP is changed and which factors 
contribute to the stabilizing effect. In this way, several additional questions could be addressed in the 




associated with U2 and the U4/U6.U5 tri-snRNP, but also to elucidate other important protein-
protein interactions, such as binding partners of the B complex-specific proteins, which are recruited 
after stable U4/U6.U5 tri-snRNP binding, or interaction partners of the hPrp4 kinase, which might be 
important for its activation and release during B complex formation.  
During my studies I was able to show how catalytically inactive forms of spliceosomal 
ATPases/helicases can potentially be used to stall spliceosome assembly at novel stages. We have 
identified and characterized a novel assembly intermediate that is formed prior to stable B complex 
formation and identification of its protein composition provided us with a comprehensive picture of 
changes in the protein inventory of the spliceosome during formation of a B complex. This approach 
may allow new insights into the assembly of the spliceosome by identification of novel intermediates 
and could potentially improve its structural determination. Upon stalling of the splicing cycle at a 
functionally distinct step, it should be possible to obtain more homogenous populations of 
spliceosomes in contrast to the situation when a kinetic termination of the splicing process is carried 
out. Structural analysis of spliceosomes in general would greatly profit from purification of more 
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2’O-me     2’O-ribose methylated 
3’ss      3‘splice site 
5’ss      5‘splice site 
A      Adenosine / ampere 
aa      Amino acid 
Amp     Ampicillin 
APS      Ammonium peroxodisulfate 
ATP      Adenosine triphosphate 
BCA      Bicinchoninic acid 
bp      Base pair 
BP      Branch point 
BPS      Branch point sequence 
BSA      Bovine serum albumin 
°C      Degree celsius 
C      Cytosine 
CTP      Cytosine triphosphate 
C. elegans     Caenorhabditis elegans 
Ci      Curie 
cm      Centimeter 
cpm      Counts per minute 
Da      Dalton 
dd      Double distilled 
DExD/H     Consensus sequence of helicases 
DMSO      Dimethyl sulfoxide 
DNA      Desoxyribonucleic acid 
D. melanogaster   Drosophila melanogaster 
DTT      Dithiothreitol 
ECL      Enhanced chemiluminescence 
E. coli      Escherichia coli 
EDTA      Ethylendiamintetraacetate 
EJC     Exon junction complex 
EM      Electron microscopy 
ESE      Exonic splicing enhancer 
ESS      Exonic splicing silencer 




f      Femto 
G      Guanosine 
g      Gram / centrifugal force 
GTP      Guanosine triphosphate 
H. sapiens    Homo sapiens 
h      Hour / human 
HCl      Hydrochloric acid 
HEPES      N-2-Hydroxyethylpiperazin-N-2-ethansulfonic acid 
hn      Heterogenous nuclear 
ILS     Internal-stem loop 
ISE     Intronic splicing enhancer 
ISS     Intronic splicing silencer 
J     Joule 
k      Kilo 
kDa      Kilodalton 
l      Liter 
LB     Luria Bertani 
LC      Liquid chromatography 
Lsm      Like-Sm 
M      Molar 
m      Milli / meter 
μ      Micro 
min      Minutes 
mM      Millimolar 
mRNA      Messenger RNA 
MS      Mass spectrometry 
MW      Molecular weight 
n      Nano 
NTP      Nucleoside triphosphate 
nts      Nucleotides 
OD      Optical density 
P      Phosphate 
p      Pico 
PAGE      Polyacrylamide gel-electrophoresis 
PCI      Phenol-chloroform-isoamyl alcohol 
pH      Preponderance of hydrogen ions 
PMSF      Phenylmethylsulfonylfluoride 
PPT     Polypyrimidine tract 
Pre-mRNA     Precursor-mRNA 




Py      Pyrimidine base 
R      Purine base 
RES     Retention and splicing 
RNA      Ribonucleic acid 
RNase      Ribonuclease 
RNP      Ribonucleoprotein 
rpm      Revolutions per minute 
RRM      RNA recognition motif 
RT      Room temperature 
S      Svedberg unit 
s      Second 
S. cerevisiae     Saccharomyces cerevisiae 
SDS      Sodium dodecylsulfate 
Sm      ‘Smith’, patient in which Sm proteins were first discovered 
sn      Small nuclear 
snRNA      Small nuclear ribonucleic acid 
snRNP      Small nuclear ribonucleoparticles 
SR      Serine arginine rich 
TEMED     N, N, N’, N’-Tetramethylethylendiamine 
Tris      Tris-(hydroxymethyl)-aminomethane 
tRNA      Transfer RNA 
U      Uridine / unit 
U snRNA     Uridine rich small nuclear RNA 
U snRNP     Uridine rich small nuclear ribonucleoparticles 
UTP      Uridine triphosphate 
UV      Ultraviolet 
V      Volt 
Vol     Volume 
v/v      Volume per volume 
W      Watts 
w/v      Weight per volume 
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